 
 
 
 
Protocol I8H-MC -BDCL (d) 
 
 
A Phase 2, Parallel, Comparator -Controlled Trial to Evaluate the 
Safety and Efficacy of LY3209590 in Insulin -Naïve Patients with 
Type 2 Diabetes Mellitus . 
  
[STUDY_ID_REMOVED] 
 
 
Approval Date: 28-Oct -2020 
CO N FI D E N TI A L I 8 H -M C -B D C L ( d) 
L Y 3 2 0 9 5 9 0 1Title P a ge 
C o nfi d e nti al I nf or m ati o n 
T h e i nf or m ati o n c o nt ai n e d i n t hi s d o c u m e nt i s c o nfi d e nti al a n d i s i nt e n d e d f or t h e u s e of cli ni c al i n v e sti g at or s.  It i s t h e pr o p ert y of 
Eli Lill y a n d C o m p a n y or it s s u b si di ari e s a n d s h o ul d n ot b e c o pi e d b y or di stri b ut e d t o p er s o n s n ot i n v ol v e d i n t h e cli ni c al 
i n v e sti g ati o n of L Y 3 2 0 9 5 9 0 , u nl e s s s u c h p er s o n s ar e b o u n d b y a c o nfi d e nti alit y a gr e e m e nt wit h Eli Lill y a n d C o m p a n y or it s 
s u b si di ari e s.  
N ot e t o R e g ul at or y A ut h oriti e s:   T hi s d o c u m e nt m a y c o nt ai n pr ot e ct e d p er s o n al d at a a n d/ or c o m m er ci all y c o nfi d e nti al 
i nf or m ati o n e x e m pt fr o m p u bli c di s cl o s ur e.  Eli Lill y a n d C o m p a n y r e q u e st s c o n s ult ati o n r e g ar di n g r el e a s e/r e d a cti o n pri or t o a n y 
p u bli c r el e a s e.  I n t h e U nit e d St at e s, t hi s d o c u m e nt i s s u bj e ct t o Fr e e d o m of I nf or m ati o n A ct ( F OI A) E x e m pti o n 4 a n d m a y n ot b e 
r e pr o d u c e d or ot h er wi s e di s s e mi n at e d wit h o ut t h e writt e n a p pr o v al of Eli Lill y a n d C o m p a n y or it s s u b si di ari e s. 
Pr ot oc ol Title: A P hase 2 ,Parallel, C o m parat or -C o ntr olle d Trial t o E val uate t he Safet y a n d 
Efficac y of L Y 3 2 0 9 5 9 0 i n I n s uli n -Naï ve Pat ie nt s wi t h  T y pe 2 Di a betes Mellit us 
Pr ot oc ol N u m ber: I 8 H -M C -B D C L 
A me n d me nt N u m ber: d
C o m p o u n d :L Y 3 2 0 9 5 9 0 
St u d y P h ase: P hase 2
S h ort Title: A St u d y  of  L Y 3 2 0 9 5 9 0 i n Partici pa nts wit h T y pe 2 Di a betes Mellit us 
S p o ns or N a me:   El i Lill y a n d C o m pa n y 
Le g al Re gistere d A d dress: I n di a na p olis, I n dia na U S A 4 6 2 8 5 
Re g ul at or y A ge nc y I de ntifier N u m ber(s) 
I N D: 1 2 9 3 9 0 
E u dra C T: 2 0 1 9- 0 0 3 3 3 9- 5 3 
A p pr o v al D ate: Pr ot oc ol A me n d me nt ( d) El ectr o nicall y Si g ne d a n d A p pr o ve d b y Lill y o n date 
pr o vi de d bel o w. 
Lill y Me dic al N a me a n d C o nt act I nf or m ati o n will be pr o vi de d se p ar atel y .
                                        
A p pr o v al D at e: 2 8- O ct- 2 0 2 0 G M T 
CONFIDENTIAL I8H-MC-BDCL (d)
LY3209590 2Protocol Amendment Summary of Changes Table
DOCUMENT HISTORY
Document Date
Original Protocol 11-Dec -2019
Amendment (a) 08-Apr -2020
Amendment (b) 12-Jun-2020
Amendment (c) 14-Aug -2020
Amendment [d] 
This amendment is considered substant ialbased on the cri teria set forth in Art icle 10(a) of 
Directive 2001/20/EC of the European Parliament and the Council o f the European Unio n.
Overall Rationale for the Amendment:
The am endment provi des informat ion to reflect terminat ion of the invest igational medical device 
study  arm evaluat ing the individualized accruing data algorithm (Algorithm 2) invest igational 
device in the Ph ase 2 Study 18H -MC-BDCL (BDCL). Study  BDCL will cont inue toevaluat e
dosing regimens of invest igational medicinal product LY3209590, a long -acting insulin receptor 
agonist that is being developed as a basal insulin administered once -weekly for treatment of type 
2 diabetes mellitus (T2DM) .  Stu dy BDCL is evaluating individualized LY3209590 dosing 
strategies in insulin -naïve study  parti cipants wi th T2DM in the paper algorithm (Algorithm 1).  
Insulin degludec is an unblinded active comparator in this study . 
Lilly is terminat ing the Algorithm 2 st udy arm due to the extent ofdata entry  errors generated by  
patients and the impact these errors have on dosing recommendations from the invest igational 
device Algorithm 2. These errors (missing, unchecked, or uncorrected by  site verificat ion) 
provi de less than com plete data set inputs that are submitted by  the invest igator into the 
Algori thm 2 dosing calculation.  The limited data set inputs have revealed shortcomings in 
dosing calculat ion confounding factors for the limited number of Algorithm 2 dosing 
recommendat ions observed fro m a limi ted number of sites and participants during the early  
enrollment phase.  In some cases, if the invest igator had not applied clinical judgement to 
override the recommended dose, a serious adverse consequence on patient hea lth and/or safet y 
associ ated wi th the invest igational device may  have resul ted.  
Lilly recognized that the planned expansio n to include all sites participat ing in the United States 
woul d increase both the number of participants utilizing the investigation al device Algori thm 2 
and the number of invest igators providing oversite of the Algorithm 2 dosing reco mmendat ions.  
Based on the limited experience to date with Algorit hm 2, it was unclear whether all potential 
issues had been identified or unforeseen fut ure issues might impact the abilit y to com plete the 
trial.It was concluded that study  expansio n couldincrease the risk for dosing errors and the 
possible ident ificat ion of previously  unident ified issues with Algorithm 2. Importantly, the 
continued use of invest igator override couldimpair our abilit y to m eet the scient ific objectives of 
the study  related to Algorithm 2 .  Thi s amendment reflects taking the prevent ive act ion of 
terminating the Algorithm 2 invest igational medical device tri alarm of Study  BDCL to prevent 
further poten tial patient safet y issues and delay in the study .
CONFIDENTIAL I8H-MC-BDCL (d)
LY3209590 3Section # and Name Description of Change Brief Rationale
Throughout the document Removal of language related to 
Algorithm 2Alignment of protocol for removal of 
Algorithm 2
Section 1.1. Synopsis
Section 6.1. Study 
Intervention(s) Administered
Section 9.2. Sample Size 
Determination
Section 10.10. Appendix 10: 
Change to Study Procedures 
due to the COVID -19 
Pandemic or Natural 
DisastersChange in number of 
participants andrandomization 
ratioBased on the removal of Algorithm 2, the 
participant number was updated .
Section 1.3. Schedule of 
ActivitiesAddition of language for 
footnote dClarification that a triplicate ECG for insulin 
degludec is only required one time.
Addition of language for 
footnote eClarification of the collection of 2 PK 
samples isfor LY3209590. 
Section 6.1. Study 
Interventions(s) 
AdministeredAddition of language for 
participants transitioning from 
Algorithm 2Clarification forparticipants in Algorithm 2 to 
proceed with study procedures for those 
treated with LY3209590.
Section 8.4. Treatment of 
OverdoseAddition of pr ocedural language Clarification added to contact the sponsor in
case of an accidental overdose.
Section 9.3.Populations for 
Analy sis
Section 9.4.1. General 
Considerations
9.4.2.2. Patient 
Characteristics
Section 9.4.6.3. 
Hypoglycemia EpisodesChange in language related 
removal of Algorithm 2Update of statistical analysis after removal of 
Algorithm 2 
Section 10.3.3. Definition of 
an Unanticipated Adverse 
Device Effect (UADE)Rem oval of section related to 
Algorithm 2Clarification that UADE will not be 
applicable after removal of Algorithm 2
Section 10.8. Appendix 8:  
Dosing Guidance for 
LY3209 590 and Insulin 
DegludecAddition of “Insulin Degludec” 
to titleClarification that dosing guidance is available 
for LY3209590 and Insulin Degludec
Section 10.10. Appendix 10: 
Change to Study Procedures 
due to the COVID -19 
Pandemic or Natural 
DisastersAddition of language for 
Rem ote VisitsClarification thatsites must receive sponso r 
approv al prior to implementing site mobile 
visits andvisits by a sponsor organized home 
nursing service provider to replace on -site 
visits.
Throughout the document Minor editorial and document 
formatting revisionsThese are minor changes; therefore, they have 
not been summarized.
CONFIDENTIAL I8H-MC-BDCL (d)
LY3209590 4Table of Contents
1. Protocol Summary ...................................................................................................... 7
1.1. Synopsis ....................................................................................................................... 7
1.2. Schema ....................................................................................................................... 10
1.3. Schedule of Act ivities (SoA) ...................................................................................... 11
2. Introduction .............................................................................................................. 22
2.1. Study  Rati onale .......................................................................................................... 22
2.2. Backgro und................................................................................................................ 22
2.3. Benefit/Risk Assessment ............................................................................................ 23
2.3.1. Protocol  Risk Mi tigation Features ............................................................................... 23
3. Objectives and Endpoints ......................................................................................... 24
4. Study Design ............................................................................................................. 26
4.1. Overall Desig n............................................................................................................ 26
4.1.1. Study  Visi ts................................................................................................................ 26
4.2. Scientific Rationale for Study  Design ......................................................................... 29
4.3. Justification for Dose .................................................................................................. 29
4.4. End of Study  Definit ion.............................................................................................. 30
5. Study Population ...................................................................................................... 31
5.1. Inclusio n Cri teria........................................................................................................ 31
5.2. Exclu sion Criteria....................................................................................................... 33
5.3. Lifest yle Considerat ions............................................................................................. 35
5.3.1. Meals, Dietary  Restri ctions, and Act ivity.................................................................... 35
5.4. Screen Failures ........................................................................................................... 36
6. Study Intervention .................................................................................................... 37
6.1. Study  Intervent ion(s) Administered ............................................................................ 37
6.1.1. Selection and Timing o f Doses ................................................................................... 38
6.1.2. Speci al Treatm ent Consi derat ions............................................................................... 38
6.1.3. Medical Devices ......................................................................................................... 40
6.2. Prepa ration/Handling/Storage/Accountabilit y............................................................. 40
6.3. Measures to Minimize Bias:  Rando mizat ion and Blinding ......................................... 40
6.4. Study  Intervent ion Compliance ................................................................................... 41
6.5. Concomitant Therapy ................................................................................................
.41
6.5.1. Antihyperglycemia Medicat ions................................................................................. 43
6.5.2. Concomitant Ant ihyperglycemia Medicat ion.............................................................. 44
6.5.3. Medicat ions that Promote Weight Loss ....................................................................... 44
6.5.4. Systemic Glucocorti coids........................................................................................... 44
6.5.5. Antihypertensive Medications ..................................................................................... 45
6.5.6. Dyslipidemia Medicat ions.......................................................................................... 45
6.6. Dose Modificat ion...................................................................................................... 45
6.7. Intervention after the End of the Study ........................................................................ 45
6.7.1. Treatment after Study  Com pletion.............................................................................. 45
7. Discontinuation of Study Intervention and Participant 
Discontinuation/Withdrawal .................................................................................... 46
CONFIDENTIAL I8H-MC-BDCL (d)
LY3209590 57.1. Discontinuati on of  Study  Intervent ion........................................................................ 46
7.1.1. Perm anent Discont inuat ion from Study Treatment ...................................................... 46
7.1.2. Temporary  Discont inuat ion........................................................................................ 47
7.2. Parti cipant Discontinuation/Wit hdrawal fro m the Study ............................................. 47
7.2.1. Discontinuati on of  Inadvertent ly Enrolled Participants ............................................... 48
7.3. Lost to Follow -up....................................................................................................... 48
8. Study Assessments and Procedures ......................................................................... 50
8.1. Efficacy Assessments .................................................................................................50
8.1.1. Primary Efficacy  Assessments .................................................................................... 50
8.1.2. Secondary  Efficacy  Assessments ................................................................................ 50
8.2. Safety Assessments .................................................................................................... 50
8.2.1. Physical Examinat ions................................................................................................ 50
8.2.2. Vital Signs.................................................................................................................. 50
8.2.3. Electrocardiograms ..................................................................................................... 51
8.2.4. Self-monitoring o f Blood Gl ucose (SMBG) ................................................................ 51
8.2.5. Safety Moni toring ....................................................................................................... 52
8.2.6. Clinical Safety  Laboratory  Assessments ..................................................................... 52
8.2.7. Body  Weight .............................................................................................................. 53
8.3. Adverse Events and Serious Adverse Events .............................................................. 53
8.3.1. Time Period and Frequency  for Collect ing AE and SAE 
Inform ation................................................................................................................. 53
8.3.2. Method of Detecting AEs and SAEs ........................................................................... 54
8.3.3. Follow-up of  AEs and SAEs ....................................................................................... 54
8.3.4. Regulatory  Reporting Requirements for SAEs ............................................................ 54
8.3.5. Pregnancy ................................................................................................................... 54
8.3.6. Cardi ovascular Events ................................................................................................ 55
8.3.7. Adverse Events of Special Interest .............................................................................. 55
8.3.8. Product Complaint s.................................................................................................... 56
8.4. Treatment of Overdose ............................................................................................... 57
8.5. Pharmacokinet ics........................................................................................................ 57
8.6. Pharmacodynamics ..................................................................................................... 57
8.7. Genet ics..................................................................................................................... 58
8.8. Biomarkers ................................................................................................................. 58
8.9. Immunogenicit y Assessments ..................................................................................... 58
8.10. Health Economics ....................................................................................................... 59
9. Statist ical Considerations ......................................................................................... 60
9.1. Statistical Hypotheses .................................................................................................60
9.2. Sample Si ze Determinat ion......................................................................................... 60
9.3. Popul ations for Analyses ............................................................................................ 61
9.4. Statistical Analyses ..................................................................................................... 61
9.4.1. General Considerations ............................................................................................... 62
9.4.2. Treatment Group Comparabilit y................................................................................. 62
9.4.3. Primary endpo int(s).................................................................................................... 63
9.4.4. Secondary  endpoint(s) ................................................................................................ 63
9.4.5. Terti ary/expl oratory  endpoint(s) ................................................................................. 63
9.4.6. Safety Analyse(s) ........................................................................................................ 63
CONFIDENTIAL I8H-MC-BDCL (d)
LY3209590 69.4.7. Pharmacokinet ic/Pharmacodynamic Analyses ............................................................ 64
9.4.8. Evaluat ion of Immunogenicit y.................................................................................... 65
9.4.9. Other Analyses ........................................................................................................... 65
9.5. Interim Analyses ......................................................................................................... 65
9.6. Data Monitoring Com mittee (DMC) ........................................................................... 65
10. Supporting Documentation and Operational Considerations ................................ 66
10.1. Appendix 1:  Regulatory , Ethi cal, and Study  Oversight 
Considerations ............................................................................................................ 66
10.1.1. Regulatory  and Ethi cal Considerat ions........................................................................ 66
10.1.2. Financial Disclo sure................................................................................................... 67
10.1.3. Inform ed Consent Process .......................................................................................... 67
10.1.4. Data Protection ........................................................................................................... 67
10.1.5. Disseminat ion of Clinical Study  Data ......................................................................... 67
10.1.6. Data Qualit y Assurance .............................................................................................. 68
10.1.7. Source Documents ...................................................................................................... 70
10.1.8. Study  and Si te Start and Cl osure ................................................................................. 70
10.1.9. Publicat ion Policy....................................................................................................... 71
10.1.10. Invest igator Informat ion............................................................................................. 71
10.1.11. Long -Term  Sample Retent ion..................................................................................... 71
10.2. Appendix 2:  Clinical Laboratory  Tests ....................................................................... 72
10.3. Appendix 3:  Adverse Events:  Definit ions and Procedures for 
Recording, Eval uating, Follow -up, and Reporting ....................................................... 75
10.3.1. Definit ion of AE......................................................................................................... 75
10.3.2. Definit ion of SAE ....................................................................................................... 76
10.3.3. Recording and Fo llow
-Up of AE and/or SAE ............................................................. 77
10.3.4. Reporting of SAEs ...................................................................................................... 79
10.4. Appendix 4:  Contraceptive Guidance and Collection of 
Pregnancy Information ............................................................................................... 80
10.5. Appendix 5:  Liver Safet y:  Suggested Acti ons and Follow -up 
Assessments ............................................................................................................... 82
10.6. Appendix 6:  New York Heart Associat ion Cardiac Disease 
Classificat ion.............................................................................................................. 83
10.7. Appendix 7:  Genet ics................................................................................................ 84
10.8. Appendix 8:  Dosing Guidance for LY3209590 and Insulin 
Degl udec .................................................................................................................... 85
10.8.1. LY3209590 Algorithm 1 (paper algorithm) .................................................................85
10.8.2. Insulin Degludec ......................................................................................................... 87
10.9. Appendix 9:  Recommended Laboratory  Testing for 
Hypersensi tivity Events .............................................................................................. 90
10.10. Appendix 10:  C hanges to Study  Procedures due to the COVID -
19 Pandemic or Natural Disasters ............................................................................... 92
10.11. Appendix 11:  Abbreviat ions...................................................................................... 94
10.12. Appendix 12:  Protocol Amendment History .............................................................. 98
11. References ............................................................................................................... 102
CONFIDENTIAL I8H-MC-BDCL (d)
LY3209590 71. Protocol Summary
1.1. Synopsis
Protocol Title: A Phase 2, Parallel, Comparator -Controlled Trial to Evaluate the Safe ty and 
Efficacy of LY3209590 in Insulin -Naïve Pat ients with Type 2 Di abetes Mellitus
Short Title: A Study  of LY3209590 in Participants with Type 2 Di abetes Mellitus
Rationale :
This study  will evaluate LY3209590 i n insulin -naïve patients with type 2 diabetes m ellitus 
(T2DM ), com pared wi th insulin degludec .  
The study  will last 26 weeks to have an adequate duration of exposure necessary to posit ively 
exclude any increase in ALT, as has been observed with a previous daily pegylated basal insulin 
lispro with a predominant ly hepat ic pharmacodynamic (PD) profile. 
Insulin degludec is an unblinded active comparator in this study  and will  be used to com pare the 
effects of LY3209590 on glycemic control, hypoglycemia, and weight gain with a daily basal 
insulin .
CONFIDENTIAL I8H-MC-BDCL (d)
LY3209590 8Objectives and Endpoint s
Object ives Endpoints
Primary
To investigate the efficacy  of 
LY3209590 compared wit h insulin
degludec in study  parti cipants with 
T2DMHbA1c change fro m baseline to 
Week 26
Secondary
Efficacy
To investigate the efficacy  of 
LY3209590 compared wit h insulin
degludec in study  parti cipants with 
T2DMHbA1c change fro m baseline to 
Week 12
Fasting glucose change fro m baseline 
to Weeks 12 and 26
Safety
To investigate the safet y of 
LY3209590 compared wit h insulin
degludec in study  participants with 
T2DMIncidence and rate of hypoglycemia 
events during the treatm ent peri od
Incidence of treatment -emergent 
serious adverse events 
Pharmacokinet ics 
To characterize the PK o f LY3209590 
and potenti al intrinsic and extrinsic 
factors i n study  partici pants with 
T2DMSteady  state AUC at Week 26
Abbreviations:  AUC = area under the curve ; HbA1c = hemoglobin A1c ; PK = pharmacokinetics ; T2DM = type 2 
diabetes mellitus.
CONFIDENTIAL I8H-MC-BDCL (d)
LY3209590 9Overall Design :
Study  I8H-MC-BDCL is a multicenter, randomized, open -label, parallel , comparator -controlled 
Phase 2 study  with 3 study  periods.  The study  is designed to eval uate the efficacy and safet y of 
LY3209590 compared wi th insulin degludec in patients with T2DM treated with a stable dose of 
metformin (alone or in combination wit h a stable dose of a DPPIV inhibitor and/or a SGLT2 
inhibitor) for at least 3 months prior to screening .
Disclosure Statement : This is a parallel, open -label , treatm entstudy  with2groups .
Number of Participant s:
Approximately  250 participants will be rando mly assigned to study  interventi onssuch that 
approximately  200 evaluable partici pants com plete the study . 
Intervention Groups and Duration :
Parti cipants will be randomized in a 1:1 ratio to receive the interventions listed below :
LY3209590 subcutaneously weekly, dosed per Algorithm 1 (Paper)
Insulin degludec subcutaneously  daily , dosed per a m odified Riddle al gorithm
The m aximum  total  durati on of  study  participat ion for each participant is up to 
33 weeks, across 
the following study  periods: 
Study  Period 1:  screening and lead -in period, approximately 2 weeks
Study  Period 2:  treatm ent peri od, 26 weeks
Study  Period 3:  safety  follow-up peri od, 5 weeks
Data Monitoring Committee : No
CONFIDENTIAL I8H-MC-BDCL (d)
LY3209590 101.2     Schema

CONFIDENTIAL I8H-MC-BDCL (d)
LY3209590 111.3. Schedule of Activities (SoA)
ProcedureStudy 
Period 1
Screen -
ingand
Lead -inStudy Period 2
Treatment PeriodEarly 
Discontinu -
ationStudy 
Period 
3
Follow
-upET Notes
eCRF Visit 
Number1 23
a 4 5 6 7 8 9 10 11 12 13 14 15 16b17 18 1920
cED1
c ED2c801c
Weeks -2 -1 0 1 2 3 4 5 6 7 8 9 10 11 12 14 16 20 24 26ED1
+531
Visit 
window, 
days±7 ±3 ±2 ±2±
3±2 ±2 ±3 ±2 ±2 ±2 ±2 ±2 ±3 ±3 ±3 ±3 ±3 ±3 ±3 ±3 ±3
Fasting X X X X X X X X X X X XMinimum 8 
hours
Informed 
consentX
Inclusion 
and 
exclusion 
criteriaX
Randomiz -
ationX
CONFIDENTIAL I8H-MC-BDCL (d)
LY3209590 12ProcedureStudy 
Period 1
Screen -
ingand
Lead -inStudy Period 2
Treatment PeriodEarly 
Discontinu -
ationStudy 
Period 
3
Follow
-upET Notes
eCRF Visit 
Number1 23
a 4 5 6 7 8 9 10 11 12 13 14 15 16b17 18 1920
cED1
c ED2c801c
Weeks -2 -1 0 1 2 3 4 5 6 7 8 9 10 11 12 14 16 20 24 26ED1
+531
Visit 
window, 
days±7 ±3 ±2 ±2±
3±2 ±2 ±3 ±2 ±2 ±2 ±2 ±2 ±3 ±3 ±3 ±3 ±3 ±3 ±3 ±3 ±3
Fasting X X X X X X X X X X X XMinimum 8 
hours
Clinical Assessments
Height X
Body 
weightX X X X X X X X X X X XSee Section 
8.2.6
Blood 
pressure 
and pulse 
rateX X X X X X X X X X X XSee Section 
8.2.2.
Demo -
graphyX
Medical 
history 
(includes 
substance 
usage and 
family 
history of 
premature 
CV disease )XSubstances: 
drugs, 
alcohol, 
tobacco ,and 
caffeine
Pre-existing 
conditions   X X X
CONFIDENTIAL I8H-MC-BDCL (d)
LY3209590 13ProcedureStudy 
Period 1
Screen -
ingand
Lead -inStudy Period 2
Treatment PeriodEarly 
Discontinu -
ationStudy 
Period 
3
Follow
-upET Notes
eCRF Visit 
Number1 23
a 4 5 6 7 8 9 10 11 12 13 14 15 16b17 18 1920
cED1
c ED2c801c
Weeks -2 -1 0 1 2 3 4 5 6 7 8 9 10 11 12 14 16 20 24 26ED1
+531
Visit 
window, 
days±7 ±3 ±2 ±2±
3±2 ±2 ±3 ±2 ±2 ±2 ±2 ±2 ±3 ±3 ±3 ±3 ±3 ±3 ±3 ±3 ±3
Fasting X X X X X X X X X X X XMinimum 8 
hours
Concomi -
tant 
medication 
reviewX X X X X X X X X X X X
Full 
physical 
examinatio
nX X X X X X
12-lead 
ECGXX
dX
dX
dX
dX
d X X X X X
AE/SAE /P
CreviewX X X X X X X X X X X X X X X X X X X X X X
Laboratory Assessments
Pharmaco -
kinetic 
samples 
(LY3209590)X
eX X X X X X X X X X X XCollected for 
participants 
randomized 
to 
LY3209590.  
See Section 
8.5
CONFIDENTIAL I8H-MC-BDCL (d)
LY3209590 14ProcedureStudy 
Period 1
Screen -
ingand
Lead -inStudy Period 2
Treatment PeriodEarly 
Discontinu -
ationStudy 
Period 
3
Follow
-upET Notes
eCRF Visit 
Number1 23
a 4 5 6 7 8 9 10 11 12 13 14 15 16b17 18 1920
cED1
c ED2c801c
Weeks -2 -1 0 1 2 3 4 5 6 7 8 9 10 11 12 14 16 20 24 26ED1
+531
Visit 
window, 
days±7 ±3 ±2 ±2±
3±2 ±2 ±3 ±2 ±2 ±2 ±2 ±2 ±3 ±3 ±3 ±3 ±3 ±3 ±3 ±3 ±3
Fasting X X X X X X X X X X X XMinimum 8 
hours
Serum 
pregnancy 
test (WCBP 
only)XSee Section 
5.1.
Urine 
pregnancy 
test (WCBP 
only) 
(local)X X X XAdditional 
pregnancy 
testing may 
be performed 
if required by 
local 
regulations.
FSH XCollect for 
women 
whose 
menopausal 
status needs 
to be 
determined.  
If menopausal 
status is 
known, this
test do esnot 
need to be 
collected.
Urinalysis X X X X X X
CONFIDENTIAL I8H-MC-BDCL (d)
LY3209590 15ProcedureStudy 
Period 1
Screen -
ingand
Lead -inStudy Period 2
Treatment PeriodEarly 
Discontinu -
ationStudy 
Period 
3
Follow
-upET Notes
eCRF Visit 
Number1 23
a 4 5 6 7 8 9 10 11 12 13 14 15 16b17 18 1920
cED1
c ED2c801c
Weeks -2 -1 0 1 2 3 4 5 6 7 8 9 10 11 12 14 16 20 24 26ED1
+531
Visit 
window, 
days±7 ±3 ±2 ±2±
3±2 ±2 ±3 ±2 ±2 ±2 ±2 ±2 ±3 ±3 ±3 ±3 ±3 ±3 ±3 ±3 ±3
Fasting X X X X X X X X X X X XMinimum 8 
hours
eGFR X X X X
Chemistry
panelX X X X X X X X X X X X X
Hepatitis B X
HbA1c X X X X X X X X
Hemat -
ologyX X X X X X X X X X
Lipid Panel 
-X X X X X X X X
Pancreatic 
amylase 
and LipaseX
Free fatty 
acid X X X X X X X X X X X X
Immuno -
genicityX X X X X X X X XSee Section 
8.9.
C-peptide X X X X
CONFIDENTIAL I8H-MC-BDCL (d)
LY3209590 16ProcedureStudy 
Period 1
Screen -
ingand
Lead -inStudy Period 2
Treatment PeriodEarly 
Discontinu -
ationStudy 
Period 
3
Follow
-upET Notes
eCRF Visit 
Number1 23
a 4 5 6 7 8 9 10 11 12 13 14 15 16b17 18 1920
cED1
c ED2c801c
Weeks -2 -1 0 1 2 3 4 5 6 7 8 9 10 11 12 14 16 20 24 26ED1
+531
Visit 
window, 
days±7 ±3 ±2 ±2±
3±2 ±2 ±3 ±2 ±2 ±2 ±2 ±2 ±3 ±3 ±3 ±3 ±3 ±3 ±3 ±3 ±3
Fasting X X X X X X X X X X X XMinimum 8 
hours
Pharmaco -
genetic 
sampleX
Nonpharma
cogenetic 
Stored 
Samples X X X X X X X X X X
Ancillary Supplies/
Diaries/
Investigational Product
Study  
participant
training/
educationXIncludes 
diabetes 
counseling, 
hypoglycemia
(8.3.7.1 ), BG 
meter, 6-point 
SMBG 
profiles, and 
diary 
completion.
CONFIDENTIAL I8H-MC-BDCL (d)
LY3209590 17ProcedureStudy 
Period 1
Screen -
ingand
Lead -inStudy Period 2
Treatment PeriodEarly 
Discontinu -
ationStudy 
Period 
3
Follow
-upET Notes
eCRF Visit 
Number1 23
a 4 5 6 7 8 9 10 11 12 13 14 15 16b17 18 1920
cED1
c ED2c801c
Weeks -2 -1 0 1 2 3 4 5 6 7 8 9 10 11 12 14 16 20 24 26ED1
+531
Visit 
window, 
days±7 ±3 ±2 ±2±
3±2 ±2 ±3 ±2 ±2 ±2 ±2 ±2 ±3 ±3 ±3 ±3 ±3 ±3 ±3 ±3 ±3
Fasting X X X X X X X X X X X XMinimum 8 
hours
Dispense 
BG meter 
and/or 
suppliesX X X X X X X XParticipant 
diaries will be 
visit specific.  
All of the 
diaries will be 
electronic.
IWRS X X X X X X X X X X X X X X X X X X X X X X X X
Remind 
Patient to 
perform 
6-point 
SMBG 
profiles 
prior to 
next visitX X X X XX X X
Review 
6-point 
SMBG 
profiles X X X X XX X X XSee next line 
for indicated 
visits.  See 
Section 4.1.1
for additional 
details.
CONFIDENTIAL I8H-MC-BDCL (d)
LY3209590 18ProcedureStudy 
Period 1
Screen -
ingand
Lead -inStudy Period 2
Treatment PeriodEarly 
Discontinu -
ationStudy 
Period 
3
Follow
-upET Notes
eCRF Visit 
Number1 23
a 4 5 6 7 8 9 10 11 12 13 14 15 16b17 18 1920
cED1
c ED2c801c
Weeks -2 -1 0 1 2 3 4 5 6 7 8 9 10 11 12 14 16 20 24 26ED1
+531
Visit 
window, 
days±7 ±3 ±2 ±2±
3±2 ±2 ±3 ±2 ±2 ±2 ±2 ±2 ±3 ±3 ±3 ±3 ±3 ±3 ±3 ±3 ±3
Fasting X X X X X X X X X X X XMinimum 8 
hours
Review 
SMBG, basal 
insulin dose, 
and hypo 
data to make 
dose 
individualiz -
ation 
assessment X X X X X X X X X X X X X X X XAssessment 
performed per 
participant 
assigned group 
(Algorithm 1 or 
insulin 
degludec)
Insert and 
Activate 
FGM 
SensorX X XPatients 
should be 
instructed to 
avoid 
immersio n 
in water 
greater than 
3 feet 
(1meter) or 
for periods
longer than 
30 minutes.
CONFIDENTIAL I8H-MC-BDCL (d)
LY3209590 19ProcedureStudy 
Period 1
Screen -
ingand
Lead -inStudy Period 2
Treatment PeriodEarly 
Discontinu -
ationStudy 
Period 
3
Follow
-upET Notes
eCRF Visit 
Number1 23
a 4 5 6 7 8 9 10 11 12 13 14 15 16b17 18 1920
cED1
c ED2c801c
Weeks -2 -1 0 1 2 3 4 5 6 7 8 9 10 11 12 14 16 20 24 26ED1
+531
Visit 
window, 
days±7 ±3 ±2 ±2±
3±2 ±2 ±3 ±2 ±2 ±2 ±2 ±2 ±3 ±3 ±3 ±3 ±3 ±3 ±3 ±3 ±3
Fasting X X X X X X X X X X X XMinimum 8 
hours
Remove 
FGM 
Sensor and 
site upload 
dataX X X X XRemove at 
ET if 
applicable.
Patients 
should not 
wear sensor 
longer than 
14days and if 
visit interval 
is >14 days, 
patient should 
be instructed 
to remove the 
sensor and 
bring to the 
visit.
Dispense IP X X X X X X X X X X X X X X
Study  
personnel 
administer 
IP at siteX X X X X X X X X
CONFIDENTIAL I8H-MC-BDCL (d)
LY3209590 20ProcedureStudy 
Period 1
Screen -
ingand
Lead -inStudy Period 2
Treatment PeriodEarly 
Discontinu -
ationStudy 
Period 
3
Follow
-upET Notes
eCRF Visit 
Number1 23
a 4 5 6 7 8 9 10 11 12 13 14 15 16b17 18 1920
cED1
c ED2c801c
Weeks -2 -1 0 1 2 3 4 5 6 7 8 9 10 11 12 14 16 20 24 26ED1
+531
Visit 
window, 
days±7 ±3 ±2 ±2±
3±2 ±2 ±3 ±2 ±2 ±2 ±2 ±2 ±3 ±3 ±3 ±3 ±3 ±3 ±3 ±3 ±3
Fasting X X X X X X X X X X X XMinimum 8 
hours
Train 
participants
in IP 
administrati
onX X X X X X XInformation 
on self -
injection can 
be reviewed 
as necessary 
throughout 
the study .
Participant 
or study 
personnel 
administer 
at siteX X X X XWeeks 13 -25:
participants 
may self-
administer 
injection at 
home or have 
injection done 
at site.
LY3209590 
and 
degludec 
accounta -
bility 
(collect 
used and 
unused IP)X X X X
CONFIDENTIAL I8H-MC-BDCL (d)
LY3209590 21Abbreviations:  AE = adverse event; BG = blood glucose; CV = cardiovascular; ECG = electrocardiogram; eCRF = electronic case report form; ED =early 
discontinuation ; eGFR = estimated glomerular filtration rate; ET = early termination; FG = fasting  glucose; FGM = flash glucose monitoring; 
FSH = follicle -stimulating hormone ;HbA1c = glycated hemoglobin; HDL = high density lipoprotein ; IP = investigational product; IWRS = interactive web 
response system; LDL = low density lipoprotein; LY = LY3209590; PC = product complaints; PK = pharmacokinetics; SAE = serious adverse event; 
SMBG =self-monito ring blood glucose; WCBP = women of child bearing potential.
aAll measures to be performed at Visit 3 should be done p rior to injection of the participant ’s assigned investigational product (IP) to ensure that appropriate 
baseline measurements are obtained.
bVisit 16 is a Phone visit .
cVisits 20 and ED1 are performed approximately 1 week after the last dose of LY and 1 day after the last dose of insulin degludec.  V isit 801 is performed for 
participants who complete V isit 20.  ED1 and ED2 are performed for participants who discontinue st udy drug but remain in the study.  
dA triplicate, central ECG will be performed in a fasting state at Visits 3, 6, 9, 15, and 17 ,prior to each PK sample. Patients randomized to insulin degludec 
treatment will undergo ECG in a fasting state without PK s ampling. Only one triplicate ECG is needed for insulin degl udec treated patients.
eCollect 2 PK samples of LY3209590 :  one predose and one approximately 2 hours postdose or as late as possible just prior to departure from the site.  ECG 
will be performed in triplicate prior to the time of each PK sampling at this visit. Note:  PK samples are not intended to be collected for participants in the 
insulin degludec treatment group.
Note:  Additional visits to ensure correct dosing, titration and study drug administration can occur anytime during the study if dee med necessary by the 
investigator and are explicitly allowed and part of the protocol.
CO N FI D E N TI A L I 8 H -M C -B D C L ( d) 
L Y 3 2 0 9 5 9 0 2 2 2. I ntr o d uct i o n 
2. 1. St u d y R ati o n ale 
L Y 3 2 0 9 5 9 0 is a l o n g -acti n g i ns uli n rece pt or a g o nist bei n g de vel o pe d f o r t he treat m e nt of t y pe 2 
di a betes m elli t us ( T 2 D M).   T his P hase 2 st u d y  of  L Y 3 2 0 9 5 9 0 will e val uate t he effects of 
L Y 3 2 0 9 5 9 0 o n gl yce mic c o ntr ol c o m pare d wit h i ns uli n de gl u dec i n i ns uli n -naï ve pat ie nt s. 
2. 2. B ac k gr o u n d 
L Y 3 2 0 9 5 9 0 was desi g ne d as a n o vel, o nce -wee kl y, l o n g- act i n g i ns uli n rece pt or a g o nist t hat is 
i nt e n de d f or t he treat me nt of h y per gl yce mia i n st u d y  p arti ci pa nts wi t h  T 2 D M. A o nce -wee kl y 
i ns uli n rece pt or a g o nist has t he p ote ntial t o i ncrease willi n g ness t o i nit iate a n d i m pr o ve 
c o m plia nce wi t h a n i ns uli n t hera p y  i n st u d y  p arti ci pa nts wi t h  T 2 D M. I n real life ,o nl y a b o ut 
2 5 % t h ese st u d y  p arti ci pa nts reac h t he tar get he m o gl o bi n A 1c ( H b A 1c )of 7 % ( Bl o n de et al . 
2 0 1 4) , a n d a o nce -wee kl y i ns uli n rece pt or a g o nist c o ul d hel p t o i ncrease t his n u m ber. T he 
p ote nti al  d o w nsi de of s uc h a l o n g -act i n g i ns uli n rece pt or a g o nist c o ul d t h e or eti call y  be a hi g her 
ri s k f or h y p o gl yce mic e ve nts or a l o n ger d urati on of s uc h e ve nts. I n c o ntrast t o t his t he oretical 
ri s k t he rece nt l y la u nc he d l o n g -act i n g i ns uli n de gl u dec has s h o w n a re d uce d p ote ntial t o i n d uce 
h y p o gl yce mia as c o m pare d t o i ns uli n glar gi ne w hile its half -life is t wice as l o n g as t hat of i ns uli n 
gl ar gi ne ( Heise et al. 2 0 1 2 ). T he c urre nt P hase 2 st u d y will t heref ore e val uate t he safet y  a n d 
efficac y  of  L Y 3 2 0 9 5 9 0 as c o m pare d t o i ns uli n de gl u dec w hile ver y  cl osel y m o ni t ori n g gl yce mic 
pr ofiles. 
Data fr o m , w hic h was t h e si n gle -asce n di n g d ose ( S A D) st u d y ,
d e m o nstrate d cl ear e vi de nce of gl uc ose l o weri n g i n st u d y  p arti ci pa nts wi t h  T 2 D M f o ll o wi n g 
si n gle d oses of  L Y 3 2 0 9 5 9 0 ra n gi n g fr o m  m g. T he p har mac o ki net ics ( P K) of 
L Y 3 2 0 9 5 9 0 f o ll o wi n g si n gle d oses de m o nstrate d pr ol o n ge d ti me -act i o npr ofile t o s u p p ort o nce -
wee kl y a d mi nistrati o n. L Y 3 2 0 9 5 9 0 reac he d ma xi m u m c o nce ntrati o n a p pr o xi matel y  4 da ys after 
d osi n g, f o ll o we d b y  a mea n eli mi nat i o n  
i n st u d y  p arti ci pa nts wi t h  T 2 D M . Wit h a l o n g eli mi nat i o n half -life, f o ll o wi n g a wee kl y  
fi xe d -d ose re gi me n, P K stea d y -state wa spre dicte d t o be reac he d i n  
wi t h a p pr o xi matel y  hi g her c o nce ntrati o n d ue t o acc u m ulati o n t h a n after a si n gle d ose. 
T heref ore ,base d o n P K m o deli n g a si n gle l o a di n g d ose strate g y  usi n g ti mes t he wee kl y  d ose 
w o ul d ac hie ve stea d y -state e x p os ure after 1d ose. Base d o n data i n St u d y  I 8 H -M C -B D C B 
( B D C B) , t he m ul ti ple -asce n di n g d ose ( M A D) st u d y , P K  f ol l o wi n g a si n gle l oa di n g d ose ( t h e 
i nit ial wee kl y d ose) d uri n g t he first wee k was de m o nstrate d t o be c o m para ble t o c o nce ntrati o n 
pr ofile at Wee k 6 (at d ose deli vere d o nce wee kl y) , s u p p orti n g t he l oa di n g d ose strate g y .N o 
cli nicall y si g nifica nt persiste nce i n h y p o gl yce mia was o bser ve d i n t he st u d y. Besi des t he k n o w n 
ri s k of h y p o gl yce mia, n o rele va nt safet y si g nals ha ve bee n o bser ve d i n t he P hase 1 st u dies. 
T he t o xi ci t y  pr ofile of L Y 3 2 0 9 5 9 0 has bee n c haracterize d i n 6 -wee k a n d 6 -m o nt h re peat -d ose 
t o xi c o l o g y  st u di es i n rats a n d d o gs, a n d re pr o d ucti ve t o xic o l o g y  st u di es i n rats a n d ra b bits. 
T hese st u dies de m o nstrate d a fa miliar s pectr u m  of  effects t y picall y ass oci ate d wi t h  c ha n ges 
sec o n dar y t o h y p o gl yce mia a n d/ or h y peri ns uli ne mia res ul ti n g fr o m  re peat d osi n g of e x o ge n o us C CI 
C CI 
C CI 
C CI 
C CI 
C CI 
C CI 
C CI 
CONFIDENTIAL I8H-MC-BDCL (d)
LY3209590 23insulin in norm oglycemic test systems. All findings were considered to be target -related wi th no
evidence of off -target effects in any of the parameters assessed. 
Additional information about LY3209590 can be found in the Invest igator’s Brochure (IB).
2.3. Benefit/R isk Assessment
The data from the SAD study  and the MAD study  (Studies BDCA and BDCB , respectively ) have
shown that LY3209590 was well tolerated and the adverse drug reactions are in line with those
reported for long- acting insulins.
Potenti al risks associa ted wi th LY3209590, deriv ed from the known ri sks of l ong-acting insulins
are hypoglycemia, hypersensit ivity react ions (localized allergy and/or sy stemic allergy ),
undesirable effects at the inject ion site (inject ion
-site reacti ons and lipody strophy ), and
peripheral  edema. Except for hypoglycemia, no other known risks o f insulin therapy have been 
observed to date in study  parti cipants or healthy volunteers exposed to LY3209590 for up to 
12weeks.
Taking into account the measures taken to minimize risk to participants participat ing in this 
study , the potenti al risks i dentified in associat ion with LY3209590 are justified by the 
anticipated benefits that may be afforded t o parti cipants wi th T2DM .
More informat ion about the known and expected benefits, risks, serious adverse events (SAE s
),
and reasonably ant icipated adverse events ( AEs)of LY3209590 may be found in the I B.
The Algori thm 1 (paper) wasdeveloped to init iate and guide LY3209590 dose adjust ment for 
this stud y to safely and efficient ly achieve gly cemic goal s. 
2.3.1. Protocol Risk Mitigation Features 
Methods to minimize potential risks are relevant for parti cipants assigned to LY3209590
Algori thm 1 and insulin degludec treatment groups.  These include
Thorough training on the protocol design elements and inclusion/exclusio n criteria; use 
of an electroni c diary ( eDiary ), aweb-interface and reporting system alo ng with 
availabilit y of associ ated instruction manuals and reference documents .
Careful data validat ion:  After patient -reported data has been entered and synced 
remotely  to the central  web server, the investigator is able to view the data through the 
web portal and generate summary  reports.  An important feature of the study  requi res
careful review of the reported informat ion with the pati ent and verificat ion of its 
accuracy  at each study  visit. 
Email notification to invest igator any time the patient reports a potential severe episode 
of hypoglycemia (requiring assistance due to neur ologi cal impairment) in the eDiary .
Specific criteria for fast ing or persistent hy perglycemia are described protocol 
Section6.1.2.3 .
Importantly, in both treatm ent groups, the final dosing decisio ns remain subject to clinical 
judgement of the invest igator.  Decisions to override an algorithm -recommended dose are 
docum ented in the electroni c case report form ( eCRF )for Algorithm 1 and insulin d egludec .
CONFIDENTIAL I8H-MC-BDCL (d)
LY3209590 243. Objectives and Endpoints
Object ives Endpoints
Primary
To investigate the efficacy  of 
LY3209590 compared wit h insulin
degludec in study  parti cipants with 
T2DMHbA1c change fro m baseline to 
Week 26
Secondary
Efficacy
To investigate the efficacy  of 
LY3209590 compared wit h insulin
degludec in study  parti cipants with 
T2DMHbA1c change fro m baseline to 
Week 12
Fasting glucose change fro m baseline 
to Weeks 12 and 26
Safety
To investigate the safet y of 
LY3209590 compared wit h insulin
degludec in study  participants with 
T2DMIncidence and rate of hypoglycemia 
events during the treatment period
Incidence of treatment -emergent 
serious adverse events 
Pharmacokinet ics 
To characterize the PK o f LY3209590 
and potenti al intrinsic and extrinsic 
factors in study  partici pants with 
T2DMSteady  state AUC at Week 26
Tertiary/Exploratory
To establish the equivalent dose of 
LY3209590 relat ive to insulin 
degludecInsulin dose at baseline and Week 26
To investigate the safet y and 
tolerabilit y of LY3209590 compared 
with insulin degludec in study  
participants with T2DMTreatment -emergent adverse events 
Incidence and rate of hypoglycemia 
events during the post-treatm ent 
follow-up period
Discontinuati on of  IP due to adverse 
events 
Clinical laboratory  resul ts
Inject ion site react ions
Liver aminotransferase change fro m 
baseline to Weeks 12 and 26
Triglyceride and FFA change from 
baseline to Weeks 12 and 26
CONFIDENTIAL I8H-MC-BDCL (d)
LY3209590 25Object ives Endpoints
Body  weight change from  baseline at 
Weeks 12 and 26
To establish the relat ionships between 
dose/exposure and key  safet y and 
efficacy  measures for LY3209590 LY3209590 exposure -response 
relationships for key  efficacy and 
safet y measures (e.g. ,glycemic 
control , hypoglycemia and safety 
labs).
To characterize the effects of 
LY3209590 on exploratory  PD 
biomarkersLipids (cho lesterol , LDL, HDL, 
triglyceri des)
Biomarkers of lipolysis (FFA)
SMBG gl ucose profiles
To characterize Cont inuous Glucose 
Moni toring Param eters derived from 
FGMVarious param eters derived fro m FGM 
(for example average daily glucose , 
Time in target range 70 to 180mg/dL, 
time in hyperglycemia, time in 
hypoglycemia)
To expl ore the development of 
LY3209590 ADAsThe frequency of ant ibody  formati on 
to LY3209590 and relat ionship to 
safet y and efficacy markers will be 
determined.
To explore the compliance wit h the 
dosing regimenIncidence and percentage of missed 
doses of LY3209590 and insulin 
degludec.
Abbreviation s:  ADA =antidrug antibodies; AUC =area under the curve; FFA =free fatty acids; FGM = flash 
glucose monitoring; HbA1c =glycated hemoglobin; HDL =high density lipoprotein; IP=investigational 
product; LDL =low density lipoprotein; PD =pharmacodynamics; PK =pharmacokinetics ;SMBG =self-
monitor ingblood glucose; T2DM =type 2 diabetes me llitus.
CONFIDENTIAL I8H-MC-BDCL (d)
LY3209590 264. Study Design
4.1. Overall Design
Study  I8H-MC-BDCL (BDCL) is a multicenter, rando mized, open -label, parallel, comparator -
controlled Phase 2 study  with 3 study  periods. The study  is designed to evaluate the efficacy and 
safet y of LY3209590 compared wi th insulin degludec in patient s with T2DM treated wi th a 
stable dose of metformin (alo ne or in co mbinat ion with a stable dose of a DPPIV inhibitor and/or 
a SGLT2 inhibitor) for at least 3 months prior to screening .
The study  will consist of 3 peri ods:  
Study  Period 1:  screening and l ead-in period,approximately  2 weeks
Study  Period 2:  treatm ent peri od,26weeks
Study  Period 3:  safety  follow-up peri od,5weeks
The study  schema is presented in Sect ion 1.2.
Study  governance considerations are described in detail in Section10.1.
4.1.1. Study Visit s
Study Period 1: Screening and Lead -in
The purpose of procedures at screening is to establish eligibilit y for incl usion in the study  (see 
Secti ons 5.1and 5.2).  During this period (upon signing the informed consent form [ ICF]) , study  
participants will be trained on disease monitoring and disease management procedures, study  
diaries ,and study  procedures. For all part icipants meet ing study  entry  criteria except for 
reporting of screening clinical laboratory  assessments, a LibrePro sensor for flash gluco se 
monitoring ( FGM )will be inserted and activated at Visit 1 for baseline FGM assessment.  If the 
patientis ult imately determined a screen failure, the sensor can be removed and discarded or the 
patientcan continue wearing for up to 14 day s and return t o the si te for reading and diagnostics.   
All confirmed eligible partici pants shoul d continue wearing the sensor for up to 14 days and to 
wear the sensor to Visit 3 for removal or bring the sensor with them to Visit 3 if this visit occurs 
longer than 14 days after insertion.
Electronic participant diaries and parti cipant paper note sheet swill be dispensed at Visit 2 and as 
specified in the Schedule of Act ivities (Section 1.3)for future vi sits. Collect ion of baseline self-
monitoring bl ood gl ucose ( SMBG )profiles will start at V isit 2. P articipants on m etformin (alone 
or in co mbination wit h a stable dose of a DPPIV inhibitor and/or a SGLT2 inhibitor) will 
continue on their same dose to allow reliable assessment of HbA1c at ra ndomizat ion.
If partici pants develop a condit ion that i s a contraindicat ion for the use of met formin, a DPPIV 
inhibitor and/or a SGLT2 inhibitor (if used at screening) or init iate other agents that are 
prohibited (see table in Sect ion6.5andSecti ons 5.1and 5.2for further details) between 
screening and randomization, they  will be considered ineligible and will be discont inued fro m 
the trial before randomization.  
SMBG :
All patients will be provided with ident ical blood glucose meters for taking self -monitored 
plasma gl ucose m easurements during the outpatient period at Visit 2.
CONFIDENTIAL I8H-MC-BDCL (d)
LY3209590 27Study Period 2: Treatment Period
Randomization (Week 0 [Visit 3])
Parti cipants who continue to be eligible for the study  will be rando mized to 1 of the 2 treatm ent 
groups .  All measures , including a urine pregnancy test, to be performed at Visit 3 (see Schedule 
of Activities, Secti on 1.3) should be done prior to inject ion of the participant ’s assigned 
investigat ional product (IP) to ensure that appropriate baseline measurements are obtained. The 
FGM sensor should also be removed prior to study treatment and data from  the sensor upl oaded 
by the site .  The participant will begin IP if the urine pregnancy test is negative. If the result of 
the serum  pregnancy test i s posi tive, the participant will be discont inued from the study (see 
Secti on7.2).
Study  personnel will inject the first dose of IP at the study  site.  The PK sample and 
electrocardi ogram s (ECGs) at randomizat ion must be co llected as described in the Schedule of 
Activities (Secti on 1.3).
Treatment
Following rando mizat ion, participants will participate in a 26-week trea tment peri od. 
For pati ents randomized to the LY3209590 group the following gui dance for IP administration is 
applicable:
During Weeks 0to 8, site personnel will administer IP at the site. Participants will 
receive educat ion and training on how to self-administer IP (for details, see the Schedule 
of Activities). The training should include information on reconstitution of IP, 
appropriate inject ion site locat ions, inject ion technique, and the signs and symptoms of 
local adverse react ions, shoul d thoseoccur.
During Weeks 9 to 12, IP will be reconst ituted and administered at the site by the 
participant , under supervisio n of trained site personnel to assure that the participant is 
capable of self -admin istrati on. 
During Weeks 13 to 25, outsi de of ti tration visi ts IP canbe self -administered by  the 
participant at hom eunless local regulat ions requi re administrati on at the si te, or 
optionally  can be administered once weekly  by si te personnel . 
Inform ation on self -inject ioncan be reviewed as necessary  throughout the study . 
Addit ional visits to ensure correct dosing, titration, and study  drug administration can 
occur any time during the study  if deemed necessary  by the invest igator .
LY3209590 will be administered as follows :  
Algori thm 1(paper al gorithm):dose adj ustment guidance provi ded(Secti on 10.8); 
study  participant will receive an init ial individualized LY3209590 dose on Day  1 wi th 
weekly adjust ments based on fasting glucose ( FG)and hypo glycemia data for the first 
12 weeks, then ever y 4 weeks .
For pati ents randomized to LY3209590 Algorithm 1, documented guidance for dose adjustment 
isprovi ded (Secti on 10.8). 
For pati ents random ized to the insulin degludec arm the following guidance for administration is 
applicable:
CONFIDENTIAL I8H-MC-BDCL (d)
LY3209590 28Insulin degludec will be self -administered daily  by participants after a training and first 
administration under site personnel supervisio n on Day  1 according to a m odified Riddle 
algorithm (Secti on 10.8).
General considerations
Study  procedures will be performed as listed in the Schedule of Activit ies (Secti on 1.3).  
To allow timely sampling for PK assessmen ts, visits for collect ion of the samples will be 
scheduled within the required time windows provided in the Schedule of Act ivities.
Parti cipants will cont inue to use concomitant metformin (alone or in co mbinat ion with a stable 
dose of a DPPIV inhibitor and / or a SGLT2 inhibitor) throughout the treatment period .  
Discontinuation or changes to dose are not permitted, except in situat ions where dose adjust ment 
or com plete di scont inuat ion is required per country- specific label or when allowed per study  
protocol  (for further details ,see Sect ion6.5.2 ).
Self Monitoring of Blood Glucose (SMBG):   All measurements have to be recorded in the 
provi ded e lectroni c diary . Parti cipants will be instructed to perform FG measurements each day . 
In addit ion, two 6- point SMBG profiles (prior to and 2 hours after the morning, midday, and 
evening meals) should be done on nonconsecut ivedays in the week prior to th e required visits 
noted i n the Schedule of Activit ies(Secti on 1.3).    
Parti cipants who develop severe , persi stent hyperglycemia based on prespecified thresho lds (see 
Secti on6.1.2.3 )will receive a new glucose -lowering intervent ion(or rescue therapy )based on 
clinical judgment of the invest igator (see table in Secti on 6.5)
.  Participants who need rescue 
therapy  will cont inue on IP in the trial until they co mplete all study  visits.  
Flash glucose monitoring (FGM):  Participants will undergo 3 FGM sessio ns using the 
LibrePro Sy stem  (Abbot t) in the 14 -day period prior to randomizati on, Visi t 15, and Vi sit 20.  
Patients will  remain blinded to these assessments until the study is completed.
Study Period 3: End-of-Treatment and Safety Follow -up, Visits 20, 801, Early 
Discontinuation 1 and 2 (ED1 and ED2)
All rando mized participants shoul d have a com prehensive efficacy and safet y evaluation at 
Visit 20and a safet y follow -up visit approximately 6 weeks after the last dose of LY3209590 
and 5 weeks after the last dose of insulin degludec . During the safet y follow-up study  period, 
participants will cont inue SMBG and may be treated wi th anappropri ate gl ucose-lowering 
regimen (see table in Sect ion 6.5) if appropriate. Participants will also be requi red to return the 
study  diary and used or unused IP to the investigative site.
Parti cipants who complete the treatment period will have a com prehensive End- of-Treatment 
efficacy  and safety  assessment (Week 26; Visit 20). Thesafet y follow -up assessment (Vi sit 801) 
shoul d occur approximately 5 weeks after t heir End -of-Treatment assessment (Visit 20). 
Parti cipants will also be required to return used and unused IP as well as the study  diary  to the 
investigat ive site at V801.
Parti cipants who discontinue IP prior to completion of the treatm ent peri od 
for any reason 
shoul d also have a comprehensive End -of-Treatment efficacy and safet y assessment ( early 
discontinuat ion [ED]1) approximately  1week after the last dose of LY3209590 or as soon as 
reasonably  possible thereafter, and should have a safet y follow
-up as sessment ( ED2) 
CO N FI D E N TI A L I 8 H -M C -B D C L ( d) 
L Y 3 2 0 9 5 9 0 2 9 a p pr o xi matel y  5 wee ks after E D 1 . St u d y  act i vit ies at Visits E D 1 a n d E D 2 are i de nt ical t o 
Wee k 2 6 ( Visit 2 0 ) a n d Vi si t 8 0 1, res pecti vel y .  
a n d t he s wi t c h t o a n alter nat i ve, 
c o m merciall y  a v aila ble i ns uli n m ust be cl osel y m o nit ore d t o pre ve nt h y p o gl yce mia d ue t o a n 
acc u m ulat i o n of i ns uli n act i o n. 
P arti ci p a nts w h o disc o nti n ue I P pri or t o t h e c o m pl eti o n of  t he treat m e nt peri o d will be 
e nc o ura ge d t o re mai n i n t he st u d y  a n d t o c o m plete a n y sc he d ule d st u d y  pr oce d ures u ntil Visi t 2 0. 
P arti ci p a nts re mai ni n g i n t he st u d y  will recei ve a n a p pr o priate gl uc ose -l o weri n g re gi me n.  Ta ble 
i n Secti o n 6. 5 pr o vi des details o n t he use of gl uc ose -l o weri n g me dicat i o ns, w hic h ca n be use d .
P arti ci p a nts w h o disc o nti n ue I P f or a ny re as o n a n d are u n w illi n g t o ret ur n f or a s afety f oll o w - u p 
visit, will be as ke d t o perf or m a n earl y  ter mi nat i o n ( E T) visit as t h ei r fi nal  st u d y  visit .  At t his 
visit ,parti ci pa nts will p erf or m  pr oce d ures liste d i n t he Sc he d ule of Act i vit ies ( Secti o n 1. 3 ). 
4. 2. Scie ntific R ati o n ale f or St u d y Desi g n 
T his st u d y  will  e v al uate L Y 3 2 0 9 5 9 0 i n pat ie nt s wit h T 2 D M, c o m pare d wit h a n acti ve c o ntr ol.  
T he st u d y  will  last 2 6 wee ks t o ha ve a n a de q uate d urati o n of  e x p os ure necessar y  t o assess 
efficac y  a n d safet y  of  L Y 3 2 0 9 5 9 0 .
I ns uli n de gl u dec is a n u n bli n de d acti ve c o m parat or i n t his st u d y  a n d will  be use d t o c o m pare t he 
effects of L Y 3 2 0 9 5 9 0 o n gl yce mic c o ntr ol, h y p o gl yce mia ,a n d wei g ht gai n wi t h  a dail y basal 
i n s uli n. 
4. 3. J u stific ati o n f or D ose 
 
 
a si n gle i nit ia l d ose , f ol l o we d b y wee kl y  d ose a dj ust m e nt sis 
rec o m me n de d f or L Y 3 2 0 9 5 9 0 d osi n g re gi me n. T he i nit ia ld os e i s deter mi ne d base d o n mea n 
baseli ne fasti n g gl uc ose, b o d y  w ei g ht, a n d a vaila ble L Y 3 2 0 9 5 9 0 data. D o se a dj ust me nt s are 
base d o n pri or fast i n g gl uc ose a n d h y p o gl yce mia e ve nts. Alt erati o ns t o t he d oses rec o m me n de d 
b y t he d ose a dj ust me nt al g orit h m are als o u n der discreti o n of t he i n vest i gat or a n d will ta ke 
h y p o gl yce mia a n d ot her st u d y  p arti ci pa nt safet y c o ncer ns i nt o acc o u nt.   I n case of a de viat i o n 
fr o m t h e al g ori t h m -rec o m me n de d d ose ,a m e dical  r ati o nale f or t hi s de viat i o n m u st be 
d oc u m e nte d b y  t he PI. 
I ns uli n de gl u dec will be a d mi nist ere d at a starti n g d ose of 1 0 I U/ da y , as descri be d i n t he 
a p pr o ve d pr o d uct la beli n g. T he st u d y  p arti ci pa nt will  start a ti tr ati o n p hase base d o n fast i n g 
gl uc ose a n d t he prese nce of h y p o gl yce mia or ot her safet y c o ncer ns. D ose a dj ust me nt s will be 
perf or m e d acc or di n g t o a m o difie d Ri d dle al g orit h m, w hic h is wi del y use d i n cli nical trials a n d 
cli nical practice ( Secti o n 1 0. 8 ).   
As i t m a y be desira ble t o ac hie ve t hera pe utic g oal of L Y 3 2 0 9 5 9 0 i n less t ha n 1 2 wee ks wi t h  l o w 
ri s k of h y p o gl yce mia , a n i nit iat i o n d ose stra te g y  m a y  b e a p pr o pri ate w here t he first d ose 
s ufficie nt t o ac hie ve a n efficaci o us e x p os ure is gi ve n i nit iall y, f o ll o we d b y i n di vi d uall y  
o pti mize d wee kl y  d ose a dj ust m e nts t o ac hie ve tar get res p o nse . Ta ble sf o rAl g orit h m 1 
( Secti o n 1 0. 8 )s h o w t he i nit ial d oses, as well as t h ose t o be use d w he n i ncreasi n g t he d ose d uri n g C CI C CI 
CONFIDENTIAL I8H-MC-BDCL (d)
LY3209590 30the dose individualization visit s.  See Section 10.8 for descri ption of the dose adjust ment 
algorithms. 
Guidance i s provi ded f or dosing suggest ions for investigators based on fast ing glucose and 
hypoglycemia of the study  parti cipant (Section 10.8).
Safety of study  parti cipants will be closely mo nitored during the early stages of dose titration to
determine whether adjust ments to the initial dose and dose adj ustment algorithmisneeded. As
additional data em erges, gui dance fro m the sponsor on the dosing algorithm may  be m odified
(Secti on 10.8).
4.4. End of Study Definition
End of the trialis the date of the last visit or last scheduled procedure shown in the Schedule of 
Activities(Secti on 1.3) for the l ast patient.
CONFIDENTIAL I8H-MC-BDCL (d)
LY3209590 315. Study Population
Prospective approval o f protocol  deviati ons to recrui tment and enro llment criteria, also known as 
protocol  waivers or exempt ions, is not permitted .The study  popul ation will consist of patients
with a diagnosis of T2DM treated wi th diet and exerci se andwith a stable dose of metformin 
(alone or i n combinat ion with a stable dose of a DPP IVinhibitor and/or a SGLT2 inhibitor) for 
at least 3 m onths pri orto screening.   Eligibilit y of patients will be based on the results of the 
assessments performed at screening as described in the Schedule of Act ivities (Secti on 1.3).  All 
screening evaluat ions m ust be com pleted and reviewed to confirm that potential participants 
meet all eligibilit y criteria. The invest igator will maintain a screening log to record det ails o f all 
participants screened and to confirm eligibilit y or record reasons for screening failure, as 
applicable.   The nature of any condit ions present at the time of the init ial screening and any 
preexist ing condit ions will be documented in the eCRF.
For screen failures and rescreening activit ies wi thin the screening period, see Section 5.4.
5.1. Inclusion Criteria
Parti cipants are eligible to be inclu ded in the study only if all o f the following criteria apply:
Type of Study Participant and Disease Characteristics
[1] Have a diagnosis of T2DM treated with astable dose of metformin (alone or 
in combinat ion with a stabl e dose of a DPPIV inhibitor and/or a SGLT2 
inhibitor) for at least 3 months prior to screening (see Inclusio n Criterion5).
Study Participant Characteristics
[2a] No m ale contraception required except in compliance wit h specific local 
government study  requi rements.
[2b] Female participants :
1) Women of child- bearing potenti al who are abst inent (if this is co mplete 
abstinence, as their preferred and usual lifest yle) or in a same sex 
relationship (as part of their preferred and usual lifest yle) must agree to 
either rem ain abst inent or stay in a same sex rel ationship wit hout sexual 
relationships wit h males. Periodic abst inence (e.g., calendar, ovulat ion, 
symptothermal, post -ovulation methods), decl aration of abst inence just for 
the duration of a trial, and wit hdrawal are not acceptable methods of
contraception.
2) Otherwi se, women of child -bearing potential participat ing must agree to 
use 1highly effect ive method (l ess than 1% failure rate) of contraception, 
or a combinat ion of 2effect ive methods of contraception for the ent irety of 
the study .
a) Women of child- bearing potenti al parti cipat ing must test negative for 
pregnancy prior to init iation of treatm ent as indicated by  a negat ive 
serum  pregnancy  test at the screening visit followed by  a negat ive urine 
pregnancy test within 24 hours prior to exposur e.
CONFIDENTIAL I8H-MC-BDCL (d)
LY3209590 32b) Either 1highly effect ive method of contraception (such as combinat ion 
oral contraceptives, implanted con tracepti ves or intrauterine device) or 
a combinat ion of 2effective methods of contraceptio n (such as male or 
female condo ms with spermicide, diaphr agms wi th spermicide or 
cervical sponges) will be used. The participant may choose to use a 
doubl e barri er method of contraception.  Barrier protection methods 
without concomi tant use of a spermicide are not a reliable or acceptable 
method. Thus, each ba rrier method m ust include use of a spermicide.
It should be noted that the use of male and female condoms as a double 
barrier m ethod i s not consi dered acceptable due to the high failure rate 
when these methods are combined.
3) Women not of childbearing poten tial may parti cipate and include those 
who are:
a) infertile due to surgical sterilizat ion (hysterectomy, bilateral 
oophorectomy , or tubal  ligation), congenital ano maly such as mullerian 
agenesis; or
b) post-menopausal –defined as either
i)A wo man at l east 40 years of age with an intact uterus, not on 
horm one therapy , who has cessat ion of menses for at least 1 y ear 
without an al ternat ive medical cause, AND a follicle-stimulat ing 
horm one >40 m IU/mL; or
ii)A wo man 55 or older not on hormone therapy , who has had at least 
12 m onths of spontaneous amenorrhea; or
iii)A wo man at l east 55 years of age with a diagnosis of menopause 
prior to starting hormone replacement therapy .
[3] A re 18 to 75 years of age ,inclusive, at the time of signing the ICF .
[4] Have a baselin e HbA 1cvalue o f 7.0% to 9.5%,inclusive , at screening . 
[5] Must have been treated with a stable dose of met formin (alone or in 
combinat ion with a stable dose of a DPPIV inhibit or and/or a SGLT2 
inhibitor) for 3 m onths pri or to screening and be willing to continu e stable 
dosing throughout the study .  
Note: All oral antihyperglycemic medications (OAMs) must be used in 
accordance with the corresponding local product label at the time of 
screening.
[6] Have a body  mass index ( BMI )between 20and 45 kg/m2,inclusive ,with no 
significant wei ght gain or l oss in the past 3 m onths ( ≥5%) .
[7] In the invest igator’s opinio n, are well -motivated, capable, and willing to:
learn how to self- inject treatm ent; visually impaired persons who are not 
able to perform the inject ions m ust have the assistance of a sighted 
individual trained to inject the IP; persons with physical limitat ions who 
are not able to perform the inject ions m ust have the assistance of an 
individual trained to inject the IP;
CONFIDENTIAL I8H-MC-BDCL (d)
LY3209590 33perform  daily fingerst ick blood gluco se monitoring as requi red in 
Secti on4.1.1 throughout the trial;
maintain study  diary, as requi red for thi s protocol; 
must have a normal wake/sleep pattern such that midnight to 0600 hours 
will reliably reflect a usual sleeping period .
[8] Are willing and able to fo llow the visit schedule during the complete duration
of the tri al.
Informed Consent
[9]Capable of giving signed informed consent as described in Section10.1,
which includes co mpliance wit h the requirements and restrictions listed in th e 
ICF and in this protocol .
5.2. Exclusion Criteria
Parti cipants are excl uded from  the study  if any of the fo llowing cri teria apply:
Medical Conditions
[10]Have a history  of greater than 1 e pisode of ketoacidosis or hy perosm olar 
state/com a requi ring hospi talizati on in the 6 m onths pri or to screening .
[11]Have had any  episodes of severe hypoglycemia and/or hy poglycemia 
unawareness wit hin the 6 months prior to screening.
[12]Cardi ovascular (CV):  have had any of the fo llow CV condi tions: acute 
myocard ial infarct ion, New York Heart Association Class III or IV heart 
failure (Secti on10.6), or cerebrovascular accident (stroke).
[13]Gastrointestinal:  have undergone gastric bypass (bariatric) surgery  or 
restri ctive bariatric surgery (e .g., Lap -Band®) prior to screening.
[14]Hepatic:  have acute or chronic hepat itis, or obvious clinical signs or 
symptoms of any other liver disease except non -alcoholic fatty  liver di sease 
(NAFLD) (i.e., patients with NAFLD are eligible for participat ion), and/or 
have elevated liver enzyme measure ments, as determined by the central 
laboratory  at screening and as indicated below:
Total  bilirubin > 1.5x the upper limit of normal (ULN) in the absence of 
Gilbert’s syndrome , or
Alanine aminotransferase ( ALT )/serum  glutamic pyruvic transaminase 
(SGPT) >2. 0x ULN, or
Aspartate aminotransferase (AST)/serum glutamic ox aloacetic transaminase 
(SGOT) > 2.
0x ULN
[15]Renal:  have an estimated glo merular filtrat ion rate (eGFR) 
<30mL/min/1.73 m2, calculated by  the Chroni c Kidney Disease -
Epidemi ology equati on, as det ermined by the central laboratory at screening .
CONFIDENTIAL I8H-MC-BDCL (d)
LY3209590 34[16]Have fast ing triglycerides >400 mg/dL or non -fasting >600 mg/dL .
[17]Have experienced significant weight loss or gain (>5%) in body  weight in the 
3 months pri or to screening (Visit 1).
[18]Have act iveor untreated malignancy , or have been in remissio n from 
clinically significant malignancy (other than basal cell or squamous cell skin 
cancer) for less than 5 y ears or are at increased risk for developing cancer or a 
recurrence of cancer in the opinio n ofthe invest igator .
[19]Have known hypersensit ivity or allergy  to any  of the study  medicat ions or 
their excipients .
[20]Have any other serious disease or condit ion (for example, known drug or 
alcoho l abuse /regular consumpt ionor psy chiatric disorder) that, in the opinio n 
of the invest igator, would pose a significant risk to the patient, preclude the 
patient from following and co mpleting the protocol, or interfere wit h the 
interpretati on of  safety, efficacy, or PD data .  
Alcoh ol abuse/r egular consumpt ion is defined as an average daily intake of 
>3units for males or >2units for females within 6months prior to the study . 
One unit is equivalent to 8 g of alcoho l:a half -pint (~240 m L) of beer, 1 glass 
(125 mL) of wine or 1 (25 mL) measure of spirits .
[21]Have had a blood transfusio n or severe blood loss within 3 mo nths prior to 
screening or have any hematologic condit ion that may interfere with HbA1c 
measurement (e .g., hem oglobinopathy , hem olytic anemia, sickle -cell disease) .
[22] Wom en of child bearing potential who
i)are p regnant or intend to become pregnant
ii)are lactating/breast feeding (including the use of a breast pump)
iii)are u nwilling to remain abst
inent or use birth control as described in 
Appendix 4
iv)test posit ive for pregna ncy at the time of screening (Visit 1).
Note: a urine pregnancy test is conducted at Visit 3.
Prior/Concomitant Therapy
[23] Are taking d rugs thatmay significantly affect glycemic control (e . g., niacin 
[allowed if <1.0 g/day ], bile acid sequestrants or pentoxyphylline )
.
[24]Are receiving chronic (>14 day s) systemic glucocorticoid therapy  (excluding 
topical, intraocul ar, intranasal, or inhaled preparations) or have received such 
therapy  for >14 days wi thin the m onth preceding screening.
[25] Are current ly taking or have taken within the 3 months preceding screening, 
prescri ption or over -the
-counter (OTC) medications to promote weight loss.  
Patients who parti cipate m ust agree not to init iate a diet and/or exercise 
program during the study  with the intent of reducing body  weight other than 
the lifest yle and dietary measures for diabetes treatment.
CONFIDENTIAL I8H-MC-BDCL (d)
LY3209590 35[26] H ave been treated with a sulfonylurea (SU), a glitazone, a lpha-glucosidase 
inhibitor, a GLP -1receptor agonist or insulin in the 3 m onths prior to
screening with the exception of short -term use of insulin for acute conditions 
(14 day s within the last 6 months prior to screening) .
[27] Are using or have used blood pressure -lowering medicat ion at a dose that has 
not been stable for 1 month prior to screening .
Prior/Concurrent Clinical Trial Experience
[28] Are current ly enrolled in any other clinical study  involving an IP or any other 
type of medical research judged not to be scient ifically or medically  
compatible with this study
.
[29] Haveparticipated, within the las t 30 days in a clinical  trial invo lving an IP. If 
the previous IPhas a long ha lf-life, 3 months or 5 half -lives (whichever is 
longer) should have passed .
[30] H ave previously co mpleted or withdrawn fro m this study  or any  othe r study  
investigat ing LY3209590.  
Other Exclusions
[
31] A re invest igator site personnel directly affiliated wit h this study  and/or thei r 
immediate families.  Immediate family is defined as a spouse, parent, child, or 
sibling, whether bio logical or legally adopted .
[
32] A re Lilly  empl oyees.
5.3. Lifestyle Considerations
Per the Schedule of Act ivities (Secti on 1.3), qualified medical staff will provide diabetes
management counseling, which will include instructions on diet and exercise and educat ion 
about the signs, symptoms, and treatm ent of hypoglyce mia, shoul d it occur. 
Prescri ption or OTC medicat ions that promote weight loss are exclusio nary if used wi thin 
3months pri or to screening (study  entry ), or between screening and rando mizat ion.  These 
medicat ions are al so not allowed at any  time during t he treatment period.  If started after 
rando mizat ion, they  shoul d be immediately  withdrawn.  
Study  parti cipants shoul d be instructed not to donate blood or blood products during the stud y or 
for 4 weeks fo llowing the study .
5.3.1. Meals , 
Dietary Restrictions , and Activity
Patients shoul d cont inue their usual exercise habits and generally fo llow a healthymeal plan 
(with consistent meal size and time of day )throughout the course of the study . Dietary  
counseling may be reviewed throughout the study , as needed.
In addit ion, pati ents shoul d not receive an intensive diet/exercise program wit h the intent of 
reducing body  weight at any  time during the study , other than the lifest yle and dietary measures 
for diabetes treatm ent.
CONFIDENTIAL I8H-MC-BDCL (d)
LY3209590 365.4. Screen Failures
Screen failures are defi ned as participant s who consent to participate in the clinical study but are 
not subsequently randomly  assigned to study  intervent ion. A minimal set of screen failure 
inform ation is required to ensure transparent reporting of screen failure participant s to meet the 
Conso lidated Standards of Reporting Trials (CONSORT) publishing requirements and to 
respond to queries from regulatory  authori ties. Minimal information includes demography, 
screen failure details, eligibilit y criteria, and any  SAE.
Individuals who do not m eet the cri teria for parti cipati on in this study  (screen failure) may be 
rescreened once . The interval between screening and rescreening should be at least 4 weeks. A
new ICF must be signed at the time of rescreening andthe study  parti cipant will be assigned a 
new ident ification number. A single r epeat t esting of suspected erroneous/ spurious central 
laboratory resul ts is allowed without rescreening the study  parti cipant.
CO N FI D E N TI A L I 8 H -M C -B D C L ( d) 
L Y 3 2 0 9 5 9 0 3 7 6. St u d y I nter ve nti o n 
St u d y  i nt er ve nt i o n is defi ne d as a n y i n vest i gat i o nal i nt er ve nt i o n(s), m ar kete d pr o d uct(s), 
pl ace b o ,or m e dical de vice (s) i nt e n de d t o be a d mi nistere d t o a st u d y  p arti ci pa nt acc or di n g t o t he 
st u d y  pr ot oc ol .
6. 1. St u d y I nter ve nti o n(s) A d mi nistere d 
L Y 3 2 0 9 5 9 0 will be pr o vi de d i n a 2 0 m g vial of l y o p hilize d p o w der.  U p o n rec o nstit uti o n per t he 
p har mac y i nstr ucti o ns pr o vi de d b y  t he s p o ns or, LY 3 2 0 9 5 9 0 will be a d mi nistere d o nce wee kl y as 
S C i nject i o ns. Eac h patie nt will recei ve 1 i nject i o n eac h wee k, as descri be d i n t h e “ Treat me nt  
Re gi me ns” ta ble bel o w . Su bc uta ne o us i nject i o ns of L Y 3 2 0 9 5 9 0 will be a d mi nistere d r otati n g 
bet wee n l ef t a n d ri g ht a b d o mi nal  r e gi o n s, a n d u p per a n d l o wer q ua dra nts. Refer t o St u d y  P eri o d 
2 i n Sect i o n 4. 1. 1 f o r details o n h o w I P will be a d mi nistere d. 
P ati e nts will  recei ve treat m e nt wi t h  L Y 3 2 0 9 5 9 0 b y  a n al g ori t h m  descri be d i n Secti o n 1 0. 8 .
T he L Y 3 2 0 9 5 9 0 Al g ori t h m  1 is apa per -base d al g orit h m t hat uses si milar pri nci pals t o t he 
esta blis he d Ri d dle al g orit h m. 
I ns uli n de gl u d ec will use t he esta blis he d Ri d dle al g orit h m a n d is a pa per- base d al gori t h m .
A p pr o xi matel y  o ne -half of  t he s u bjects will be ra n d o mize d i n eac h of  t he 2 re ma i ni n g treat me nt 
gr o u ps .
I ns uli n de gl u dec will be pr o vi de d as 1 0 0 u nits/ m L i n a prefille d pe n.  It will be a d mi nistere d 
o nce dail y  at a p pr o xi matel y  t he sa me t i me of da y, r otati n g bet wee n left a n d ri g ht a b d o mi nal 
r e gi o ns ,a n d u p per a n d l o wer q ua dra nts. 
See Secti o n 6. 7. 1 f o r tra nsit i o ni n g t o treat me nt after st u d y  c o m plet i o n. 
Tre at me nt Re gi me ns 
Re gi me n D ose 
R a n d o miz ati o n t hr o u g h Wee k 2 6 
L Y D ose Al g orit h m 1 
(pa per )L Y i njecti o n 
I ns uli n de gl u dec i ns uli n de gl u dec i njecti o n ( o pe n -la bel) 
A b bre viati o ns:  L Y = L Y 3 2 0 9 5 9 0 .
T he i n vest i gat or or his/ her desi g nee is res p o nsi ble f or t he f o ll o wi n g: C CI 
CONFIDENTIAL I8H-MC-BDCL (d)
LY3209590 38explaining the correct use of the investigational agent(s) to the patient 
verifying that instructions are fo llowed properly
maintaining accurate records of IPdispensing and collect ion
at the end of the study  returning all unused medication to Lilly , or i ts desi gnee, 
unless the sponsor and sites have agreed all unused medicat ion is to be destroyed 
by the site, as allowed by local law .
Clinical study materials will be labeled according to the country ’s regul atory  requi rements.
6.1.1. Selection and Timing of Doses
For p atients rando mly assigned to LY3209590, an init ial dose will be determined using Table 1 
forAlgorithm 1 (see Secti on10.8).  The weekly dose adj ustment thereafter will be based on 
guidance provi ded in Secti on10.8.  The doses will be administered at approximately the same 
time and day  each week .  
If a patient misses a scheduled dose of LY3209590, it should be administered a ssoon as 
possible, but no later than 3 days after the scheduled administration. If more than 3 day s have 
elapsed since the scheduled administration, the dose should be skipped and the next inject ion 
will occur at the next scheduled day and time.
Insulin degludec should be administered at the same time each day  adjusted per themodified 
Riddle algori thm (Secti on 10.8.2 ).  
Patients who
miss a dose of insulin degludec should inject their daily dose during waking hours 
upon discovering the missed dose. Instruct patients to ensure that at least 8 hours have elapsed 
between consecut ive insulin degludec inject ions (Tresiba ®USPI).
The actua l date, time and dose of each dose administrati ons(LY3209590 and insulin degludec)
will be recorded in the participant ’s diary  (and participant’s medical record when administered at 
the site).
For details on the titration algorithms to be used, refer to Secti on 10.8.
6.1.2. Special Treatment Considerations 
6.1.2.1. Standards of Medical Care
Invest igators and other study  team  members are expected to treat patients according to the 
nationally established standards of care for diabetes management in respect ive participat ing 
countri es, except where that treatment would be in conflict with the pro tocol -provi ded treatm ent 
requi rements. If there are no local standards of care for diabetes, the invest igators should fo llow 
current published standards of care from the American Diabetes Association (ADA 2016) and 
the European Associat ion for Study  of Diabetes (Inzucchi et al. 2015) during their pat ients’ 
participat ion in this study . Standards of prevent ion of persistent hyperglycemia and ketone 
monitoring must be followed during the course of the study  to prevent DKA.
This sect ion provi des gui dance on m anagement of episodes of hypoglycemic events and events 
ofsevere, persistent hy perglycemia. For effect ive implementation of measures described here, it 
is important that patients, and their caregivers, if applicable, be well -educated about the signs 
and symptom s of hyperglycemia ( for example , severe thi rst, dry  mouth, f requent micturi tion, or 
CONFIDENTIAL I8H-MC-BDCL (d)
LY3209590 39dry skin) and hypoglycemia ( for example , intense hunger, sweat ing, tremor, restlessness, 
irritabili ty, depressi on, headaches, di sturbed sleep, or transient neurologi cal disorders). Patients 
shoul d be instructed to contact the invest igative sit e in the event of severe, persistent 
hyperglycemia or severe hypoglycemia between study  visits.
6.1.2.2. Management of Increased Hypoglycemia Risk
The allowable oral antihyperglycemic medicat ions(OAMs)are non -secretagogues; therefore, 
clinically relevant increases in the risk of hypoglycemia due to the OAMs are not expected in 
this trial.  To date, effects of LY3209590 on hypoglycemia are not different as compared to other 
basal insulin s. An object ive of the study  is to assess the ri sk of hypoglycemia in insulin naïve 
T2DM patients receiving LY3209590 as com pared to insulin degludec .
In this study , increased risk o f hypoglycemia is defined as having a single episode of severe 
hypoglycemia or having more than 1 epi sode of docum ented hypoglycemia within a 1 -week 
period at any  time during the treatment period . Documented hypoglycemia is defined as any 
time a participant reports a SMBG ≤70 mg/dL (<3.9 mmo l/L)or any  invest igator c onfirmed case 
of severe hypoglycemia .  
In cases where a patient experiences hypoglycemia as described above, to confirm the increased 
risk, the study  sites must ensure that the patient has been fully co mpliant with the assigned 
therapeuti c regimen and a lso that there is no evidence o f other possible causes of hypoglycemia 
(e.g., omission o f meal, unexpected increase in exercise) .
Patients fulfilling the definit ion of increased risk of hypoglycemia should first decrease their 
dose of IP per the respective dosing al gorithm, followed by  discont inuat ion of IP, if needed.  If 
the patient continue sto experience hypoglycemic events after the discont inuat ion of IP, the 
investigator should discont inue the patient fro m OAM therapy .  
6.1.2.3. Management of Patients with Se vere, Persistent Hyperglycemia During the 
Treatment Period
An addit ional therapeut ic intervent ion shoul d be consi dered in pati ents who develop severe, 
persistent hy perglycemia after randomization based on the following criteria ( FDA 2008):
a)average FG >270 mg/dL (>15.0 mmo l/L) over any 2 -week period or longer during the 
first 6 weeks postrandomizat ion; or
b)average FG >240 mg/dL (>13.3 mmo l/L) over any 2 -week period or longer fro m Week 6 
to Week 12 postrandomizat ion; or
c)average FG >200 mg/dL (> 11.1 mmo l/L) over any 2 -week period or longer after 
Week 12.
Invest igators should first confirm that the patient does not have an acute condit ion causing severe 
hyperglycemia and, after the first 12 weeks of the study , that the patient i s fully com pliant w ith 
the assigned therapeutic regimen.  The invest igator will decide, in consultat ion with the patient, 
on an appropriate glucose -lowering intervention (rescue intervent ion) after considering relevant 
clinical criteria. See table in Secti on 6.5for allowed m edicat ions.  Pati ents who receive a new 
intervent ion for hyperglycemia m anagement should al so conti nue administering IP for the 
remaining peri od in the trial.
CONFIDENTIAL I8H-MC-BDCL (d)
LY3209590 406.1.3. Medical Devices
The sponsor will provide marketed blood gluco meters and syringes for subcutaneous inject ion.
6.2. Preparation/Handling/Storage/Accountability
The invest igator or designee must confirm appropriate temperature condit ions have been 
maintained during transit for all study  intervent ion received and any discrepancies are reported 
and reso lved before use of the study  intervent ion.
Only participants enro lled in the study  may receive study  intervent ion and only authorized site 
staff may su pply or administer study  intervent ion. All study  intervent ion must be stored in a 
secure, environmentally controlled, and monitored (manual or automated) area in accordance 
with the l abeled storage conditions with access limited to the invest igator and au thorized si te 
staff.
The invest igator, institution, or the head of the medical inst itution (where applicable) is 
responsible for study  interventi on accountabilit y, reconciliat ion, and record maintenance (i .e., 
recei pt, reconciliat ion, and final disposit ion records).
Further gui dance and information for the final disposit ion of unused study  interventi ons will be
provi ded by the sponsor.
The study  site must store all study  intervent ions in a locked and secure environment. 
Invest igators should consult the st udy drug information provided in the Pharmacy Instructions 
provi ded by the sponsor or label for the specific administration informat ion (including 
warnings ).
6.3. Measures to Minimize Bias: Randomization and Blinding
This is an open -label study; thus, it will be unblinded.  H owever, the specific intervent ion to be 
taken by  a parti cipant will be assigned using an interactive web–response system ( IWRS ). The 
site will  contact the IWRS pri or to the start of study  intervent ion administration for each 
participant. The site will record the intervent ion assignment in the appropriate data capture tool .  
Potenti al bias will be reduced by  the f ollowing steps: central rando mizat ion, stratificat ion, 
blinded adjudicat ion for CV endpoints .
Patients who m eet all cri teria for enrollment will be randomized to treatment at Visit 3.  
Assignment to treatment groups will be determined by a co mputer -generated random sequence 
using the
IWRS.  The IWRS will be used to assign IP to each patient.  Site personnel will 
confirm that they  have l ocated the correct IP by  entering a confirmat ion number found on the IP 
label into the IWRS.
To achieve between -group com parabilit y for site factor, the randomizat ion will be stratified by  
baseline HbA1c (<8.5%, ≥8.5% ), DPPIV (yes/no), SGLT2 (y es/no), country ,and baseline BMI 
(<30, ≥30).  The randomization scheme will be performed using IWRS ,which will ensure 
balance between treatment groups .
CONFIDENTIAL I8H-MC-BDCL (d)
LY3209590 416.4. Study Intervention Compliance
The assessment of treatment compliance with I P (LY3209590 or insulin degludec) will be 
determined by the fo llowing:
Inform ation about the once weekly IP inject ions administered at home by  the pat ient will 
be entered into the patient diary  by the pat ient and reviewed by  the si te personnel at each 
study visit; this informat ion will be co llected in the electronic study  diary ;
IP accoun tabilit y will be checked according to the Schedule of Act ivities (Secti on 1.3).  
Study  parti cipants will be instructed to return all dispensed vials, any unused pens and/or 
all empty  cartons at the next visit to the study  site for the purpose of performing drug 
accountabilit y.  
Other aspects of compliance will also be assessed at each visit, including the patient’s adherence 
to the visit schedule, co mpliance with the conco mitant OAM requirements and other medicat ion 
guidances (Secti on6.5), com pletionof study  diary, resul ts of SMBG, and any other parameters 
the invest igator considers necessary.  Patients considered to be poorly co mpliant with their 
medicat ions and/or study  procedures (for example, missed visits or specific diagnostic tests) will 
receive addit ional training and instructions, as required.
When participants are dosed at the site, they  will receive IPdirect ly from  the invest igator or 
designee, under medical supe rvisio n.  The date and time of each dose administered in the clinic 
will be recorded in the source documents and recorded in the diary.  
When participants administer study  treatm entat home, compliance wit h study  treatm entwill be 
assessed at each visit. Compliance will be assessed by  direct questi oning, counting returned 
pens, etc. during the site visits. 
A record of the number of the pens and study  medicati onsdispensed to and taken by  each 
participant m ust be m aintained and reconciled wit h study  intervention and compliance records.  
Intervention start and stop dates, including dates for intervent ion delays and/or dose reductions 
will also be recorded in the eCRF.
6.5. Concomitant Therapy
Any medicat ion or vaccine (including over -the-counter or prescript ion medicines, vitamins, 
and/or herbal supplements or other specific categories of interest) that the participant is receiving 
at the time of enrollment or receives during the study  must be recorded in the eCRF along wi th:
Reason for use
Dates of administratio n including start and end dates , and
Dosage information including dose and frequency for concomitant therapy  of special  
interest .
In addit ion, for permitted concomitant glucose- lowering agents, the dosage will also be 
docum ented and collected.
Lilly Medica l shoul d be contacted if there are any  questi ons regarding concomitant or prior 
therapy .
CONFIDENTIAL I8H-MC-BDCL (d)
LY3209590 42Parti cipants will be permitted to use concomitant medicat ions that they  requi re during the study , 
except prohibited medicat ions described in Secti on 5.2 and Sections 6.5.1 through 6.5.4 below.
In addit ion, certain permitted medicat ions (for example, treat ments for blood pressure or 
dyslipidemia) described in Sect ions6.5.5 and 6.5.6 shoul d be continued, but not changed, during 
the study .
Invest igative site staff will inform pat ients that they must consult with the investigator or a 
designated site staff member upon being prescribed any new medicat ions during the study , 
except when init iated for treatm ent of m edical  emergencies.  
Non-study medicat ions taken by pat ients who are screened but not randomized will not be 
reported to Lilly  unless an SAE or AE occurs that the invest igator believes may have been 
caused by  a study  procedure.
The table below provi des a summary  of criteria for use of concomitant medications that may 
interfere wi th planned assessments during the study .
CONFIDENTIAL I8H-MC-BDCL (d)
LY3209590 43Criteria for Use of Concomitant Medications that may Interfere with Efficacy and Safety 
Assessments in Study BDCL
Drug ClassUse During 
Screening/Lead -InConditions for Use After Randomization
Acute 
Therapy aRescue 
Therapy During Safety 
Follow -up Period
Drugs with approved weight loss 
indicationbProhibitedN N/A N
Systemic glucocorticoid therapyc Excluded except for 
acute therapya Y N/A N
Antihy perglycemia medications
GLP-1 RAs Prohibited N N Y
DPP-4 inhibitors Permitted N Y Y
SGLT2 inhibitors Permitted N Y Y
SC Insulins and insulin 
mixturesProhibited except for 
acute therapy aY Y Y
Inhaled insulins Prohibited N N N
Meglitinides Prohibited N Y Y
Alpha-glucosidase inhibitors Prohibited N N Y
Sulfon ylureas Prohibited N Y Y
Thiazolidinediones Prohibited N N N
Metformin d Required N Y e Y
Abbreviations: DPP-4 = dipeptidyl peptidase -4; GLP -1 RA = glucagon like peptide -1 receptor agonist; N = no; N/A 
= not applicable; SC = Subcutaneous; SGLT2 = sodium -glucose cotransporter 2; Y = Yes.
aAcute therapy = treatment for up to 14 days.
bIncludes Saxenda ®(liraglutide 3.0 mg), Xenical ®(orlistat), Meridia ®(sibutramine), Sanorex ®(mazindol), 
Adipex -P® (phentermine), Belviq® (lorcaserin), Qsymia ®(phentermine/topiramate combination), Contrave ®
(naltrexone/bupropion) or similar other body weight loss medications i ncluding over-
the-counter medications 
(e.g., allī® [orlistat 60 mg capsules] ). 
cDoes not apply to topical, intraocular, intranasal, intraarticular, or inhaled preparations; 
dSwitch ingmetformin manufacturers is allowed, as long as the dosage is the sam e.  Changing to a metformin 
formulation with a different action profile (i.e ., from short -acting to long -acting metformin) is not permitted.
eFor rescue therapy, metformin dose may be increased if the dose is below maximum approved dose per country -
specif ic label.
6.5.1. Antihyperglycemia Medications
The only glucose -lowering agents allowed as rescue therapy  during the study  are concomitant 
metformin, SLGT -2 inhibitors, DPP-4 inhibitors, meglitinides , sulfonylureas and insulin .  In 
addition, short- term insulin use (up to 14 day s) formanagement of medical emergencies is 
allowed prior to study  entry  and during the study .  Rescue therapy  with other gl ucose -lowering 
agents may be medically  indicated in certain situatio ns after rando mizat ion (see table in 
Secti on6.5).  These situations are described in Section 6.1.2.3 (severe, persistent hyperglycemia) 
and in Sect ion7.1.1 (permanent discontinuation o fIP).  
CONFIDENTIAL I8H-MC-BDCL (d)
LY3209590 44If any new glucose -lowering medicat ion is initiated after randomization at Visit 3, other than IP, 
rescue therapy , or short -term use of insulin for medical emergencies, the patient will be required 
to immediately discont inue the medication and the appropriate study deviat ion report will be 
generated.  Any  such vi olation of the protocol that lasts longer than 14 day s will  exclude the 
patient from the per -protocol popul ation for analyses.
6.5.2. Concomitant Antihyperglycemia Medication
Patients treated with metformin inthis study  must be on a stable dose for at least 3 months prior 
to screening.  The prescreening dose and formulation (short -acting or long -acting) mus t be 
maintained fro m the time of screening through the patient’s last visit, except as required for 
rescue therapy  (Secti on 6.1.2.3 ).
Dose adjust ments of allowable OAM therapy are permitted after randomizat ion (during the 
treatm ent peri od) under the following circumstances:
in situations that requi re short -term treatm ent interrupti on in line wit h the product 
labeling for each respect ive country;
in situations that require dose adj ustment or discontinuat ion per country -specific label, 
for example, in the case of reduced eGFR;
in the case of increased hypoglycemia risk during the treatment period (as described in 
Secti on 6.1.2.2 ).
Dose reduction of allowable OAM therapy  during the tri al shoul d be properly  docum ented.
In pati ents who requi re rescue therapy , dose increase of allowable OAM therapy  is permitted, but 
the dose and the reason for change must be properly  documented in the eCRF.
Guidance for treatm ent during the sa fety follow-up peri od is provi ded in Sect ion 4.1.1 .
6.5.3. Medications that Promote Weight Loss
Prescri ption or OTC medicat ions that promote weight loss are exclusionary if used wi thin the 
3months pri or to screening, or any  time after screening (see Section 6.5).  If started after 
screening, these medicat ions should be stopped immediately.  In addit ion, pati ents shoul d not 
receive an intensive diet/exercise program with the intent of reducing body  weight at any  time 
during the study , other than the lifest yle and dietary measures for diabetes treatme nt (see 
Secti on5.3).
6.5.4. Systemic Glucocorticoids
Chronic systemic glucocortico id therapy (excluding to pical, intraocular, intranasal , or i nhaled 
prepara tions) is exclusio nary if used >14 consecut ive days during the 1- month peri od before 
screening or between screening and rando mizat ion at Visit 3.  
Patients treated with these medicat ions after randomizat ion will be excluded from the efficacy  
evaluable pop ulation for analyses if they receive: 
>14 day s consecut ive days of therapy, or
More than one course of therapy  during the study .
CO N FI D E N TI A L I 8 H -M C -B D C L ( d) 
L Y 3 2 0 9 5 9 0 4 5 6. 5. 5. A nti h y perte nsi ve Me dic ati o ns 
If use d, a nti -h y perte nsi ve t hera p y  s h o ul d be ke pt sta ble t hr o u g h o ut t he trial t o all o w assess me nt s
of  t he effect of ra n d o mize d t hera pies o n bl o o d press ure . 
6. 5. 6. D ysli pi de mi a Me dic ati o ns 
If use d, d ysli pi de mia t h era p y s h o ul d be ke pt sta ble t hr o u g h o ut t he tri al  t o all o w assess me nts of  
t h e effect of ra n d o mize d t hera pies o n li pi d e n d p o i nts . 
6. 6. D ose M o dific ati o n
D osi n g will be i n di vi d ualize d base d o n F G fr o m S M B G . See Secti o n 1 0. 8 f o r details o f d ose 
m o dificati o n. 
6. 7. I nter ve nti o n after t he E n d of t he St u d y 
After t he e n d of t he treat me nt peri o d patie nts s h o ul d c o nti n ue t o m o nit or t heir F G le vels. T he 
treati n g p h ysicia n s h o ul d t he n ma ke t he decisi o n base d o n l ocal cli nical pract ice, if a n d w hat 
a d di ti o nal  a n ti h y per gl yce mic treat me nt nee ds t o be a d mi nistere d. 
I n vest i gat i o nal pr o d uct will n ot be m a de a vaila ble t o patie nts after c o ncl usi o n of t he st u d y .After 
I P i s disc o nt i n u e d, a n a p pr o pri at e di a betes treat m e nt re gi me n will be i nit iate d b y  t he i n vesti g at or. 
6. 7. 1. Tre at me nt after St u d y C o m pleti o n 
T he l ast st u d y  tr e at m e nt a d mi nistrati o n f or patie nts treate d wit h L Y 3 2 0 9 5 9 0 will be at Wee k 2 5 
a n d f or pati e nts treate d wit h i ns uli n de gl u dec t he e ve ni n g bef ore t he last st u d y  vi sit  at Wee k 2 6 .  
T he was h o ut of L Y 3 2 0 9 5 9 0 ma y ta ke u p t o 1 0 wee ks t o c o m plete . A n y a p pr o priate 
a nt i h y per gl yce mic treat me nt m ust t heref ore be i nstit ute d sl o wl y a n d u n der re g ular s u per visi o n of 
bl o o d gl uc ose pr of iles after disc o nt i n uat i o n of L Y 3 2 0 9 5 9 0. If a n ot her basal i ns uli n is use d as a 
r e pl ace me nt f or L Y 3 2 0 9 5 9 0 or i ns uli n de gl u dec, i ns uli n t hera p y will be i nst it ute d usi n g t he 
Ri d dle al g ori t h m as nee d e d base d o n F G ( Secti o n 1 0. 8 ). Si nce 
 
  T heref ore, a sl o w u p -
ti tr ati o n of  a n ot her basal i ns uli n is necessar y t o pre ve nt h y p o gl yce mia d ue t o o verla p pi n g i ns uli n 
acti o n. F or e xa m ple, n o i ns uli n w o ul d be re q uire d u nt il t he st u d y partici pa nt’s bl o o d gl uc ose 
i ncreases t o > 1 0 0 m g/ d L, a n d t he n dail y basal i ns uli n w o ul d be i nit iate d a n d a dj uste d base d o n 
F G. 
St u d y  p arti ci pa nts assi g ne d t o t he i ns uli n de gl u dec treat me nt gr o u p will s witc h t o a n ot her 
gl uc ose l o weri n g re gi me n per i n vesti gat or g ui da nce after t he last st u d y  tr e at me nt  a d mi nistrati o n.  
If t he y s wi tc h t o a n i ns uli n treat m e nt a n d i ns uli n de gl u dec is c h ose n, t h e y  ca n c o nti n ue wi t h  t he 
sa me d ose use d u ntil Visit 2 0 of  t he st u d y .  If  t h e y  s wi tc h t o a n ot her basal i ns uli n (e. g. ,i ns uli n 
glar gi ne), st u d y  p arti ci pa nts s h o u l d i nject a dail y d ose, w hic h is 2 0 % l o wer t ha n t he last d ose of 
i ns uli n de gl u dec use d bef ore Visit 2 0a n d t it rate u n der s u per visi o n of t he i n vesti gat or usi n g t he 
c o u ntr y -s pecific l a b el  f or t h ei r pre -st u d y  basal  i ns uli n. C CI 
CONFIDENTIAL I8H-MC-BDCL (d)
LY3209590 467. Discontinuation of Study Interventi on and Participant 
Discontinuation/Withdrawal
7.1. Discontinuation of Study Intervention
Study  drug m ay be perm anently discont inued or temporarily wit hheld during the study .  
Parti cipants who perm anent ly discont inue study drug early will undergo early terminat ion 
procedures, which include
an ET visit or,
post-treatm ent follow-up visits ( ED1, ED2 )(Section 4.1.1).
The invest igator will co mplete any  AE reporting and necessary  follow-
up.
7.1.1. Permanent Discontinuation from Study Treatment
Possible reasons leading to permanent discontinuatio n of invest igational product include, but are 
not limited to :
Participant d ecision
othe patient or the pati ent’s designee, for example, parents or legal guardian 
requests to discont inue IP.
Hepatic event or liver test abnormality :Participants who are discontinued from IPdue 
to a hepatic event or liver test abnormalit y shoul d have addi tional hepatic safety  data 
collected via eCRF
Discontinuati on of  the IPfor abnormal liver tests should be considered by the 
investigator when a participant meets one of the following condit ions after consultation 
with the sponsor -designated m edical  monitor:
oALT or AST >8X ULN
oALT or AST >5X ULN for more than 2 weeks
oALT or AST >3X ULN and total bilirubin level (TBL) >2X ULN or 
internat ional norm alized rati o (INR) >1.5
oALT or AST >3X ULN with the appearance of fat igue, nausea, vo miting, 
right upper -quadrant pain or tenderness, fever, rash, and/or eosinophilia 
(>5%)
oalkaline phosphatase (ALP) >3X ULN
oALP >2.5X ULN and TBL >2X ULN
oALP >2.5X ULN with the appearance of fatigue, nausea, vo miting, right 
quadrant pain or tenderness, fever, rash, and/or eosinophilia (>5%)
In addit ion, participan tswill be discont inued fro m the IPin the fo llowing ci rcumstances:
if a pat ient is inadvertent ly enrolled and it is determined that continued treatment with 
IP woul d not be medically  appropriate ( see Section 7.2.1)
CONFIDENTIAL I8H-MC-BDCL (d)
LY3209590 47if a pat ient is di agnosed wi th an act ive or untreated malignancy (other than basal or 
squamous cell skin cancer, in situ carcino mas of the cervix, or in situ prostate cancer) 
after randomiz ation
if the invest igator or sponsor decides that the patient should be wit hdrawn from IP; if 
the invest igator decides to permanent ly discont inue IP because of an SAE or a 
clinically significant laboratory  value, Lilly or i ts designee shoul d be alerted 
immediately
if the invest igator, after consultation with Lilly Medi cal, determines that a systemic
hypersensit ivity react ion has occurred related to study  drug administration, the 
participant shoul d be permanent lydiscontinu edfrom IP .
See the S chedule of Activitiesfor data to be collected at the time of intervent ion discont inuat ion 
and fo llow-up and for any  further evaluat ions that need to be completed.
Patients who stop the IPpermanent ly may receive another glucose -lowering intervent ion, if 
appropriate, and will cont inue participat ingin the trial according to the protocol to collect all 
planned efficacy  and safet y measurements.
7.1.2. Temporary Discontinuation
In certain situat ions after rando mizat ion, the investigator may need to temporarily discont inue 
(interrupt) IP(for example, due to an AE or a clinically significant laboratory value).  The 
maximum t ime allowed for a temporary interruption of IP is 14 days. If IPinterruption is due to 
an AE, the event is to be documented and fo llowed according to the pro cedures in Secti on 8.3of
this protocol .  Invest igators should inform the sponsor that IPhas been temporarily interrupted.  
Every  effort shoul d be m ade by  the invest igator to maintain patients on IPand to restart IPafter 
any tem porary  interrupti on, as soon as i t is safe to do so.  The data related to temporary  
interrupti on of  IPwill be documented in source doc uments and entered in the eCRF.
7.2. Participant Discontinuation/ Withdrawal from the Study
A participant will be discont inued ( withdraw n)from the study in the fo llowing ci rcumstances: 
if he or she is diagnosed with any  type of diabetes mellitus other than T2DM
at any  time at his/her own req uest 
at the discretion of the invest igator for safet y, behavi oral, com pliance, or administrative 
reasons
if the participant beco mes pregnant during the study  
if enro llment in any other clinical study invo lving an IPor enrollment in any other ty pe of 
medical research judged not to be scient ifically or medically co mpat ible with this study
participat ion in the study needs to be stopped for medical, safet y, regul atory , or other 
reasons consistent with applicable laws, r egulations, and good clinical pract ice (GCP)
investigator decisio n
othe invest igator decides that the participant should be discont inued from 
the study
CONFIDENTIAL I8H-MC-BDCL (d)
LY3209590 48oif the participant, for any  reason, requi res treatm ent wi th another 
therapeuti c agent that has been demo nstrated to be effect ive for treatm ent 
of the study  indicati on, discont inuat ion from the study  occurs pri or to 
introducti on of  the new agent
participant deci sion:
othe patient or the pati ent’s designee, for example, parents or legal guardian 
requests to be w ithdrawn fro m the study .
Discontinuati on is expected to be uncommo n.
At the time of discont inuing from the study , if possible, an early discont inuat ion visit should be 
conducted, as shown in the Schedule of Act ivities(Secti on 1.3). See Schedule of Activit iesfor 
data to be collected at the time of study  discont inuation and fo llow
-up and for any  further 
evaluat ions that need to be completed .  The participant will be permanently discont inued both 
from the study  intervent ionand fro m the study  at that time .
If the participant withdraws consent for disclosure of future informat ion, the sponsor may  retain 
and cont inue to use any data collected before such a withdrawal o f consent.   If a participant 
withdraws fro m the study , he/she may  request destructi on of  any sam ples taken and not tested, 
and the invest igator must document this in the site study records.
7.2.1. Discontinuation of In advertently Enrolled Participants
If the sponsor or invest igator ident ify a participant who did not meet enrollment criteria and was 
inadvertent ly enro lled, then the participant shoul d be discont inued fro m study  treatm ent unl ess 
there are extenuating circu mstances that make it medically necessary for the participant to 
continue on study  treatm ent.  If the invest igator and the sponsor clinical research physician 
(CRP )agree it is medically appropriate to continue, the invest igator must obtain documented 
approval  from the sponsor CRP to allow the inadvertently  enrolled parti cipant to continue in the 
study  with or wi thout treatm ent wi th IP. Safet y follow-up is as outlin ed in Sect ion 1.3(Schedule 
of Activities), Section 8.3(Adverse Events and Serious Adverse Events), and Section 8.2(Safet y 
Assessments) of the protocol .
7.3. Lost to Follow -up
A participant will be considered lost to follow -up if he or she repeatedly fails to return for 
scheduled visits and is unable to be contacted by  the study  site.
The fo llowing acti ons m ust be taken ifa participant fails to return to the clinic for a required 
study  visit:
The site must attempt to contact the participant and reschedule the m issed visit as soon as 
possible and counsel the participant on the importance o f maintaining the assigned visit 
schedule and ascertain whether or not the participant wishes to and/or sh ould continue in 
the study .
Before a participant is deemed lost to f ollow-up, the invest igator or designee must make 
every effort to regain contact with the participant (where possible, 3 telephone calls and ,
if necessary ,a certified letter to the partici pant’s last known mailing address or local 
CONFIDENTIAL I8H-MC-BDCL (d)
LY3209590 49equivalent m ethods). These contact attempts should be documented in the participant ’s 
medical record .
Shoul d the participant continue to be unreachable, he/she will be considered to have 
withdrawn from  the study . 
Discontinuati on of  specific sites or of the study  as a who le are handled as part of Secti on10.1.
CONFIDENTIAL I8H-MC-BDCL (d)
LY3209590 508. Study Assessments and Procedures
Study  procedures and the study  visit s at whi ch they  are perform ed, including tolerance limits for 
the study  visits, are listed in the Schedule of Act ivities (Sect ion1.3).  Adherence to the study 
design requirements, including those specified in the Schedule of Act ivities, is essent ial and 
requi red for study conduct .
Efficacy and safet y assessments included i n this study  are generally  regarded as reliable and 
accurate with respect to the efficacy and safet y assessments in individuals and populat ions with 
T2DM .
8.1. Efficacy Assessments
8.1.1. Primary Efficacy Assessments
The primary  efficacy  measure is HbA1c change from  baseline to Week 26.
8.1.2. Secondary Efficacy Assessments
Secondary  efficacy assessments for this study are:
• HbA1c change fro m baseline to Week 12
• FGchange from baseline to Weeks 12 and 26.
8.2. Safety Assessments
Planned time po ints for all safet y assessments are provided in the Schedule o f Activities, 
Secti on1.3.
The fo llowing safety  assessments will be evaluated as secondary  object ives:  
Incidence and ra te of hypoglycemia 
Incidence of treatment -emergent SAEs
Clinical laboratory  assessments with specific focus on liver aminotransferase changes .
8.2.1. Physical Examinations
A co mplete physical examinat ion will include, at a minimum, assessments of the CV, 
Respiratory , Gastroi ntestinal and Neuro logical systems. Height and weight will also be 
measured and recorded.
Invest igators should pay special attention to clinical signs related to previous serious illnesses.
Addit ionally , invest igators should inspect inject ion sites during the physical examinat ion.  
8.2.2. Vital Signs
For each participant , vital signs measurements should be conducted according to the Schedule of 
Activities (Secti on1.3)
.
Sitting blood pressure ( BP)and pulse rate will be measured using automated electronic 
sphygmo mano meter according to the Schedule o f Activities (Secti on1.3).  Vi tal sign 
measurements should be taken before obtaining an ECG tracing and before collect ion of blood 
CONFIDENTIAL I8H-MC-BDCL (d)
LY3209590 51samples for laboratory  testing, at vi sits where required (see Schedule of Act ivities, Secti on1.3).
The parti cipant shoul d be required to sit quiet ly for 5 minutes before vital sign measurements are 
taken.  An appropriately sized cuff (cuff bladder encircling at least 80% of the arm) should be 
used to ensure the accuracy  of BP m easurements.  The arm use d for the BP measurement should 
be supported at heart level.  Blood pressure shoul d be m easured consistent ly using the same arm 
throughout the study .  For each parameter (pulse rate, sy stolic BP, and diastolic BP), 3 
measurements will be taken using the sa me arm; the recordings should be taken at least 1 minute 
apart, and each measurement of sitting pulse rate and BP will be recorded in the eCRF.
8.2.3. Electrocardiograms
For each patient, triplicate 12 -lead digital ECGs and single safet y ECGs will be collected 
according to the Schedule of Act ivities (Secti on1.3).  Patients must be supine for approximately 
5 to 10 minutes before ECG collect ion and rem ain sup ine but awake during ECG collect ion.
ECGs will be performed prior to collect ion of any  blood sam ples.
ECGs will be interpreted by  a qualified physician ( the invest igator or qualified designee) at the 
site as soon as possible after the time of ECG collecti on, and ideally  while the pati ent is still 
present, to determine whether the patient meets entry  criteria at the relevant visit(s) and for 
immediate patient management should any  clinically  relevant findings be ident ified.  
Digital ECGs will be electroni cally transmitted to a central ECG laboratory  designated by  Lilly .  
The central ECG laboratory  will perf orm a basic quali ty control  check (for example, 
demographics and study  details) then store the ECGs in a database.  At a f uture time, the stored 
ECG data may be overread at the central ECG laboratory  for further eval uation of  machine -read 
measurements or to meet regulatory  requi rements.  
The m achine -read ECG intervals and heart rate may  be used for data analysis and report w riting 
purposes unless an overread of the ECGs is conducted prior to complet ion of the final study  
report (i n which case the overread data would be used).
8.2.4. Self-monitoring of Blood Glucose (SMBG )
At Visit 2, patients will receive plasma -equivalent glucose m eters andstrips. SMBG readings 
shoul d be perform ed for monitoring patientsafet y (hypoglycemia) and may  be checked as 
frequently as necessary .  Pati ents shoul d record all SMBG measurements in the study diary
provi ded.  Patients with missing SMBG values m ay need to be retrained on the importance of 
SMBG m onitoring.
Patients will  also m easure FG daily  and as needed to evaluate symptoms of hypoglycemia.
Patients willbe instructed to perform 6-point SMBG profiles over a 24 -hour period on 
2nonconsecut ive days during the 7-day period prior to visits indicated in the Schedule o f 
Activities (Secti on1.3).  The 6-point profile consists o f pre-meal and 2 -hour postprandial SMBG 
measurements for the morning, midday, and evening meals in 1 day .  Pre -meal measurements 
shoul d be taken before the patientbegins eat ing the meal.  Patients shoul d record thei r glucose 
measurements in their study  diaries and bring the diary  to the investi gative si te at eac h study  
visit. 
CONFIDENTIAL I8H-MC-BDCL (d)
LY3209590 528.2.5. Safety Monitoring
The principle invest igator will monitor safet y and laboratory  data throughout the study and 
shoul d discuss s afety concerns wit h the sponsor immediately upon occurre nce or awareness of 
the concern to determine whether the participant should continue or discontinue study  drug .
8.2.5.1. Hepatic Safety Monitoring
If a study  patient experiences elevated ALT ≥3X ULN, ALP ≥2X ULN, or elevated TBL ≥2X 
ULN, liver testing ( Secti on10.6) shoul d be repeated within 3 to 5 days including ALT, AST, 
ALP, TBL, direct bilirubin, gamma -glutamyl  transferase, and creat ine kinase to confir m the 
abnorm ality and to determine if it is increasing or decreasing.  If the abnormalit y persists or 
worsens, clinical and laboratory  monitoring shoul d be ini tiated by  the invest igator and in 
consultation wit h the study  Lilly  Medical .  Moni toring of ALT, AST, TBL, and ALP should 
continue until levels normalize or return to approximate baseline levels. 
Hepatic Safety Data Collection
Addit ional safet y data should be co llected via the eCRF if 1 or more of the fo llowing condi tions 
occur: 
elevation of ALT to ≥5X ULN on 2 or more consecutive blood tests
elevated TBL to ≥2X ULN (except for cases of known Gilbert’s syndro me)
elevation of ALP to ≥2X ULN on 2 or more consecutive blood tests
patient discont inued fro m treatm ent due to a hepatic event or abnormalit y of 
liver tests
hepat ic event considered to be a SAE .
8.2.6. Clinical Safety Laboratory Assessments
See Secti on10.2 for the list of clinical laboratory  tests to be perform ed and the Schedule of 
Activities(Secti on 1.3)for the timing and frequency .
The invest igator must revi ew the laboratory  report, docum ent thi s review, and record any  
clinically relevant changes occurring during the study  in the AE section of the eCRF. The 
laboratory  reports m ust be filed wit h the source documents. Clinically significant abnorm al 
laboratory  findings are those which are not associated with the underlying disease, unless judged 
by the investigator to be more severe than expected for the participant's condit ion.
All laboratory  tests wi th values considered clinically  significantly a bnorm al during parti cipat ion 
in the study  or wi thin 6 weeks after the l ast dose of study  intervent ion (that i s, wi thin the fo llow-
up period) shoul d be repeated until the values return to normal or baseline or are no longer 
considered clinically significant by the investigator or Lilly medical.
If such values do not return to normal/baseline wit hin a peri od of  time judged reasonable 
by the investigator, the etio logy should be identified and the sponsor notified.
All protocol -requi red laboratory  assessments, as defined in Section10.2, must be 
conducted in accordance with the laboratory  manual  and the Schedule of Act ivities.
CONFIDENTIAL I8H-MC-BDCL (d)
LY3209590 53If laboratory  values fro m non-protocol  specified l aboratory  assessments perform ed at the 
institution’s l ocal laboratory  requi re a change in parti cipant m anagement or are 
considered clinically significant by  the investi gator (e .g., SAE or AE or dose 
modificati on), then the results m ust be recorded in the eCRF.
8.2.7. Body Weight
Body  weight will be m easured at prespecified t ime points (see Schedule o f Activities, 
Secti on1.3).  Pati ents will  be weighed in a light hospital gown or standard clinical research site 
scrubs at approximately  the same t ime in the morning after an overnight fast and after evacuat ion 
of bowel  and bladder contents, if possible.  
Weight will be measured once at s creening (non -fasting) and recorded in the source document 
and eCRF.  At lead- in and rando mizat ion (Visit 2 and Visit 3, respectively) and all subsequent 
visits indicated in the Schedule of Act ivities (Section 1.3), weight will be measured twice, with 
the pati ent stepping off the scale between measurements.  
Both wei ght m easurements will be recorded in the source document and the eCRF.  Calibrated 
(within 6 m onths pri or to study  start) scal es shoul d be used.  The same scale should be used for 
all weight m easurements throughout the study  and shoul d not be m oved during the conduct of 
the study .
8.3. Adverse Events and Serious Adverse Events
AEswill be reported by  the parti cipant (or, when appropriate, by a caregiver, surrogate, or the 
participant's legally  authori zed representative).
The invest igator and any qualified designees are responsible for detecting, documenting, and 
recording events th at meet the definit ion of an AE or SAE and remain responsible for fo llowing 
up AEs that are serious, are considered related to the study  intervent ion or study  procedures, or 
that caused the participant to discontinue the study intervent ion or the study  (see Secti on 7).
8.3.1. Time Period and Frequency for Collecting AE and SAE Information
All AEs occurring after signing the ICF are recorded in the eCRF and assessed for serious 
criteria.
The SAE reporting to sponsor begins after the patient has signed the ICF and has received study  
drug.  However, if an SAE occurs after signing the ICF, but prior to receiving LY3209590, it 
needs to be reported ONLY if it is c onsidered reasonably possibly related to study  procedures.
All SAEs will be recorded and reported to the s ponsor or designee immediately and under no 
circumstance shoul d this exceed 24 hours, as indicated in Secti on10.3. The invest igator will 
submit any  updated SAE data to the sponsor within 24 hours of i t being available.   
Invest igators are not obligated to actively seek AE or SAE after conclusio n of the study  
participat ion. However, if the invest igator learns of any SAE, including a death, at any t ime after 
a participant has been discharged from the study
, and he/she consi ders the event to be reasonably  
related to the study  intervent ion or study  parti cipati on, the invest igator must prompt ly notify  the 
sponsor .
CONFIDENTIAL I8H-MC-BDCL (d)
LY3209590 548.3.2. Method of Detecting AEs and SAEs
The m ethod of recording, evaluat ing, and assessing causalit y of AE and SAE and the procedures 
for com pleting and transmitt ing SAE reports are provided in Section10.3.
Care will be taken not to introduce bias when detecting AEs and/or SAEs. Open -ended and 
non-leading verbal quest ioning of the participant is the preferred method to inquire about 
AEoccurrences .
8.3.3. Follow -up of AEs and SAEs
After the initial AE/SAE report, the investigator is required to proactively fo llow each participant 
at subsequent visits/ contacts. All SAEs, and AEs of special int erest (AESIs) (as defined in 
Secti on 8.3.7 ), will be followed unt il reso lution, stabilizat ion, the event is otherwise explained, 
or the participant is lost to follow -up (as defined in Secti on7.3). Further informat ion on fo llow-
up procedures is provi dedin Section10.3.
8.3.4. Regula tory Reporting Requirements for SAEs
Prom pt notificat ion by the invest igator to the sponsor of a SAE is essent ial so that l egal 
obligat ions and ethical responsibilit ies towards the safet y of parti cipants and the safet y of a study  
intervent ion under clinical investigat ion are m et.
The sponsor has a legal responsibilit y to notify both the l ocal regulatory  authori ty and other 
regul atory  agencies about the safet y of a study  intervent ion under clinical investigation. The 
sponsor will co mply wi th country -specific regulatory  requi rements relating to safet y reporti ng to 
the regulatory  authori ty, Inst itutional Review Boards (IRB)/Independent Ethics Committees 
(IEC) , and invest igators.
Invest igator safet y reports must be prepared for suspected unexpected serio us adverse react ions 
(SUSAR) according to local regulatory  requi rements and sponsor policy  and f orwarded to 
investigators as necessary .
An invest igator who receives an invest igator safety report describing a SAE or other specific 
safet y informat ion (e.g., summary or list ing of SAEs) from the sponsor will review and then file 
it along wi th the IBand will notify the IRB/IEC, if appropriate according to local requirements.
8.3.5. Pregnancy
Pregnancy (maternal or paternal exposure to IP) does not meet the d efinit ion of an AE.  
However, to fulfill regulatory  requi rements, any pregnancy  should be reported following the 
SAE process described in Section10.4 to collect data on the outcome for both mother and fetus
.
Details o f all pregnancies in female participants and, if indicated, femal e partners of m ale 
participants will be co llected after the start of study intervent ion and unt il 90 days after the l ast 
dose.
If a pregnancy  is reported, the investigator should inform the sponsor within 24 hours of learning 
of the pregnancy  and shoul d follow the procedures outlined in Section10.4.
Abnorm al pregnancy outcom es (e.g., spontaneous abortion, fetal death, stillbirth, congenital 
anomalies, ectopi c pregnancy ) are considered SAEs.
CONFIDENTIAL I8H-MC-BDCL (d)
LY3209590 558.3.6. Cardiovascular Events
Deaths and nonfatal CV A Es will  be adjudicated by  a commi ttee of  physicians external to Lilly 
with cardi ology expertise.  The nonfatal CV AEs to be adjudicated include:  myocardial  
infarction ; hospi talizat ion for unstable angina; hospitalizat ion for heart failure; coronary  
interventions (such as coronary  artery  bypass graft or percutaneous coronary  intervent ion); and 
cerebrovascular events, including cerebrovascular accident (stroke) and transient ischemic 
attack.
8.3.7. Adverse Events of Special Interest
Adverse events of special interest (AESIs) for this program include:
a.Hypoglycemia
b.Allergic/hypersensit ivity react ions
If any o f these AESIs are reported, sites will be prompted to collect additional details/data.
8.3.7.1. Hypoglycemia
Patients will  collect inform ation on epi sodes of hypogly cemia starting from Visit 2 unt il the last 
study  visit (Visi t 801 or ET vi sit).  For that purpose, pati ents will  be trained about si gns and 
symptoms of hypoglycemia, how to treat hy poglycemia, and how to collect in study  diaries
appropriate informat ion foreach episode of hypoglycemia according to the Schedule of 
Activities (Secti on1.3).  
Parti cipants are encouraged to perform SMBG , whenever hypoglycemia may be suspected, 
either by symptom s experienced or perceived increased risk as related to dietary  intake, physical 
activity, or inadvertent or aty pical  insulin dosing. All patients will be instructed to treat a SMBG
≤70mg/dL ( <3.9 mmo l/L) as hypoglycemia.
Parti cipants will be instructed to report hy poglycemia in the eDiary  any time he/she experiences 
signs or symptom s ofhypoglycemia with or without a SMBG ≤70 mg/dL (<3.9 mmo l/L).
Severe hypoglycemia is defined as an event requi ring assistance o f another person to actively  
administer carbohydrate, glucagon, or other resuscitat ive act ions. During these episodes, the 
participant has an altered mental status and cannot assist in his/her own care, may be
semico nscious or unconscious, or experience co ma with or wi thout sei zures, and may require 
parenteral  therapy .Glucose measurements may not be available during such an event , but 
neuro logical recovery  attributable to the restoration of blood glucose concentration to normal is 
considered sufficient evidence that the event was induced by a low blood glucose concentration 
(≤70 mg/dL [ <3.9 mmo l/L]). 
If a hypoglycemic event meets the criteria of severe as confirmed by the invest igator , it needs to 
be recorded as serious on the AE eCRF and reported to Lilly as a SAE.
In each case of suspected or confirmed hypoglycemia, it is important that the event be properly 
categori zed, the eff ect of the intervention be assessed, and the frequency and durati on of 
hypoglycemia be evaluated.  The role of dietary changes and physical exercise (or any  other 
contributing factor) in the development of an event should be established.  The patient shoul d 
receive addit ional educat ion, if deemed appropriate.   Management of increased risk of 
hypoglycemia is described in Section 6.1.2.2 .
CONFIDENTIAL I8H-MC-BDCL (d)
LY3209590 568.3.7.2. Allergic/Hyper sensitivity Reactions
All allergic or hy persensi tivity react ions, including injection site react ions(ISR) ,will be reported 
by the investigator as either AEs or, if any serious criterion is met, as SAEs.  Symptoms of a 
local ISRmay include ery thema, indurat ion, pain, pruritus, and edema.  If an inject ion site event 
is reported, the AE will be recorded, and additional data will be provided to the sponsor in the 
eCRF.
Addit ional data, such as ty pe of react ion and treatment receive d, will  be collected on any  AEs or 
SAEs that the invest igator deems related to IPvia an eCRF created for this purpose.  The IP
shoul d be temporarily  interrupted in any  individual suspected of having a severe or serious 
allergic reaction to IP(Section 7.1.2 ).  The IPmay be restarted when/if it is safe to do so, in the 
opinio n of the invest igator.  If IPis permanent ly discontinued, see Secti on7.1.1 for procedures 
requi red in this situation .
If an ISR isreported, the informat ion will be provided to the sponsor in the eCRF.  If criteria for 
a SAE are m et, the invest igator will also complete the SAE form and urgently report the SAE.
8.3.7.3. Systemic Hypersensitivity Reactions
Many  drugs, but parti cularly biologic agents ,carry the ri sk of systemic hypersensit ivity 
reacti ons. If such a react ion occurs, a dditional data describing each symptom should be provide d
to the sponsor in the eCRF.  
Sites shoul d have appropri ately  trained medical  staff and appropri ate medical equipment 
available when study  parti cipants are receiving study  drug . It is recommended t hat participants
who experience a systemic hypersensit ivityreact ion be treated per the local standard of care .  
In the case of generalized urticaria or anaphylaxis, addit ional samples should be co llected as 
described in Appendix 10.9, “Reco mmended Laboratory  Test ing for Hypersensi tivity Events”.
Laboratory  resul ts are provi ded to the sponsor via the central laboratory .
8.3.8. Product Complaints
A product complaint is any written, electronic, or oral communicat ion that alleges a deficiency
related to the identit y, qualit y, durabilit y, reliabilit y, safety, effectiveness, or performance of a 
Lilly product after it is released for distribut ion.When the abilit y to use the product safely is 
impacted, the fo llowing are also product complaints: 
a.Deficiencies in labeling informat ion, and
b.Use errors for device or combinat ion products due to ergonomic design elements of the 
product.
Sponsor collects prod uctcomplaints on investi gational  products, m edical devices, and drug 
delivery  systems used in clinical studies in order to ensure the safety  of study  participants, 
monitor qualit y, and to facilitate process and product improvements.
Com plaint sare al so collected on comparators and other materials supplied, as required and 
instructed for the study .
CONFIDENTIAL I8H-MC-BDCL (d)
LY3209590 57Parti cipants will be instructed to contact the investigator as soon as possible if he or she has a 
complaint or probl em wi th the invest igational product, medical device ,or delivery system, so 
that the situation can be assessed.
Product complaints will be reported by  the invest igator to the sponsor per instructions provided 
on the study -specific Product Complaint Form.
With each co mplaint related to a me dical  device or delivery  system , the invest igator will assess 
and indicate on the complaint form whether the product complaint could have l ed to an SAE had 
precauti ons not been taken.
8.4. Treatment of Overdose
In the case of an accidental overdose, contact the sponsor i n regards to patient management. 
For p articipants with suspected or confirmed overdose with LY3209590, there is no specific 
antidote. The pa rticipan t shoul d monitor and be moni tored for hypoglycemia. Treatment is 
supportive, depending on the participant ’s symptoms. The m anagement of hypoglycemia should 
take into accoun t the l ong durat ion of action of LY 3209590, and if there is any concern 
regarding sustained glucose monitoring or nutrient access, the invest igative staff should consider 
imposi ng close medical monitoring, e.g., hospitalization.  
In the event of an overdose with insulin degludec, refer to the Product Label.
8.5. Pharmacokinetics
At the visit s and t imes specified in the Schedule of Act ivities
(Secti on1.3),venous blood 
samples will be co llected to determine the plasma concentrations of LY3209590.  After Visit 3, 
PK samples can be taken at any time during visit s that requi re PK ( Secti on1.3).  Note:  PK 
sample collect ion is not intended for pa rticipant s rando mized to insulin degludec treatment.
Instructi ons for the collect ion and handling of blood samples will be provided by the sponsor .  
The actual  date and time (24- hour clock time) of each sampling will be recorded.
All the samples will be analyzed at a laboratory  designated by the sponsor and stored at a facilit y 
designat ed by  the sponsor. 
Plasma concentrations o f LY3209590 will ut ilize a validated enzyme -linked immunosorbent 
assay (ELISA) method.  
Bioanaly tical samples collected to m easure IP concentration will be retained for a maximum of 
1year fo llowing last pati ent visit for the study .
8.6. Pharmacodynamics
In addit ion to pharmacodynamics ( PD)parameters discussed in the efficacy and safet y sections,
fasting free fatty  acids (FFA) and tri glyceri des will be evaluated as PD bio markers of lipo lysis, 
which is a sensit ive measure of peripheral insulin activit y.
Samples co llected to measure FFA will be ident ified by the pat ient number (coded) and retained 
at a facilit y selected by  Lilly  or its desi gnee f or a maximum  of 2 years fo llowing last pati ent visi t 
for the study  at a facilit y selected by Lilly  or its desi gnee. 
CONFIDENTIAL I8H-MC-BDCL (d)
LY3209590 588.7. Genetics
A blood sam ple for deoxyribonucleic acid (DNA )isolation will be co llected fro m participants. 
See Secti on10.7 for informat ion regardin g genet ic research and Secti on10.1.11 for details about 
sample retention and custody .
8.8. Biomarkers
Biomarker research is performed to address questions of relevance to drug disposit ion, target 
engagement, PD, mechanism of act ion, variabilit y of patient response (including safety ), and 
clinical outcome.  Sample co llection is incorporated into clinical studies to enable examinat ion of 
these quest ions through measurement of bio molecul es including deoxy ribonucleic acid, 
ribonucleic acid, proteins, lipids, and other cellular elements.
Serum  and plasma samples for non -pharmacogenetic bio marker research will be co llected at the 
times specified in the Sc hedule of Act ivities (Section 1.3) where local regulat ions allow.
Samples will  be used for research on the drug target, disease process, variable r esponse to 
LY3209590 pathways associated with T2DM, mechanisms o f action of LY3209590 and/or 
research methods or in validating diagnostic tools or assay (s) related to T2DM.
All samples will be coded with the patient number.  These samples and any data gene rated can 
be linked back to the patient only by the invest igator site personnel.  
Samples will  be retained for a m aximum  15 years after the l ast pati ent vi sit for the study , or f or a 
shorter period if local regulat ions and ethic review boards impose shor ter time limits, at a facilit y 
selected by  Lilly.  This retenti on peri od enables use of new techno logies, response to regulatory  
questions, and invest igation of variable response that may not be observed unt il later in the 
development of LY3209590 or after LY3209590 become(s) commercially available.
8.9. Immunogenicity Assessments
At the visit s and t imes specified in the Schedu le of Act ivities (Secti on1.3), venous blood
samples will be collected for analysis to determine antibody  producti on against LY3209590 .  
Antibodies may be further characterized for cross
-reactive binding to insulin. In vivo laboratory  
indicators for glycemic control ( e.g.,blood gluc ose,HbA1c , and /ordaily insulin dose )may be 
utilized to detect a potential neutralizing effect of anti-drug ant ibodies ( ADA )against 
LY3209590. To interpret the results of immunogenicit y, a venous blood sample will be 
collected at the same time po ints to determine the plasma concentrations of LY3209590 .  All 
samples for immunogenicit y shoul d be taken predose when applicable and possible .
Treatment -emergent (TE) ADAs are defined in Section 9.4.8 .If the immunogenicit y sample at 
the last scheduled assessment or discont inuat ion visit is TE -ADA posit ive, addit ional samples 
may be taken unt il the signal returns to baseline (i.e. ,no long er TE -ADA posit ive) or for up to 
1year after last dose.   
Samples will  be retained for a m aximum  of 15 y ears after the last patient visit, or for a shorter 
period if local  regulat ions and Ethical Review Boards (ERBs) allow, at a facilit y selected by  the 
sponsor.  The duration allows the sponsor to respond to future regulatory  requests rel ated to 
LY3209590 .  Any samples remaining after 15 years will be destroyed. 
CONFIDENTIAL I8H-MC-BDCL (d)
LY3209590 598.10. Health Economic s
No heal th economic outcomes are planned.
CONFIDENTIAL I8H-MC-BDCL (d)
LY3209590 609. Statistical Considerations
9.1. Statistical Hypotheses
The primary  hypothesis is to test whether LY3209590 treatm ent isnon-inferior to insulin
degludec in HbA1c change from baseline to Week 26 in study  partici pants who are insulin naïve 
T2DM , using a non -inferiorit y margin (NIM) of 0.4% .
9.2. Sample Size Determination
Approximately 250 participants will be rando mized to study treatm ents (LY3209590
Algori thm1andinsulin degludec )such that approximately  125 part icipants will be rando mized 
to each treatment. Assuming a 20% dropout rate, approximately 200 partici pants will complete 
the study (approximately  100 pa rticipants per treatment group ). 
The200 participants who complete the treatment will provide more than 8 0% stati stical power to 
demonstrate the non -inferiorit y in the change in HbA1c fro m baseline to 26 weeks for 
LY3209590 Algori thm 1versus insulin degludec ,based on the fo llowing assumpt ions:
True m ean difference = 0%
SD of 1.1%
NIM of 0.4%
Using 2 -sided alpha level o f 0.1
CONFIDENTIAL I8H-MC-BDCL (d)
LY3209590 619.3. Populations for Analyses
The following popul ations are defined:
Population Description
Entered /Enrolled 
Popul ationAll participants who sign the ICF
Randomized Popul ation All participants assigned to treatment, regardless of whether they  
take any  doses of study  treatm ent, or if t hey took the correct 
treatm ent.  The participants previously randomized to 
Algori thm2 will be pool ed wi th the participants rando mized to 
Algori thm 1 and all  of these participants will be analyzed as one 
treatm ent group of LY3209590.
Efficacy Population Parti cipants in randomizat ion populat ion excluding the 
participants previously rando mized to Algorithm 2. 
SafetyPopul ation All participants rando mly assigned to study  treatment and who 
take at least 1 dose of study  treatm ent. The participants 
previousl y rando mized to Algorithm 2 will be pooled with the 
participants randomized to Algorithm 1 and all o f these 
participants will be analyzed as one treatment group of 
LY3209590.
Pharmacokinet ic 
Popul ationAllrandomized participants who received at least 1 d ose of  
LY3209590 and have at least 1 evaluable PK sample.
Abbreviations:  ICF = informed consent form; PK = pharmacokinetics.
9.4. Statistical Analyses
Statistical analysis o f this study  will be the responsibilit y ofsponsor or its designee .
All tests of treatment effects will be conducted at a 2-sided al pha level of 0.1, unl ess otherwise 
stated, and all confidence intervals (CIs) will be given at a 2 -sided 90% l evel.
Any change to the data analysis methods described in the protocol will requi re an amendment 
only if it changes a princi pal feature of the protocol.  Any other change to the data analysis 
methods described in the protocol, and the just ification for making the change, will be described 
in the statist ical analysis plan ( SAP)and the clinical study  report.  Addi tional expl oratory  
analyses o f the data will be conducted as deemed appropriate.
The SAP will include a more technical and detailed descript ion of the statistical analyses 
described in this sect ion. This sect ion is a summary o fthe planned statist ical analyses of the 
most im portant endpoints including primary and key  secondary  endpoints.
CONFIDENTIAL I8H-MC-BDCL (d)
LY3209590 629.4.1. General Considerations
Unless otherwise stated, the efficacy  analyses will  be conducted on efficacy analyses set (EAS) 
based on the Efficacy Popul ation using the data up to the study  treatm ent discont inuat ion 
(defined as the observed data with co llection date before or at the last dose date +10 days).
Sensit ivity analyses for selected efficacy measures may  be conducted on the Rando mized 
Popul ation using the data up to the study  treatm ent discont inuat ion. 
Unless otherwise stated, t he safet y analyses except for hy poglycemia will be conducted on the 
safet y analyses set based on the Safet y Popul ation using all data collected during the study  
including treatm ent and follow -up peri od regardl ess of the treatment disposit ion status. The 
details for analys eson hypoglycemia will be documented in the SAP.
Unless otherwise specified, t he baseline value used for the analyses will be the last non-missing
value obtained for each participant prior to or on the date of first study  IP dose (or randomizat ion
visit date if first dose date is missing) . The baseline liver enzyme lab measures will be the 
average o f allassessments prior to and at randomization visi t.
9.4.2. Treatment Group Comparability
9.4.2.1. Patient Disposition
All randomized pa rticipant s who discontinue the study /treatm entwill be identified, and a reason 
for thei r discont inuat ion will be given.  The reasons for study/treatment discont inuation swill be 
listed and will be summarized by treatment. The discontinuat ion due to adverse event will be 
summarized by  adverse event and treatm ent. The percentage of participants discont inuing fro m 
each treatment will be compared using the Fisher’s exact te st.
Reasons for discont inuat ion prior to randomization will also be summarized.
9.4.2.2. Patient Characteristics
Dem ographic and baseline characterist ics will be summarized by treatment group for 
Randomized Populat ion and Efficacy Population . Categorical variable s will  be summarized by  
frequencies and percentages, and comparisons between treatment groups will be assessed using a 
Pearson Chi -Square test. Continuous variables will be summarized by mean and standard 
deviat ion, and compar isons between the treatment g roups will be performed using a 1 -way 
analysis of variance with treatment as the fixed effect.
9.4.2.3. Concomitant Therapy
Summary of concomitant therapies will be provided by  treatm ent group for all rando mized 
participants .
9.4.2.4. Treatment Compliance
Treatment complian ce will  be assessed using the EAS and summarized by treatment . The 
incidence of missed dose and the percentage of missed dose will be evaluated.
Adherence to the dosing algorithm was assessed based on the number and percentage of 
investigator prescribed doses that did not fo llow the inv estigator -calculated al gorithm dose and 
CONFIDENTIAL I8H-MC-BDCL (d)
LY3209590 63the number and percentage of participant actual administration dose that did not fo llow the 
investigator prescribed dose .
9.4.3. Primary endpoint(s)
The primary  object ive is to compare the HbA1c change fro m baseline to Week 26 between 
LY3209590 treatm ent and insulin degludec .  It i s intendedto estimate the treatment differences 
inthe change in HbA1c from baseline to 26 weeks if participants adhere dto the treatment 
without intercurrent events (stop of the study  medicati on and/or use of rescue medication). It is a 
type of hypotheti cal estimand based on International Council for Harmonisation ( ICH) E9(R1).  
Only data before the occurrence of the inte rcurrent events (use of rescue medicat ion or stop of 
the study  medicat ion) will be included in the analysis and the result ing missing values will be 
imputed implicit ly in the mixed -effect m odel for repeated m easurements ( MMRM) analysis .  
The MMRM model wil l include treatm ent, strata (country , DPPIV [y es/no], SGLT2 [y es/no] and 
baseline BMI [<30, ≥30]), visit, and treatment by visit interaction as fixed factors and the 
baseline of the dependent vari able as a continuous covariate. 
As a sensit ivity analysis, the treatm ent differences in HbA1c change from baseline to Week 26,
only if patients coul d com plete the treatm ent, will also be estimated. More details will be 
specified in the SAP. 
9.4.4. Secondary endpoint(s)
The following secondary  efficacy outcom es will  be analyzed:
Fasting glucose and c hange fro m baseline at 12 and 26weeks
HbA1c change fro m baseline to 12 weeks
9.4.5. Tertiary/exploratory endpoint(s)
Refer to the SAP for analyses related to tertiary /expl oratory  endpoints.
9.4.6.
Safety Analyse (s)
Unless otherwise stated, allsafet y analyses will be based on the safet y analysis set . Safet y 
measures include treatm ent exposure, adverse events, vital signs, hypoglycemic episodes, 
laboratory  measurements, ECG and immunogenicity .
9.4.6.1. Adverse Events
AEs will be summarized as TEAEs (defined as events that are newly  reported after 
rando mizat ion or reported to worsen in severit y from baseline).  The incidence of participants
with at least 1 TEAE and the incidence of TEAEs by  preferred term  and system organ class will 
be presen ted by  treatm ent group.  The frequency  and percentage of participant s for each 
preferred term will be presented.  The incidence of participant s with at least 1 TEAE assessed as 
possibly  related to the invest igational drug will be summarized by  treatm ent gr oup, in addit ion to 
the incidence of these possibly  related TEAEs by  preferred term .  In addi tion, a summary  of 
TEAEs by  severi ty will be presented descript ively by treatment group.
Reported and adjudicated CVswill be listed by participant , and if there a re a sufficient number 
of cases they  may be summarized by  treatm ent group.
CONFIDENTIAL I8H-MC-BDCL (d)
LY3209590 64All SAEs will be listed by  participant .  If a sufficient number of SAEs are reported, incidence 
summaries similar to incidence of TEAEs will be included.
Discontinuati ons due to AE will be summarized by treatment group and preferred term .
9.4.6.2. Vital Signs
Descript ive statistics for the actual measurements and changes from baseline will be presented 
by treatment group and visit.  Corresponding figures may be presented. Vital signs will  be
analyzed using a MMRM model.
9.4.6.3. Hypoglycemia Episodes
The incidence and rate per year of hypoglycemi awill be presented for the periods between 0to 
12 weeks and 12to 26 weeks , 0to 26 weeks and the follow-up peri odand analyzed according to 
the hypoglycemia definit ions described in the ADA classification system (ADA 2019). The 
analyses for hypoglycemia will be performed on Efficacy  Popul ation and addit ionally  severe 
(level 3) hypoglycemia analys eswill also be perfo rmed for the Safet y Popul ation.
9.4.6.4. Laboratory Measures
Summary  statistics will be provided for laboratory  measures by  treatm ent group and by visit. An 
additional listing will be presented for all laboratory measurements that are outside the normal 
range.
Descript ive statistics for the laboratory analyses will be presented by treatment group and visit.   
Laboratory  analyses wi th categori cal responses will be summarized by  visit and treatment group 
using frequency  and percentage.
The maximum/minimum post- baseline observation (as applicable for a lab) will be compared to 
the baseline observat ion by examining the proportion of participant s whose test values are within 
and outsi de the reference ranges.
9.4.6.5. Electrocardiograms
ECG is mainly for participant safet y monitoring. Exploratory  analysis may  be conducted as 
necessary .
9.4.6.6. Adverse Events of Special Interest
Hypoglycemia and allergic/hypersensit ivity react ionsare defined as AESIs (Secti on 8.3.7 ).
Descript ive statistics for the AESIs will be presented by treatment group.  
9.4.7. Pharmacokinetic/Pharmacodynamic Analyses
LY3209590 concentration data will be analyzed using a populat ion PK appr oach via nonlinear 
mixed -effects m odeling wi th the NONMEM software. The relationships between LY3209590
dose and/or concentration and efficacy, tolerabilit y, and safet y as well as bio marker endpoints 
will be characterized if exploratory  analyses of the PD data warrant further PK/PD analyses upon 
review. Such analyses may include, but are not necessarily limited to, glucose, HbA1c, QTc, 
hypoglycemia, and vital signs.
CO N FI D E N TI A L I 8 H -M C -B D C L ( d) 
L Y 3 2 0 9 5 9 0 6 5 I n a d dit i o n, if p o p ulat i o n P K a n d P K/ P D m o dels ca n be esta blis he d ,t h e i m pact of a d dit i o na l 
parti ci pa nt fact ors ,s uc h as a ge, wei g ht, ge n der a n d re nal f u nct i o n o n P K a n d/ or P D para meters, 
ma y be e xa mi ne d. S h o ul d a nt i dr u g a nti b o d y be detecte d fr o m i m m u n o ge nicit y testi n g, its 
i m pact o n L Y 3 2 0 9 5 9 0 P K or a n y  r el e va nt P D para meters will als o be e xa m i ne d. 
9. 4. 8. E v al u ati o n of I m m u n o ge nicit y 
T he fre q ue nc y a n d perce nta ge of parti ci pa nts wi t h  pree xist i n g A D A a n d wit h T E -A D A t o 
L Y 3 2 0 9 5 9 0 ma y be ta b ulate d. Treat me nt -e mer ge nt A D As are defi ne d as t h ose wit h a titer 
2- f o l d ( 1 dil uti o n) greater t ha n t he mi ni m u m re q ui re d dil ut i o n if n o A D As were detecte d at 
baseli ne (treat me nt -i n d uce d A D A) or t h ose wit h a 4 -f o l d ( 2 dil uti o ns) i ncrease i n titer c o m pare d 
t o baseli ne if A D As were detecte d at baseli ne (treat me nt -b o oste d A D A). 
T he fre q ue nc y of cr oss -reacti ve bi n di n g t o i ns uli n ma y als o be ta b ulate d i n T E A D A + s u bjects, 
w he n a vaila ble. 
T he rel at i o ns hi p bet wee n t he prese nce of a nt i b o dies a n d t he P K para meters a n d P D res p o nse 
i ncl u di n g safet y a n d efficac y  t o L Y 3 2 0 9 5 9 0ma y be assesse d. 
9. 4. 9. Ot her A n al yses 
Detail e d a nal ysis pla n f o r F G M will be d oc u m e nte d i n S A P. 
9. 5. I nteri m A n al yses 
9. 6. D at a M o nit ori n g C o m mittee ( D M C) 
N o D M C i s pla n ne d f or t his st u d y .C CI 
CONFIDENTIAL I8H-MC-BDCL (d)
LY3209590 6610. Supporting Documentation and Operational Considerations
10.1. Appendix 1: Regulatory, Ethical, and Study Oversight 
Considerations
10.1.1. Regulat ory and Ethical Considerations
This study  will be conducted in accordance wit h the protocol and with the fo llowing:
Consensus ethical principles derived from international guidelines including the 
Declaration of Helsinki and Council for International Organ izations of Medical Sciences 
(CIOMS) International Ethical Guidelines
Applicable ICH Good Clinical Practice (GCP) Guidelines
Applicable laws and regulations
The protocol, protocol amendments, ICF, IB, and other relevant documents (e .g., adverti sements) 
must be submi tted to an IRB/IEC by  the invest igator and reviewed and approved by the IRB/IEC
before the study  is init iated.
Any amendments to the protocol will require IRB/IEC approval before implementation of 
changes made to the study  design, except for chan ges necessary  to eliminate an immediate 
hazard to study  parti cipants.
Under emergency  circumstances, deviations from this protocol to protect the rights, safety , or 
well-
being of participants are allowed without prior approval of Lilly and the IRB/IEC. The site 
shall document and report these emergent deviat ions to Lilly  and the IRB/IEC wi thin 5 working 
days after the emergency occurred.
Deviat ion(s) fro m this protocol , signed 1572, applicable regulat ions, and any condit ions of 
approval  imposed by an IRB /IEC or applicable regulators shall be documented (including date of 
and reason for deviation). Site personnel must ident ify and report deviations to the sponsor 
within 5 working days.
If appropriate, actions to secure compliance may be taken by  Lilly.  T hese act ions may include 
removal or discont inuat ion ofstudy  intervent ion materials , rem oval/disposal o f devices fro m the 
investigator, or terminat ion of an invest igator’s participat ion in the study .
The invest igator will be responsible for the fo llowing:
Provi ding wri tten summaries of the status of the study  to the IRB/IEC annually  or m ore 
frequently in accordance with the requirements, policies, and procedures established by 
the IRB/IEC
Notifying the IRB/IEC of SAEs or other significant safet y findings as requi red by  
IRB/IEC procedures
Provi ding oversight of the conduct of the study  at the site and adherence to requirements 
of 21 CFR, ICH gui delines, the IRB/IEC, European regulat ion 536/2014 for clinical 
studi es (if applicable), and all other applicable lo cal regulat ions
CONFIDENTIAL I8H-MC-BDCL (d)
LY3209590 6710.1.2. Financial Disclosure
Invest igators and sub -invest igators will provide the sponsor with sufficient, accurate financial 
inform ation as requested to allow the sponsor to submit complete and accurate financial 
certification or disclosure statem ents to the appropri ate regul atory  authori ties. Invest igators are 
responsible for providing informat ion on financial interests during the course of the study  and for 
1 year after com pletion of the study .
10.1.3. Informed Consent Process
The invest igator or his/he r representative will explain the nature of the study , including the risks 
and benefits, to the parti cipant or his/her legally  authori zed representati ve and answer all
questions regarding the study .
Parti cipants m ust be inform ed that thei r parti cipat ion is voluntary. Participants or thei r legally 
authori zed representative will be required to sign a statement of informed consent that meets the 
requi rements of 21 CFR 50, local regulations, ICH guidelines, Health Insurance Portabilit y and 
Accountabilit y Act ( HIPAA) requirements, where applicable, and the I RB/IEC or study center.
The m edical  record m ust include a statem ent that wri tten inform ed consent was obtained before 
the participant was enter ed in the study  and the date the written consent was obtained. The 
authori zed person obtaining the informed consent must also sign the ICF.
Parti cipants m ust be re -consented to the most current versio n of the ICF(s) during th eir 
participat ion in the study.
A copy  of the ICF(s) m ust be provi ded to the participant or the participant’s legally authorized 
representati veand is kept on file.
Parti cipants who are rescreened are required to sign a new ICF.
10.1.4. Data Protection
Parti cipants will be assigned a unique identifier by the sponsor. Any participant records ,datasets
or tissue samples that are transferred to the sponsor will contain the identifier only; participant 
names or any  information which would make the participant ident ifiable will not be transferred.
The parti cipant must be inform ed that hi s/her personal  study -related data will  be used by  the 
sponsor in accordance wit h local data protecti on law. The l evel of discl osure must al so be 
explained to the participant who will be required to give consent for their data to be used as 
described in the informed consent
The participant must be inform ed that hi s/her m edical  records m ay be examined by Clinical 
Qualit y Assurance auditors or other authorized personnel appo inted by  the sponsor, by  
appropriate IRB/IEC members, and by inspectors from regulatory  authori ties.
10.1.5. Dissemin ation of Clinical Study Data
Reports
The sponsor will disclose a summary o f study  information, including tabular study results, on 
publicly available websites where require d by local law or regul ation. 
Data
CONFIDENTIAL I8H-MC-BDCL (d)
LY3209590 68The sponsor provides access to all individual pa rticipant data collected during the trial, after 
anonymizat ion, wi th the excepti on of  pharmacokinetic or genetic data.   Data are available to 
request 6 months after the indicat ion studied has been approved in the United States and 
European Unio nand after primary publicat ion acceptance, whichever is later.  No expirat ion date 
of data requests is current ly set once data are made available.  
Access i s provi ded af ter a proposal  has been approved by  an independent review committee 
ident ified for this purpose a nd after receipt of a signed data sharing agreement.   Data and 
docum ents, including the study  protocol , statistical analysis plan, clinical study  report, bl ank or 
annotated case report forms, will be provided in a secure data sharing environment for up to
2years per proposal.  
For details on submitting a request, see the instructio ns provided at 
www.clinicalstudy datarequest.com .
10.1.6. Data Quality Assurance
All participant data relat ing to the study  will be recorded on printed or electronic CRF unless 
transmit ted to the sponsor or designee electronically  (e.g., laboratory  data). The invest igator is 
responsible for verifying that data entries are accurate and correct by  physically  or electronically 
signing the CRF.
The invest igator must maintain accurate docum entati on (source data) that supports the 
inform ation entered in the CRF.
The invest igator must permit study -related m onitoring, audi ts, IRB/IEC review, and regulatory  
agency  inspect ions and provide direct a ccess to source data documents.
Moni toring de tails describing strategy  (e.
g., risk -based init iatives in operations and qualit y such 
as Risk Management and Mit igation Strategies and Analyt ical Risk-Based Monitoring), methods, 
responsibilit ies and requirements, including handling of nonco mpliance issue s and m onitoring 
techniques (central, remote, or on -site monitoring) are provided in the contracts .
The sponsor or designee is responsible for the data management of this study  includin g qualit y 
checking o f the data.
The sponsor assumes accountabilit y for actions delegated to other individuals (e
.g., Contract 
Research Organizat ions).
Study  monitors will perform  ongoing source data verification to confirm that data entered into 
the CRF by  authori zed si te personnel  are accurate, com plete, and verifiable fro m source 
docum ents; that the safet y and ri ghts of  parti cipants are being protected; and that the study  is 
being conducted in accordance with the current ly approved protocol and any other study 
agreem ents, ICH GCP, and all applicable regu latory requirements.
Records and documents, including signed ICFs, pertaining to the conduct of this study  must be 
retained by the invest igator for 15years after study completion unless local regulat ions or 
institutional policies requi re a l onger retenti on period. No records may be destroy ed during the 
retenti on peri od wi thout the wri tten approval  of the sponsor. No records may be transferred to 
another location or party  without wri tten notificat
ion to the sponsor .
CONFIDENTIAL I8H-MC-BDCL (d)
LY3209590 69In addit ion, sponsor or its representatives will periodically check a sample of the participant data 
recorded against source documents at the study  site.  The study  may be audi ted by  sponsor or its 
representatives, and/or regulatory  agencies at any  time.  Invest igators will be given notice before 
an audit occurs.  
Data Capture System
The invest igator is responsible for ensuring the accuracy, completeness, legibilit y, and timeliness 
of the data reported to the sponsor.
An electronic data capture sy stem  (EDC) will be used in this study  for the collect ion of CRF 
data.   The investigator maintains a separate source for the data entered by  the invest igator or 
designee into the sponsor -provided EDC system.  The invest igator is responsible for the 
ident ificat ion of any data to be considered source and for the confirmat ion that data reported are 
accurate and complete by  signing the CRF .
Addit ionally , electroni c Clinical Outcome Assessment (eCOA) data (participant -focused 
outcom e instrument) will be direct ly recorded by  the parti cipant, caregiver, and/or invest igator 
site pers onnel, into an instrument (for example, hand held smart phone or tablet).  The eCOA 
data will serve as the source documentation and the invest igator does not maintain a separate, 
written or electronic record of these data.    
If eCOA records are stored at a third -party  site, investi gator si tes will  have continuous access to 
the source documents during the study  and will  receive an archival copy  at the end of the study  
for retenti on
Data collected via the sponsor- provided data capture systems will be stored at third -parties. The 
investigator will have cont inuous access to the data during the study  and unt il deco mmissio ning 
of the data capture sy stem s.  Pri or to decommissio ning, the invest igator will receive an archival 
copy  of pertinent data for retention.
Data m anaged by  a central  vendor, such as laboratory  test data, will be stored electronically  in 
the central  vendor’s database system and reports/electronic transfers will be provided to the 
investigator for review and retention.  Data will subsequent ly betransferred fro m the central  
vendor to the sponsor data warehouse.
Data from co mplaint forms submitted to sponsor will be encoded and stored in the global 
product complaint management sy stem .
Study Procedures
Electronic Clinical Outcomes Assessment
The us e of eCOA e -diaries shoul d also allow more complete and accurate capturing of 
hypoglycemic events, and dosing as well as more frequent and timely  interact ions between 
investigator and patients as the intensit y of their individual diabetes management increa ses.
Physicians and designated clinical staff will have access via the eCOA portal (secured web -based 
site) to blood glucose ( BG)readings, hypoglycemic events, and dosing informat ion for each 
patient once transferred. It is recommended that investigato rs review pat ient data via the eCOA 
portal  at least once weekly for clinical decisio n making and safety  monitoring. More frequent 
reviews may be necessary  for individual  patient management.
CONFIDENTIAL I8H-MC-BDCL (d)
LY3209590 70An instructi on m anual will be provided to patients and invest igative sites. Addit ional instructi on 
and training will be provided to the invest igative sites regarding data collect ion, review, 
retenti on, and archival processes. In the event of eCOA eDiary malfunct ion or l oss, the pati ent 
will be instructed to immediatel y contact the investigat ive site for instructions regarding 
replacement of the equipment.
Hypoglycemia
Hypoglycemic events will be entered by  the pat ient throughout the clinical study  in eCOA along 
with date and time of the BG level if measured and hy poglycemia treatm ent and outcom e data. 
Self-Monitoring Blood Glucose
Patients will  be instructed to perform Daily Fast ing BG values are expected as well as 6 -point 
SMBG according to the Schedule of Activities(Secti on 1.3).
10.1.7. Source Documents
Source documents provide evidence for the existence of the participant and substantiate the 
integrity of the data collected. Source documents are filed at the invest igator’s site.
Data reported on the CRF or entered in the eCRF that are transcribed fro m source documents 
must be consistent with the source documents or the discrepancies must be explained. The 
investigator may  need to request previous medical records or transfer records, depending on the 
study . Also, current medical records must be availabl e.
10.1.8. Study and Site Start and Closure
The sponsor designee reserves the right to close the study  site or terminate the study  at any  time 
for any  reason at the sol e discret ion of the sponsor. Study  sites will be cl osed upon study  
completion. A study  site is considered closed when all required documents and study  supplies 
have been co llected and a study -site closure visi t has been perform ed.
The invest igator may init iate study -site closure at any  time, provi ded there i s reasonable cause 
and sufficient notice is given in advance of the intended terminat ion.
Reasons for the early closure of a study  site by the sponsor or investigator may  include but are 
not limited to:
Failure of the invest igator to comply wit h the protocol, the requirements of the IRB/IEC 
or local health authori ties, the sponsor's procedures, or GCP guidelines
Inadequate recruit ment of parti cipants by  the investi gator
Discontinuati on of  further study  intervent ion developm ent
If the study  is prem aturely  terminated or suspended, the sponsor shall prom ptly inform  the 
investi gators, the IECs/IRBs, the regulatory  authorit ies, and any contract research organizat ion(s) 
used in the study  of the reason for terminat ion or suspensio n, as specified by the applicable 
regul atory  requi rements. The invest igator shall prompt ly inform  the participant and should 
assure appropriate participant therapy  and/or fo llow-up.
CONFIDENTIAL I8H-MC-BDCL (d)
LY3209590 7110.1.9. Publication Policy
The publicat ion policy is described in the letters of agreement between the sponsor and the
investigators and inst itutions.
10.1.10. Invest igator Information
PIs who are a diabetologist, internal medicine specialist, or primary care physician wit h 
experience in the care of t ype 2 diabetes patients using basal insulin will part icipate as 
investigators in this clinical trial .
10.1.11. Long -Term Sample R etention
Sample retenti on enables use of new techno logies, response to regul atory  quest ions, and 
investigat ion of variable response that may not be observed unt il later in the development of  
LY3209590 or after LY3209590 beco mescommer cially available.
The fo llowing tabl e lists the m aximum retenti on peri od for sam ple ty pes.  The retention period 
begins after the last participant visit for the study . Any samples remaining after the specified 
retenti on peri odwill be destroy ed.
Sample Type CustodianRetention Period After 
Last Patient Visit*
Long -term storage sam ples Sponsor or Designee 15 years
Biomarkers Sponsor or Designee 15 years
PK Sponsor or Designee 1year
Genet ics Sponsor or Designee 15 years
PD Sponsor or Designee 2 years
Immunogenicit y Sponsor or Designee 15 years
Abbreviations:  PD = pharmacodynamics; PK = pharmacokinetics.
*Retention periods may differ locally.
CONFIDENTIAL I8H-MC-BDCL (d)
LY3209590 7210.2. Appendix 2: Clinical Laboratory Tests
Addit ional tests may be performed at any  time during the study  asdetermined necessary  by the 
investigator or required by  local regulati ons.
Invest igators must document their review of each laboratory  safety  report.
Refer to Section 10.9 for recommended laboratory  testing for hypersensit ivity events.
CONFIDENTIAL I8H-MC-BDCL (d)
LY3209590 73Clinical Laboratory Tests a
Hematology Clinical Chemistr y
Hemoglobin Sodium
Hematocrit Potassium
Erythrocy te count (RBC) Chloride
Mean cell volume (MCV) Bicarbonate
Mean cell hemoglobin (MCH) Total bilirubin
Mean cell hemoglobin concentration (MCHC) Direct bilirubin
Leukocytes (WBC) Alkaline phosphatase
Neutrophils, segmented Alanine aminotransferase (ALT)
Lymphocy tes Aspartate aminotransferase (AST)
Monocytes Gamma glutamyltransferase (GGT)
Eosinophils Blood urea nitrogen (BUN)
Basophils Creatinine
Platelets Uric acid
Calcium
Urinalysis Phospho rus
Protein Glucose
Nitrite Total protein
Blood Albumin
Urine leukocyte esterase Creatine kinase (CK)
Cholesterol
Hormones
Pregnancy test serum and urine (females only) bTriglycerides
Follicle stimulating hormone 
Endocrine
C-Peptide Lipid Panel
HDL cholesterol
Pancreas (Exocrine) LDL cholesterol
Pancreatic amylase
Lipase Hemoglobin A1c
Free Fatty Acid
Hepatitis B
Hepatitis B Core Antibody
Hepatitis B Surface Antigen
Hepatitis B Surface Antibody
Drug concentratio nc
LY3209590
Immunogenicit y
Anti-LY3209590
Calculation
eGFR (Calculated by CKD -EPI equation)Pharmacogenetic samplec
Non-pharmacogenetic samplesc
Serum
EDTA Plasma
CONFIDENTIAL I8H-MC-BDCL (d)
LY3209590 74Abbreviations:   CKD -EPI = chronic kidney disease epidemiology collaboration;
EDTA =Ethylenediaminetetraacetic acid ; eGFR = estimated glomerular filtration rate; HDL = high density 
lipoprotein; LDL = low density lipoprotein; RBC = red blood cells; WBC = white blood cells.
aAll tests will be performed by a Lilly -designated central laboratory, unless otherwise noted.
bUrine pregnancy tests (analyzed on -site) to be performed at Visits 3 and 801/ ED2,and serum pregnancy test 
(analy zed by  central laborato ry) to be performed at Visits 1 and 3 for women of childbearing potential.  
Additional pregnancy tests may be performed at the investigator’s discretion during the st udy.
cResults will not be provided to the investigative sites.
CONFIDENTIAL I8H-MC-BDCL (d)
LY3209590 7510.3. Appendix 3: Adverse Events: Definitions and Procedures for 
Recording, Evaluating, Follow -up, and Reporting
10.3.1. Definition of AE
AE Definition
An AE is any  untoward m edical occurrence in a patient or clinical study  parti cipant, 
temporally  associ ated wi th the use of study  intervent ion, whether or not considered 
related to the study  intervent ion.
NOTE: An AE can therefore be any unfavorable and uni ntended si gn (including an 
abnorm al laboratory  finding), symptom, or disease (new or exacerbated) temporally 
associ ated wi th the use of study  intervent ion.
Events Meeting the AE D efinition
Any abnormal laboratory  test resul ts (hematol ogy, clinical chemistry , or uri nalysis) or 
other safet y assessments (e .g., ECG, radio logical scans, vital signs measurements), 
including those that worsen fro m baseline, considered clinically significant in the 
medical and scient ific judgment of the investigator (i .
e., not related to progression of 
underlying disease).
Exacerbat ion of a chronic or intermittent pre -exist ing condit ion including either an 
increase in frequency and/or intensit y of the condi tion.
New condit ions detected or diagnosed after study  intervent ion administrati on even 
though it m ay have been present before the start of the study .
Signs, symptoms, or the clinical sequelae of a suspected drug -drug interaction.
Signs, symptoms, or the clinical sequelae of a suspected overdose of either study  
intervent ionor a concomitant medicat ion. Overdose per se will not be reported as an 
AE/SAE unless it is an intentional overdose taken with possible suicidal/self -harming 
intent. Such overdoses should be reported regardless of sequelae.
Note: “Lack of efficacy ”or “failure of expected pharmaco logical act ion”per se will 
notbe reported as an AE or SAE. Such instances will be captured in the efficacy 
assessments. However, the signs, symptoms, and/or clinical sequelae result ing from 
lack of efficacy  will be reported as AE or SAE if they fulfil the definit ion of an AE or 
SAE.
Events NOT Meeting the AE D efinition
Any clinically  significant abnormal laboratory  findings or other abnormal safet y 
assessments which are associated with the underlying disease, unless judged by the 
investigator to be more severe than expected for the participant’s condit ion.
CONFIDENTIAL I8H-MC-BDCL (d)
LY3209590 76The disease/disorder being studied or expected progressio n, signs, or symptom s of the 
disease/disorder being studied, unless more severe than expected for the parti cipant’s 
condi tion.
Medical or surgical procedure (e .g., endoscopy , appendectomy): the condit ion that 
leads to the procedure is the AE.
Situations in which an untoward medical occurrence did not occur (social and/or 
convenience admissio n to a hospital).
Anticipated day -to-day fluctuations of pre -exist ing disease(s) or condit ion(s) present or 
detected at the start of the study  that do not worsen.
10.3.2. Definition of SAE
If an event is not an AE per definit ion above, then it cannot be an SAE even if serious condit ions 
are met (e .g., hospitalizat ion for signs/symptoms of the disease under study , death due to 
progression of disease).
A SAE is defined as any untoward medical occurrence that, at any dose:
Results in death
Is life -threatening
The term  'life-threatening' in the definit ion of 'serious' refers to an event in which the 
participant was at ri sk of death at the time o f the event. It does not refer to an event, which 
hypotheti cally  might have caused death, if it were more severe.
Requires inpatient hospitalization or prolongation of existing hospitalization
In general, hospitalizat ion signifies that the participant has been admi tted to hospi tal
for observat ion and/or treatment that would not have been appropriate in the 
physician’s office or outpatient setting. Com plicati ons that occur during 
hospi talizati on are AEs. If a co mplication prolongs hospitalization or fulfills any other 
serious cri teria, the event is serious. When in doubt as to whether “hospitalizat ion” 
occurred or wa s necessary, the AE should be considered serious.
Hospitalization for elect ive treatment of a pre -existing condit ion that di d not worsen 
from baseline is not considered an AE.
Results in persistent disability/incapacity
The term disabili ty means a substan tial disrupt ion of a person’s abilit y to conduct 
norm al life f unctions.
This definit ion is not intended to include experiences of relat ively minor medical 
significance such as unco mplicated headache, nausea, vomit ing, di arrhea, 
influenza, and accidental tr auma (e .g., sprained ankle) which may interfere with or 
prevent every day life f unctions but do not constitute a substant ial disruption .
CONFIDENTIAL I8H-MC-BDCL (d)
LY3209590 77Is a congenital anomaly/birth defect
Other situations:
Medical or scient ific judgment should be exercised in decidin g whether SAE reporting 
is appropriate in other situations such as important medical events that may not be 
immediately  life-threatening or result in death or hospitalization but may jeopardize the 
participant or m ay requi re medical or surgi cal intervent ion to prevent one of the other 
outcom es listed in the above definit ion. These events should usually be considered 
serious.
Examples of such events include invasive or malignant cancers, intensive treatment in 
an emergency room or at home for allergic bronchospasm, blood dyscrasias or 
convulsio ns that do not result in hospitalizat ion, or development of drug dependency or 
drug abuse .
10.3.3. Recording and Follow -Up of AE and/or SAE
AE and SAE Recording
When an AE/SAE occurs, it is the responsibilit y of the inv estigator to revi ew all 
docum entati on (e .g., hospital progress notes, laboratory  reports, and di agnosti cs 
reports) related to the event.
The invest igator will then record all relevant AE/SAE informat ion in the CRF.
It is notacceptable for the invest igator to send photocopies of the participant’s medical 
records in lieu of co mpletion of the AE/SAE CRF page.
There m ay be instances when copies of medical records for certain cases are requested 
by Sponsor .  In this case, all par ticipant i dentifiers, wi th the except ion of the 
participant number, will be redacted on the copies of the medical records before 
submissio n to Sponsor .
The invest igator will attempt to establish a diagnosis of the event based on signs, 
symptoms, and/or oth er clinical informat ion. Whenever possible, the diagnosis (not 
the individual signs/symptoms) will be documented as the AE/SAE .
CONFIDENTIAL I8H-MC-BDCL (d)
LY3209590 78Assessment of Intensity
The invest igator will make an assessment of intensity for each AE and SAE reported during 
the study  and assign it to 1 of the fo llowing categori es:
Mild: An event that is easily tolerated by the participant, causing minimal disco mfort 
and not interfering with everyday act ivities.
Moderate: An even t that causes sufficient discomfort and interferes wit h norm al 
everyday act ivities.
Severe: An event that prevents normal every day activi ties. An AE that is assessed as 
severe should not be confused with a SAE. Severe is a category utilized for rating th e 
intensity of an event; and both AEs and SAEs can be assessed as severe.
An event is defined as ‘serious’ when it meets at least 1 of the predefined outcomes as 
described in the definit ion of an SAE, NOT when it is rated as severe.
Assessment of Causali ty
The invest igator is obligated to assess the relationship between study intervent ion and 
each occurrence of each AE/SAE.
A “reasonable possibilit y”of a rel ationship conveys that there are facts, evidence, 
and/or arguments to suggest a causal relat ionship, rather than a relat ionship cannot be 
ruled out.
The invest igator will use clinical judgment to determine the relat ionship.
Alternat ive causes, suc h as underlying disease(s), concomitant therapy , and other ri sk 
factors, as well as the temporal relationship of the event to study  intervent ion 
administration will be considered and invest igated.
The invest igator will also consult the Invest igator’s Broch ure (IB) and/or Product 
Inform ation, for marketed products, in his/her assessment.
For each AE/SAE, the invest igator must document in the medical notes that he/she has 
reviewed the AE/SAE and has provided an assessment of causalit y.
There m ay be si tuationsin which an SAE has occurred and the invest igator has 
minimal informat ion to include in the init ial report to Sponsor .  However, it is very  
important that the invest igator always make an assessment of causalit y for every  event 
before the init ial transmiss ion of the SAE data to Sponsor .
The invest igator may change his/her opinio n of causalit y in light of fo llow-up 
inform ation and send a SAE follow -up report wi th the updated causalit y assessment.
The causalit y assessment is one of the cri teria used when dete rmining regulatory  
reporting requirements.
CONFIDENTIAL I8H-MC-BDCL (d)
LY3209590 79Follow -up of AEs and SAEs
The invest igator is obligated to perform or arrange for the conduct of supplemental 
measurements and/or evaluat ions as medically indicated or as requested by Sponsor to 
elucidate the nature and/or causalit y of the AE or SAE as fully  as possible. This m ay 
include addit ional laboratory  tests or i nvest igations, histopathological examinat ions, or 
consultation wit h other health care professio nals.
New or updated informat ion will be recorded in the originally completed CRF.
The invest igator will submit any updated SAE data to Sponsor within 24 hours of 
recei pt of the inform ation.
10.3.4. Reporting of SAEs
SAE Reporting to Sponsor via an Electronic Data Collection Tool
The primary  mechanism  for reporting an SAE to Sponsor will be the electronic data 
collect ion tool .
If the electronic system is unavailable, then the site will use the paper SAE data 
collect ion tool  (see next secti on) in order to report the event within 24 hours.
The site will enter the SAE data into the electronic sy stem  as soon as i t becom es 
available.
After the study  is com pleted at a given site, the electronic data collect ion tool  will be 
taken off -line to prevent the entry  of new data or changes to exis ting data.
If a site receives a report of a new SAE fro m a study  parti cipant or receives updated 
data on a previously reported SAE after the electronic data collection tool has been 
taken off -line, then the site can report this informatio n on a paper SAE f orm (see next 
section) or to Lilly Medical by tel ephone.
SAE Reporting to Sponsor or Designee via Paper CRF
Facsimile transmissio n of the SAE paper CRF is the preferred method to transmit this 
inform ation to the Lilly Medical .
Initial notificati on via telephone does not replace the need for the invest igator to 
complete and sign the SAE CRF pages within the designated reporting time frames.
CONFIDENTIAL I8H-MC-BDCL (d)
LY3209590 8010.4. Appendix 4: Contraceptive Guidance and Collection of Pregnancy 
Information
Definitions:
Woman of Childbearing Potential (WOCBP)
A wo man is considered fertile fo llowing menarche and unt il beco ming post -menopausal unless 
perm anent ly sterile (see below).
If fertilit y is unclear (e .g., amenorrhea in adolescents or athletes) and a menstrual cycle cannot be 
confirmed before first dose of study  intervent ion, additional eval uation shoul d be considered.
Women in the fo llowing categori es are not considered WOCBP
1.Prem enarchal
2.Prem enopausal  female wi th 1 of the f ollowing:
Docum ented hysterectomy
Docum ented bilateral  salpingectomy
Docum ented bilateral  oophorectomy
For individuals wit h perm anent infert ility due to an alternate medical cause other than the 
above, (e .g., mullerian agenesis, androgen insensit ivity), invest igator discret ion shoul d be 
applied to determining study  entry .
Note:  Documentation can co me from the site personnel’s :review of the participant’s 
medical records, medical examinat ion, or m edical history  intervie w.
3.Postmenopausal  female is defined as, women with:
i.A wo man at l east 40 years of age with an intact uterus, not on hormone therapy , 
who has cessat ion of menses for at least 1 y ear wi thout an al ternat ive medical 
cause, AND a follicle-stimulat ing hormone >40 mIU/m L; or
ii.A wo man 55 or older not on hormone therapy , who has had at l east 12 m onths of 
spontaneous amenorrhea; or
iii.A wo man at l east 55 years of age with a diagnosis of menopause prior to starting 
horm one repl acement therapy .
The invest igator will attempt to collect pregnancy  information on any male participant’s female 
partner who becomes pregnant while the male participant is in this study . This applies only  to 
male participants who receive study  intervent ion
.
After obtaining the necessary  signed informed consent from the pregnant female partner direct ly, 
the invest igator will record pregnancy informat ion on the appropriate form and submit it to the 
sponsor within 24 hours of learning of the partner’s pregnancy. The female partner will also be 
followed to determine the outcome of the pregnancy . Informati on on the status of the mother 
and child will be forwarded to the sponsor. Generally, the fo llow-up will be no l onger than 6 to 
8weeks following the est imated delivery  date. Any terminat ion of the pregnancy will be 
reported regardless of fetal status (presence or absence o f anomalies) or indicat ion for the 
procedure. 
CONFIDENTIAL I8H-MC-BDCL (d)
LY3209590 81Female Participants who become pregnant
The invest igator will co llect pregnancy information on any female participant who becomes 
pregnant while part icipating in this study .The init ial information will be recorded on the 
appropriate form and submitted to the sponsor within 24 hours of learning o f a participant's 
pregnancy. 
The parti cipant will be followed to determine the outcome of the pregnancy . The invest igator 
will co llect fo llow-up inform ation on the participant and the neonate and the informat ion will be 
forwarded to the sponsor. Generally, fo llow-up will not be required for longer than 6 to 8 weeks 
beyo nd the est imated delivery date. Any termination of pregnancy will be reported, regardless o f 
fetal status (presence or absence of ano malies) or indicat ion for the procedure.
While pregnancy  itself is not considered to be an AE or SAE, any pregnancy  com plicat ion or 
elective termination o f a pregnancy  for medical  reasons will be reported as an AE or SAE. 
A spontaneous abortion (occurring at <22 weeks gestational age) or still birth (occurring at 
>22weeks gestational age) is always conside red to be an SAE and will be reported as such. 
Any post -study pregnancy related SAE considered reasonably related to the study intervention 
by the investigator will be reported to the sponsor as described in Sect ion8.3.4 .While the 
investigator is not obligated to actively seek this informat ion in former study  parti cipants, he or 
she m ay learn of an SAE through spontaneous reporting.
Any female part icipant who becomes pregnant while participat ing in the study  will discont inue 
study  interventi on or be wi thdrawn from  the study .
CONFIDENTIAL I8H-MC-BDCL (d)
LY3209590 8210.5. Appendix 5:Liver Safety: Suggested Actions and Follow -up 
Assessments 
Hepatic Monitoring Tests
Hepatic Hematology a Haptoglobin a
Hemoglobin
Hematocrit Hepatic Coagulation a
RBC Prothrombin Time
WBC Prothrombin Time, INR
Neutrophils, segmented
Lymphocy tes Hepatic Serologies a,b
Monocytes Hepatitis A antibody, total
Eosinophils Hepatitis A antibody, IgM
Basophils Hepatitis B surface antigen
Platelets Hepatitis B surface antibody
Hepatitis B Core antibody
Hepatic Chemistry a Hepatitis C antibody
Total bilirubin Hepatitis E antibody, IgG
Direct bilirubin Hepatitis E antibody, IgM
Alkaline phosphatase
ALT Anti -nuclear antibody a
AST
GGT Alkaline Phosphatase Isoenzymes a
CPK
Anti -smooth muscle antibody (or anti -actin antibody) a
Abbreviations:  ALT = alanine aminotransferase; AST = aspirate aminotransferase; CPK = creatinine 
phosphokinase; GGT = gamma -glutamyl transferase; Ig = immunoglobulin; INR = international normalised 
ratio; RBC = red blood cells; WBC = white blood cells.
aAssay ed by Sponsor -designated or local laboratory.
bReflex/confirmation dependent on regulatory requirements and/or testing availability.
CONFIDENTIAL I8H-MC-BDCL (d)
LY3209590 8310.6. Appendix 6: New York Heart Association Cardiac Disease 
Classification
Functional Capacity
Class I
Study  parti cipan tswith cardi ac di sease but wi thout resul ting limit ation of  physical  activity.  
Ordinary  physical  activity does not cause undue fatigue, palpitat ion, dy spnea, or anginal pain.
Class II
Study  parti cipants with cardi ac di sease result ing in slight limitat ion of physical activit y.  They  
are comfortable at rest.  Ordinary  physical act ivity resul ts in fat igue, palpitat ion, dy spnea, or 
anginal pain.
Class III
Study  parti cipants with cardi ac di sease result ing in marked limit ation of  physical  activity.  They 
are com fortable at rest.  Less than ordinary  activi ty causes fat igue, palpitat ion, dyspnea, or 
anginal pain.
Class IV
Study  parti cipants with cardi ac di sease result ing in inabilit y to carry  on any  physical  activi ty 
without discomfort.  Symptoms of heart failure or the anginal syndrome may be present even at 
rest.  If any  physical
 activi ty is undertaken, disco mfort increases 
1994 Revisio nsto Cl assificati on of  Funct ional Capaci ty and Objective Assessment of Patients 
with Diseases of the Heart
Reprinted with permission
www.am ericanheart.org
© 2011, American Heart Associat ion, Inc.
CONFIDENTIAL I8H-MC-BDCL (d)
LY3209590 8410.7. Appendix 7:  Genetics
Use/Analysis of DNA
Genet ic variat ion may impact a participant’s response to study  intervent ion, suscept ibilit y to, and 
severit y and progressi on of  disease.  Vari able response to study  intervent ion may be due to 
genet ic determinants that impact drug absorption, distribut ion, metabo lism, and excreti on; 
mechanism o f action of  the drug; di sease et iology; and/or m olecular subt ype of the disease being 
treated. Therefore, where local regulations and IRB/IEC allow, a blood sample will be co llected 
for DNA analysis fro m consenting part icipants.
DNA samples will be used for research related to study  intervent ion or T2DM and related 
diseases.  They  may also be used to develop tests/assays including diagnost ic tests related to 
study  interventi on and/or intervent ions of this drug class and T2DM. Genet ic research may 
consist of the analysis of one or more candidate genes or the analysis o f genet ic markers 
throughout the geno me or analysis o f the ent ire geno me (as appropriate).
The samples may  be analyzed as part of a mult i-study  assessment of gene tic factors involved in 
the response to study  intervent ion or study  intervent ions of this class to understand study  disease 
or rel ated condi tions.
The results of genet ic analyses may be reported in the clinical study  report (CSR) or in a separate 
study  sum mary .
The sponsor will store the DNA samples in a secure storage space with adequate measures to 
protect confident iality.
The samples will be retained as described in Section10.1.11 .  
CO N FI D E N TI A L I 8 H -M C -B D C L ( d) 
L Y 3 2 0 9 5 9 0 8 5 1 0. 8. A p pe n di x 8:  D o si n g G ui d a nce f or L Y 3 2 0 9 5 9 0 a n d Ins ul i n  D e gl u dec 
1 0. 8. 1. L Y 3 2 09 5 9 0 Al g orit h m 1 ( p a per al g orit h m) 
I n St u d y B D C L , a pa per d osi n g Al g orit h m 1 will be use d b y i n vest i gat ors f or i nit iat i n g a n d 
a dj usti n g L Y 3 2 0 9 5 9 0 t o ac hie ve t he tar get F G ≤ 1 0 0 m g/ d L ( < 5. 6 m m o l/ L). 
I n sit uati o ns w here st u d y  partici pa nt safet y is a c o ncer n, i n vesti gat ors ma y a dj ust t he d ose of 
L Y 3 2 0 9 5 9 0 rec o m me n de d b y  t he d ose -a dj ust me nt al g ori t h m  i n Ta ble 2; h o we ver, cli nical 
r ati o nale m ust be d oc u m e nte d i n t he e C R F a n d Lill y  Me dical m ust be i nf or m e d a b o ut t his 
de viat i o n a n d ass ociate d me dical rati o nale .  If t he in vesti gat or has safet y c o ncer ns a b o ut t he 
al g ori t h m , t he in vest i gat or is t o c o ntact t he Lill y C R P. 
At  t he ti me of site visit, t he i n vesti gat or will assess t he st u d y  p arti ci pa nt’s gl yce mic c o ntr ol f or 
t h e pre vi o us wee k a n d, if necessar y, i nf or m t he st u d y  p arti ci pa nt a b o ut a n y  n ee de d d ose 
a dj ust m e nt. T he d ose will be base d o n t he st u d y  p arti ci pa nt’s F G val ue fr o mS M B G a n d 
h y p o gl yce mia d o c u m e nte d i n t he pre vi o us wee k. A d here nce t o t he d osi n g al g orit h m pr o vi de d 
f o r t hi s st u d y  i s re q ui r e d f r o m  Visi t 3 (ra n d o mizat i o n) u p t o Wee k 2 5 a n d will be m o nit ore d 
p eri o di call y  b y t he st u d y  tea m .  
G e n er al Al g orit h m C o n si d er ati o n s: 
T he treat -t o -tar get F G i n t he al g orit h m is ≤ 1 0 0 m g/ d L ( < 5. 6 m m o l/ L).  L Y 3 2 0 9 5 9 0 d ose 
a dj ust m e nts will be deter mi ne d base d o n t he me dia n of t he F G fr o mS M B G of  at l east 3 
da ys ( u p t o 7 da ys ) o btai ne d i n t he pre vi o us wee k lea di n g u p t o t he visit. 
T he L Y 3 2 0 9 5 9 0 d ose ma y  n ot be i ncrease d if a n y  S M B G rea di n g was d oc u me nte d at 
≤ 7 0 m g/ d L ( < 3. 9 m m o l/ L) at a n y  ti me i n t he prece di n g wee k. D o se decreases of 0. 5 m g 
a dj ust m e nt m a y  be per mi tte d if m ul ti ple e pis o des of h y p o gl yce mia wit h S M B G 
≤ 7 0 m g/ d L ( < 3. 9 m m o l/ L) were rec or de d, or d ose decrease of 1 m g if se vere 
h y p o gl yce mia (re q uiri n g assista nce) occ urre d, or if a n y  S M B G was d oc u m e nte d at ≤ 5 4 
m g/ d L ( ≤ 3. 0 m m o l/ L) i n t he prece di n g wee k. 
I n d osi n g calc ulat i o ns w here r o u n di n g is re q uire d, r o u n d t o t he nearest 0. 2 5 m g 
T he i nit ial ( Wee k 0, Visit 3) L Y 3 2 0 9 5 9 0 d ose is base d o n t he baseli ne me dia n fasti n g gl uc ose 
a n d b o d y  w ei g ht at Visit 3 .  Beca use of t he l o n g half -life of L Y 3 2 0 9 5 9 0, t he c ha n ge i n fast i n g 
gl uc ose res p o nse f o ll o wi n g t he i nit ial d ose ma y ta ke se veral wee ks t o reac h desire d res p o nse; 
t h eref ore, t o mi ni mize t he ti me nee de d t o ac hie ve t he desire d tar get gl yce mic res p o nse, t he i nit ial 
d ose was  i n or der t o ac hie ve stea d y -state c o nce ntrati o n wit hi n t he first wee k.  
Di rect i o ns are pr o vi de d bel o w t o deter mi ne t he i nit ial d ose usi n g Ta ble 1 a n d f or d ose 
a dj ust m e nts at s u bse q ue nt visits usi n g Ta ble 2.  E xa m ples f or Visit s 3 -6 are pr o vi de d i n it alic 
text. 
Vi sit 3 ( R a n d o mi z ati o n Vi sit): 
1. Deter mi ne t he i nit ial d ose b y o btai ni n g t he partici pa nt’s b o d y w ei g ht a n d m e dia n F G i n 
t h e wee k pri or t o Visit 3 a n d c o ns ult i n g Ta ble 1. 
F or ex a m ple, if a p artici p a nt we i g hts 8 3 k g a n d h as a me di a n F G of 1 8 5 m g/ dl , 
acc or di n g t o T a ble 1, t he i niti al d ose of  L Y 3 2 0 9 5 9 0 is 1 0. 5 m g. C CI 
CO N FI D E N TI A L I 8 H -M C -B D C L ( d) 
L Y 3 2 0 9 5 9 0 8 6 T a bl e 1. D et er mi n ati o n of I niti al D o s e aof L Y 3 2 0 9 5 9 0 at Vi sit 3 u si n g M e di a n of 
B a s eli n e F a sti n g Gl u c o s e a n d B o d y W ei g ht 
Me di a n B aseli ne 
F asti n g Gl uc ose 
( m g/ d L) Me di a n B aseli ne 
F asti n g Gl uc ose b
( m m ol/ L) B o d y Wei g ht ( kg) at Visit 3
≤ 8 0 8 0. 1 – 1 0 0 1 0 0. 1 – 1 2 0 ≥ 1 2 0. 1 
≤ 1 4 0 ≤7. 7 3 m g 4. 5 m g 6 m g 7. 5 m g 
1 4 1 –1 8 0 7. 8 –1 0. 0 6 m g 7. 5 m g 1 0. 5 m g 1 2 m g 
1 8 1 –2 2 0 1 0 . 1 –1 2. 2 9 m g 1 0. 5 m g 1 2 m g 1 3. 5 m g 
> 2 2 0 > 1 2. 2 1 2 m g 1 3. 5 m g 1 5 m g 1 6. 5 m g 
aT he i nitial d ose reflects t he 3 -f ol d i ncrease nee de d t o re d uce t he ti me t o tar get gl yce mic res p o nse a n d s h o ul d 
O N L Y be a d mi nistere d o nce at Visit 3.  
b C o n versi o ns fr o m m g/ d L t o m m ol/ L were r o u n d e d off t o pre ve nt o verla p bet wee n t hres h ol d ra n ges a n d t o 
a d dre ss t hat t he gl uc ose meter dis pla ys 1 si g nifica nt di git after t he deci mal w he n re p orti n g m m ol/ L rea di n gs. 
Vi sit 4 ( W e e k 1) 
1. Calc ulate t h e t otal  wee kl y  d ose L Y 3 2 0 9 5 9 0 m g fr o m  t he d ose a d mi nistere d at Visit 3 .
(t his is t h e d ose a d mi nistere d at Visit 3) 
Fr o m t he Visit 3 ex a m ple, t he L Y 3 2 0 9 5 9 0 t ot al we ekly d ose is .
2. Use Ta ble 2 t o deter mi ne t he d ose a dj ust me nt  nee de d f or Visit 5af ter caref ull y 
re vie wi n g partici pa nt ’s fast i n g gl uc ose ( 3 -7 da ys pri or t o visit) a n d h y p o gl yce mia 
d oc u m e nte d si nce t h e last L Y 3 2 0 9 5 9 0 d ose .
T he p artici p a nt re p orte d n o hy p o glyce mi a si nce t he l ast d ose of L Y 3 2 0 9 5 9 0 a n d 
h a d a me di a n F G of 1 7 5 m g/ d L.  Usi n g t he Week 1 ( Visit 4) c ol u m n, t he 
L Y 3 2 0 9 5 9 0 weekly d ose s h o ul d be i ncre ase d by 3m g. 
3. 5 m g + 3m g = 6. 5 m g L Y 3 2 0 9 5 9 0 s h o ul d be a d mi nistere d at Visit 4. 
T a bl e 2. W e e kl y D o s e A dj u st m e nt of L Y 3 2 0 9 5 9 0 u si n g t h e Pr e vi o u s W e e k’ s 
d o s e ( D), M e di a n F a sti n g Gl u c o s e a n d H y p o gl y c e mi c E pi s o d e s  
Me di a n F asti n g 
Gl uc ose 
( m g/ d L) aMe di a n F asti n g 
Gl uc ose 
( m m ol/ L) a, e Wee k 1 
( Visit 4) 
( 2 n d d ose) Wee k 2 
( Visit 5) 
( 3 r d d ose) S u bse q ue nt Wee k c
D ose ≤5 m g D ose > 5 m g 
< 8 0 m g/ d L or 
ha ve a n y  n oct ur nal 
h y p o gl yce mia or 
m ulti ple e pis o des of 
h y p o gl yce mia d< 4. 4 m m ol/ L or 
ha ve a n y  n oct ur nal 
h y p o gl yce mia or 
m ulti ple e pis o des of 
h y p o gl yce mia dDb–1. 5 m g Db–1. 5 m g Dc–1. 5 m g Dc–2 m g 
8 0 – 1 0 0 m g/ d L 4. 4 –5. 5 Db–1 m g Db–0. 5 m g N o c ha n ge  N o c ha n ge 
1 0 1 –1 4 0 m g/ d L 5. 6 –7. 7 N o c ha n ge N o c ha n ge Dc+ 0. 2 5 m g Dc+ 0. 5 m g 
1 4 1 – 1 8 0 m g/ d L 7. 8 –1 0. 0 Db+ 3 m g Db+ 1. 5 m g Dc+ 0. 5 m g Dc+ 1 m g 
> 1 8 0 m g/ d L >1 0. 0 Db+ 5 m g Db+ 3 m g Dc+ 0. 7 5 m g Dc+ 1. 5 m g C CI 
C CI 
CO N FI D E N TI A L I 8 H -M C -B D C L ( d) 
L Y 3 2 0 9 5 9 0 8 7 aBase d o n me dia n fasti n g gl uc ose fr o m at least 3 fasti n g gl uc ose fr o m pre vi o us wee k. 
bD f or Wee k 1 ( Visit 4) is   of t he i nitial d ose fr o m Ta ble 1.  D f or Wee k 2 ( Visit 5) is Wee k 1 ( Visit 4) d ose.  
cL Y 3 2 0 9 5 9 0 d ose a dj ust me nt starti n g at Wee k 3 ( Visit 6) will de pe n d o n w het her pre vi o us ( Wee k 2) d ose ( D) is 
≤ 5 m g o r > 5 m g a n d will be a dj uste d wee kl y u p t o Wee k 1 2 ( Visit 1 5), t he n at Wee k 1 6 ( Visit 1 7), Wee k 2 0 
( Visit 1 8), a n d Wee k 2 4 ( Visit 1 9).    
dT he L Y 3 2 0 9 5 9 0 d ose ma y n ot be i ncrease d if a n y S M B G rea di n g was d oc u me nte d at ≤ 7 0 m g/ d L ( < 3. 9 m m ol/ L) 
at a n y  ti me i n t he prece di n g wee k.  I f m ulti ple e pis o des of h y p o gl yce mia wit h S M B G ≤ 7 0 m g/ d L ( < 3. 9 m m ol/ L) 
were rec or de d, f oll o w g ui da nce f or d ose re d ucti o n acc or di n g t o t he a p plica ble Visit n u m ber.  D ose decreases of 1 
m g s h o ul d be ma de w he n se vere h y p o gl yce mia (re q uiri n g assista nce) occ urre d, or if a n y S M B G was d oc u me nte d 
at ≤ 5 4 m g/ d L ( ≤ 3. 0 m m ol/ L) i n t he prece di n g wee k. 
eCo n versi o ns fr o m m g/ d L t o m m ol/ L were r o u n d e d off t o pre ve nt o verla p bet wee n t hres h ol d ra n ges a n d t o 
a d dress t hat t he gl uc ose meter dis pla ys 1 si g nifica nt di git after t he deci mal w h e n re p orti n g m m ol/ L rea di n gs .
Vi sit 5 ( W e e k 2) 
1. C o nfir m t h e d ose of  L Y 3 2 0 9 5 9 0 m g a d mi nistere d at Vi si t 4. 
Fr o m t he Visit 4 ex a m ple, t he L Y 3 2 0 9 5 9 0 weekly d ose w a s 6 . 5 m g. 
2. Use Ta ble 2 t o deter mi ne t he d ose a dj ust me nt  nee de d f or Visit 5af ter caref ull y 
re vie wi n g partici pa nt ’s fast i n g gl uc ose ( 3 -7 da ys pri or t o visit) a n d h y p o gl yce mia 
d oc u m e nte d si nce t he last L Y 3 2 0 9 5 9 0 d ose .
T he p artici p a nt re p orte d n o hy p o glyce mi a si nce t he l ast d ose of L Y 3 2 0 9 5 9 0 a n d 
h a d a me di a n F G of 1 63 m g/ d L.  Usi n g t he Week 2 ( Visit 5) c ol u m n, t he 
L Y 3 2 0 9 5 9 0 weekly d ose s h o ul d be i ncre ase d by 1. 5 m g. 
6. 5 m g + 1. 5 m g = 8. 0 m g L Y 3 2 0 9 5 9 0 s h o ul d be a d mi nistere d at Visit 5. 
Vi sit 6 ( W e e k 3) 
1. C o nfir m t h e d ose of  L Y 3 2 0 9 5 9 0 a d mi nistere d at Visit 5 ( Wee k 2) .
Fr o m t he Visit 5 ex a m ple, t he L Y 3 2 0 9 5 9 0 weekly d ose w a s 8 . 0 m g. 
2. Use Ta ble 2 t o deter mi ne t he d ose a dj ust me nt  nee de d f or Visit 6af ter caref ull y 
re vie wi n g parti ci pa nt ’s fast i n g gl uc ose ( 3 -7 da ys pri or t o visit) a n d h y p o gl yce mia 
d oc u m e nte d si nce t he last L Y 3 2 0 9 5 9 0 d ose .  L o o ki n g at t he s u bse q ue nt wee k c ol u m n, 
a p pl y t he pri or wee kl y d ose i nf or mat i o n t o t h e a p pr o priate c ol u m n ( ≤ 5 m g or > 5 m g) t o 
o btai n t he d ose i ncre me nt. 
T he p artici p a nt re p orte d n o hy p o glyce mi a si nce t he l ast d ose of L Y 3 2 0 9 5 9 0 a n d 
h a d a me di a n F G of 1 3 3 m g/ d L.  Usi n g t he S u bse q ue nt Week a n d  > 5 m g d ose 
c ol u m n i n T a ble 2 ,t he L Y 3 2 0 9 5 9 0 d ose s h o ul d be i ncre ase d by 0. 5 m g .
8. 0 +0. 5 = 8. 5 m g of L Y 3 2 0 9 5 9 0 s h o ul d be a d mi nistere d at Visit 6. 
S u bse q ue nt visit s are ma na ge d usi n g t he sa me a p pr oac h as f or Visit 6 ( Wee k 3), al wa ys 
c o nfir mi n g t he L Y 3 2 0 9 5 9 0 d ose a d mi nistere d at t he pri or visit, t he me dia n fast i n g gl uc ose 
d uri n g t he wee k pri or t o t he visits, a n d h y p o gl yce mia stat us si nce t he last d ose of st u d y  dr u g. 
1 0. 8. 2. I ns uli n De gl u dec 
I ns uli n de gl u dec will be a d m i nistere d at a starti n g d ose of 1 0 U nits.  F or s u bse q ue nt d ose 
a dj ust m e nts, a d osi n g al g orit h m (a da pte d fr o m Ri d dl e et al . 2 0 0 3) will be use d b y i n vesti gat ors C CI 
CONFIDENTIAL I8H-MC-BDCL (d)
LY3209590 88for initiating and adjust ing insulin degludec to target an FG ≤100 m g/dL ( <5.6mmo l/L) for 
patients to achieve glycemic goal.  
In situations where patient safet y is a concern or where dose adjust ments have not had the 
desired therapeut ic effect, investigators may make increased or decreased adjustments to the 
dose of insulin degludec recommended by the dose -adjustment algorithmand have to document 
the clinical rat ionale for the deviat ionas well as inform Lilly Medical per email.
At the time of site visit or telephone visit, the investigator will assess the patient’s glycemic 
control for the previous week and, if necessary, inform the patient about any needed dose 
adjustm ent.  The dose will be based on the patient’s blood glucose value . Adherence to the 
dosing algorithm provided for this study  is mandatory from Visit 3 ( randomization ) up to 
Visit 20(Week 26), inclusive . Dose increases may be made at weekly intervals and no sooner 
than 5 days fo llowing the last dose increase .  In some cases, pati ent visi ts coul d occur sooner 
than 5 days apart due to the allowable visit window; howeve r, there should be no dose increase if 
at least 5 days have not elapsed since the previous dose increase.  In contrast, the insulin 
degludec dose may be reduced at any  time on the judgm ent of the investigator. Any deviat ions 
from this gui dance m ust be supported by  clinical evidence and accompanied by  information of  
Lilly Medical .  
Insulin dose algorithms have been reviewed by Strange (
2007).  The insulin degludec dose 
increase algorithm is adapted from Riddle et al. 2003 and will be determined based on the 
definit ion of what i
s term ed the “Algori thm FG.”  The Algori thm FG is the m edian of the FG 
(determined from SMBG) of D ays5, 6,and 7 since the last insulin dose increment .  If the 
interval  since the l ast dose adj ustment has been lo nger th an 7days, t he dose increase is 
determined by the median of the FG of the last 3 days. If the patient only measured their FG on 
2 of the last 3 day s, then the l esser of  those 2 FG values should be used as the Algorithm FG.  If 
only 1 FG m easurement is available for t he last 3 days, then the invest igator should use his/her 
discreti on in determining whether there should be a dose adjust ment based on that single FG 
value.
As it is desi red to achieve glycemic goals in as many  patients as possible, contingencies are 
provi ded to accommodate prespecified protocol visits and toincrease the dose of insulin 
degludec in a timely  manner.  Therefore, if the last dose increment was 5 days previous, then the 
dose increment is determined by  the Algori thm FG, whi ch is the l esser of th e 2 FG values from 
Day 4 and D ay 5. If the dose increment was 6 days previous, then the Algo rithm FG is the l esser 
of the 2 FG values fro m Day 5 and D ay 6.  
In both of these cases, if only 1 of the 2 FG values is 
available, then the invest igator should us e his/her di screti on in determining whether there should 
be a dose adjust ment based on that single FG value.
The dose increase algorithm is defined as fo llows:
If the Algorithm FG is 101 to 120 mg/dL (5.6 to 6.7 mmo l/L), increase the dose by  2 U
If the Alg orithm FG is 121 to 140 m g/dL (6.8 to 7.8 mmo l/L), increase the dose by  4 U
If the Algorithm FG is 141 to 180 mg/dL (7.9 to 10.0 mmo l/L), increase the dose by 6 U
If the Algorithm FG is 180 mg/dL (10.0 mmo l/L), increase the dose by  8U
The treat-to-target FG is ≤100 mg/dL (<5.6 mmo l/L).  The insulin degludec dose will not be 
increased if any SMBG was documented at ≤70 mg/dL (<3.9 mmo l/L) at any  time in the 
CONFIDENTIAL I8H-MC-BDCL (d)
LY3209590 89preceding week.  Dose decrease s of 2 to 4 U per adjust ment may be permitted if multiple 
episodes of hypoglycemia with SMBG ≤70 m g/dL ( <3.9 mmo l/L) were recorded, if severe 
hypoglycemia (requiring assistance) occurred, or if any  SMBG was docum ented at ≤54 mg/dL 
(≤3.0 mmo l/L) in the preceding week.
CONFIDENTIAL I8H-MC-BDCL (d)
LY3209590 9010.9. Appendix 9:  Recommended Laboratory Testing for Hypersensitivity 
Events
Guidance for l aboratory  assessments for hy persensi tivity events
Laboratory  assessments should be performed if the participant experiences generalized urticaria 
or if anaphylaxis is suspected
Collect sample after the participant has been stabilized, and within 1 to 2 hours of the 
event; however, samples may be obtained as late as 12 hours after the event as analytes 
can remain altered for an extended period of time.  Record the time at which th e sample 
was collected.
Obtain a fo llow
-up sam ple at the next regularly scheduled visit or after 4 weeks, 
whichever i s later.
CO N FI D E N TI A L I 8 H -M C -B D C L ( d) 
L Y 3 2 0 9 5 9 0 9 1 T a bl e 4. Cli ni c al L a b T e st s f or H y p er s e n siti vit y E v e nt s 
C CI 
CONFIDENTIAL I8H-MC-BDCL (d)
LY3209590 9210.10. Appendix 10:  Changes to Study Procedures due to the COVID -19 
Pandemic or Natural Disasters
Remote Visits during the Study
If COVID -19 or natural disaster -related travel or shelter -in place restrictions are requested by  
local/regi onal authori tiesor for ot her reasons related to the pandemic or natural disasters which 
make it impossible for the participant to travel to the study  site for the m andatory  titration visi ts, 
mitigations are required to ensure safe and timely dosing of study partici pants. 
The stud y site must receive pri or approval by Lilly foreither site mobile visits performed by  
trained site personnel or visits performed by a qualified ho me nursing service provider organized 
by the sponsor, with video -conferencing abilit y, to exceptionally repla ce the on -site visi ts. 
Protocol  procedures, including blood draws, data -downloads, participant (re -) education, study  
drug dose select ion and study  drug dosing may  be perform ed at the parti cipants’ ho me by 
qualified personnel unt il travel or other restric tions are lift ed. Collection of ECGs is optional 
during m obile visi ts
The allowed visit windows can be extended based on advice fro m Lilly Medical in this 
exceptional case to allow more flexibilit y in performing the ho me vis its. 
Early Discontinuation Procedures
If a participant is quarantined or contracts COVID -19 or i s unable to attend the visit for other 
reasons during the course of the study  and therefore m obile visit s cannot be organized, study  
treatm ent m ust be di scont inued early and dosing decisi ons for the al ternat ive treatment are 
exceptionally allowed to be performed by telephone. 
After termination o f study  treatm ent LY3209590 shoul d be repl aced by  a non -insulin 
secretagogue and not by  an insulin treatm ent to prevent hypoglycemia in this remot e setting.  
The recommended alternat ive treatments are DPPIV inhibitors, SGLT2 inhibitors or GLP1 
agonists. The al ternative treatm ent shoul d be started at the lowest recommended dose as soon as 
the participant’s median fast ing glucose rises above 140mg/dl during any 7- day period af ter the 
end of study  treatment.
If the invest igator sees an indication for treatment with another insulin product, a decisio n shoul d 
be discussed wit h Lilly Medical.
Parti cipants treated wi thinsulin degludec can cont inue this treatment at the discret ion of the 
investigator. 
If remote or tel ephone visits are impossible and prohibit review of glycemic control ,the 
participant m ust be hospi talized for a safe transit ion to an al ternative ant idiabet ic treatment.
Participants willcontinue to enter their blood glucose -and hypoglycemia -informat ion into thei r 
electroni c diari es during the follow -up peri od to give the invest igative site continued remote 
access to these data. 
Study  supplies for blood glucose monitori ng as well as alternat ive treatments will be provided to 
the participant unt il the end of the safet y follow
-up peri od (6 weeks after the last dose of 
LY3209590 or 5 weeks after the last dose of insulin degludec).  If circumstances permit ,efforts 
may be made to obtain an immunogenicit y blood sam ple after this follow -up. After the end of 
CONFIDENTIAL I8H-MC-BDCL (d)
LY3209590 93the safet y follow-up peri od, study  supplies have to be returned or disposed as directed by  the 
sponsor.
Replacement of study participants
The dropout rate will be mon itored regul arly during the study . If the dropout rate is over 15% 
prior to com pletion of 12 weeks of treatment, additio nal participants may be enrolled to ensure 
approximately  200 partici pants complete 12 weeks of treatment.
Documentation
The sites mustident ify and docum ent the details o f how all pa rticipants and visit s were affected 
by the COVID -19 pandemic restrict ions.
CONFIDENTIAL I8H-MC-BDCL (d)
LY3209590 9410.11. Appendix 11: Abbreviations
Term Definition
ADA anti-drug antibody
AE adverse event:  Any untoward medical occurrence in a patient or clinical investigation 
participant administered a pharmaceutical product that does not necessarily have a 
causal relationship with this treatment.  An adverse event can therefore be any 
unfavorable and unintended sign (including an abnormal laboratory finding), symptom, 
or disease temporally associated with the use of a medicinal (investigational) product, 
whether o r not related to the medicinal (investigational) product.
ALP alkaline phosphatase
ALT alanine aminotransferase
AST aspartate aminotransferase
BG blood glucose
BMI body mass index
BP blood pressure
CI confidence interval
CIOMS Council forInternational Organizations ofMedical Sciences
Com panion diagnostic An in vitro diagnostic device (assay or test) that provides information that is essential 
for the safe and effective use of a corresponding therapeutic product
complaint A complaint is any written, electronic, or oral communication that alleges deficiencies 
related to the identity, quality, purity, durability, reliability, safety or effectiveness, or 
performance of a drug or drug delivery system.
compliance Adherence to all study -related, good clinical practice (GCP), and applicable regulatory 
requirements.
CONSORT Consolidated Standards of Reporting Trials
CRP clinical research physician: Individual responsible for the medical conduct of the study.  
Responsibilities of the CRP may be performed by a physician, clinical research 
scientist, global safety physic ian or other medical officer.
CV cardiovascular
DKA diabetic ketoacidosis
DMC data monitoring committee
DNA deoxyribonucleic acid
EAS efficacy analyses set
ECG electrocardiogram
CONFIDENTIAL I8H-MC-BDCL (d)
LY3209590 95eCOA electronic clinical outcome assessment
eCRF electronic case report form
EDC electronic data capture system
ED early  discontinuation
eDiary electronic diary
eGFR estimated glomerular filtration rate
ELISA enzyme-linked immunosorbent assay
enroll The act of assigning a participant to a treatment.  Participants who are enrolled in the 
study are those who have been assigned to a treatment.
enter Participants entered into a study are those who sign the informed consent form directly 
or through their legally acceptable representatives.
ERB ethical review board
ET early  termination
FFA Free fatty acids
FG fasting glucose
FGM flash glucose monitoring
GCP good clinical practice
HbA1c Hemoglobin A1c
IB Investigator’s Brochure
ICF informed consent form
ICH International Council for Harmonisation
IMP Investigational Medicinal Product
Informed consent A process by which a participant voluntarily confirms his or her willingness to 
participate in a particular study, after having been informed of all aspects of the study 
that are relevant to the participa nt’s decision to participate.  Informed consent is 
documented by means of a written, signed and dated informed consent form.
INR internatio nal no rmalized ratio
IP: investigational 
productA pharmaceutical form of an active ingredient or placebo being tested or used as a 
reference in a clinical trial, including products already on the market when used or 
assembled (formulated or packaged) in a way different from the authorized form, or 
marketed products used for an unauthorized indication, or marketed p roducts used to 
gain further information about the authorized form.
CONFIDENTIAL I8H-MC-BDCL (d)
LY3209590 96interim analysis An interim analysis is an analysis of clinical study data, separated into treatment groups, 
that is conducted before the final reporting database is created/locked.
IRB/IEC Institutio nal Review Boards/Independent Ethics Committees 
ISR injection site reaction
ITT intention to treat:  The principle that asserts that the effect of a treatment policy can be 
best assessed by evaluating on the basis of the intention to treat a participant (that is, the 
planned treatment regimen) rather than the actual treatment given.  It has the 
consequence that participant allocated to a treatment group should be followed up, 
assessed, and an alyzed as members of that group irrespective of their compliance to the 
planned course of treatment.
IWRS interactive web -response sy stem
MAD multiple -ascending dose
NAFLD non-alcoholic fatty liver disease
NIM non-inferio rity margin
NIMP Non-investiga tional Medicinal Product
OAM oral antihy pergly cemic medications
OTC over the counter
participant Equivalent to CDISC term “subject”: an individual who participates in a clinical trial, 
either as recipient of an investigational medicinal product or as a control
PC product complaint
PK/PD pharmacokinetics/pharmacodynamics
PPS per-protocol set:  The set of data generated by the subset of participant who sufficiently 
complied with the protocol to ensure that these data would be likely to exhibit the 
effects of treatment, according to the underlying scientific model.
PRO/ePRO patient -reported outcomes/electronic patient -reported outcomes
QTc corrected QT interval
SAD single -ascending dose
SAE serious adverse event
SAP statistical analysis plan
SC subcutaneous
screen The act of determining if an individual meets minimum requirements to become part of 
a pool of potential candidates for participation in a clinical study. 
CONFIDENTIAL I8H-MC-BDCL (d)
LY3209590 97SGOT serum glutamic oxaloacetic transaminase
SGPT serum glutamic pyruvic transaminase
SMBG self-monitoring blood glucose
SU sulfon ylurea
SUSARs suspected unexpected serious adverse reactions
T2DM type 2 diabetes mellitus
TBL total bilirubin level
TE treatment -emergent
TEAE Treatment -emergent adverse event:  An untoward medical occurrence that emerges 
during a defined treatment period, having been absent pretreatment, or worsens relative 
to the pretreatment state, and does not necessarily have to have a causal relationship 
with this treatment.
ULN upper limit of normal
WOCBP woman of childbearing potential
CONFIDENTIAL I8H-MC-BDCL (d)
LY3209590 9810.12. Appendix 12:  Protocol Amendment History
TheProtocol  Amendment Summary of Changes Table for the current amendment is located 
directly before the Table of Contents (TOC).
Amendment [c] 
This amendment is considered substant ialbased on the cri teria set forth in Art icle 10(a) of 
Directive 2001/20/EC of the European Parliament and the Council o f the European Unio n.
Overall Rationale for the Amendment:
The am endment provi des informat ion to reflect and reinforce invest igational medical device 
requi rements absent in the init ial study  protocol  for Al gorithm 2.  These requi rements are 
consistent with country  regul ations where Algorithm 2 will be used.
Section # and Name Description of Change Brief Rationale
Section 1.1. Synopsis
Section 1.2. Schema
Section 4.1.1. Study VisitsAddition of language regarding 
randomizationClarify  that randomization distribution may 
vary based on country due to removal of 
randomization into LY3209590 Algorithm 2 
(digital) for the European Union (EU)
Section 1.3. Schedule of 
Activities (SoA)Addition of p roduct complaint 
review in AE/SAE reviewProduct complaint review was added to 
ensure alignment with Lilly guidance
Section 2.3. Benefit/Risk 
AssessmentAddition of language related to 
LY3209590 Algorithm 1(paper) 
and LY3209590 Algorithm 2 
(digital)Additions to clarify regulatory designation of 
LY3209590 Algorithm 1 (paper) and 
LY3209590 Algorithm 2 (digital)
Section 2.3.1. Protocol Risk 
Mitigation F eatures for 
Investigational Algorithm 2Addition of language for 
protocol risk mitigation Summarization of key risk mitigations for the 
protocol including investigational medical 
device
Section 4.1.1. Study Visits Updated description of 
Algorithm 2 Clarification of Algorithm 2 as an 
investig ational individualized accruing data 
algorithm
Section 6.1. Study 
Interventions(s) AdministeredAddition of language describing 
the algorithms used in the studyClarification and description of algorithms 
Section 6.1.3. Medical 
DevicesAddition of language for 
Algorithm 2Algorithm 2 was added based on regulatory 
feedback c lassification as an investigational
medical device
Section 6.2. 
Preparation/Handling/Storage/
AccountabilityAddition of language for 
accountability and access to 
Algorithm 2Descriptio n of labeling and appropriate 
access controls by authorized trained 
personnel to meet regulatory requirements
Section 8.3.8. Product 
ComplaintsAddition of required section Product complaint section added to align 
with Lilly  template and guidance
Section 9. Statistical 
ConsiderationsClarifications throughout Clarifications and corrections provided to 
ensure consistency with the statistical 
analy sis plan
Section 9.2. Sample Size 
DeterminationRevised language related to 
statistical power Language added to reflect the change in 
statistical power resulting from removal of 
Algorithm 2 from t he EU
CONFIDENTIAL I8H-MC-BDCL (d)
LY3209590 99Section # and Name Description of Change Brief Rationale
Section 10.1.1. Regulatory 
and Ethical ConsiderationsAddition of language related to 
emergency circumstancesClarification of guidance during emergency 
circumstances requiring prior approval of 
Lilly  for regulatory  compliance
Section 10.3.3. Definition of 
an Unanticipated Adverse 
Device Effect (UADE)Addition of section related to 
unanticipated adverse device 
effect (UADE)Guidance on definitions and proc edures for 
handling UADE
Section 10.8.1. LY3209590 
Algorithm 1 (paper algorithm)Addition of language for 
investigatorsClarified guidance for investigators 
contacting Lilly Medical to be consistent 
with guidance provided for Algorithm 2
Section 10.8.2 .LY3209590 
Algorithm 2 (digital 
algorithm)Addition of language related to 
dosing and input of data for 
Algorithm 2Clarification for investigators on theuse of 
Algorithm 2
Section 10.8.3. Insulin 
DegludecAddition of language related to 
dosingDosing cl arification for starting dose of 
insulin degludec
Throughout Minor editorial and document 
formatting revisionsThese are minor changes; therefore, they 
have not been summarized.
Amendment [b]: 12 Jun 2020
This amendment is considered substant ialbased on the cri teria set forth in Art icle 10(a) of 
Directive 2001/20/EC of the European Parliament and the Council o f the European Unio n.
Overall Rationale for the Amendment:
This provides guidance if COVID -19 rel ated l ocal restri ctions impact the partic ipant’s abilit y to 
attend thei r onsi te study  visits as ori ginally scheduled.
Section # and 
NameDescription of Change Brief Rationale
Section 10.10 
Appendix 10Added Appendix 10: Changes to Study 
Procedures due to the COVID -19 
Pandemic or Natural DisastersMitigation if COVID -19 related restrictions 
make it impossible for the participant to travel to 
sites for originally scheduled visits.
Amendment [a]: 08 April 2020
This amendment is considered substant ialbased on the cri teria set forth in Article 10(a) of 
Directive 2001/20/EC of the European Parliament and the Council o f the European Unio n.
Overall Rationale for the Amendment:
This amendment addresses Food and Drug Administration (FDA) feedback. 
Section # and 
NameDescription of Change Brief Rationale
1.3. Schedule of 
ActivitiesMoved text from under ‘Notes’ for the 
12-lead ECG to footnote dTo include all information relevant to the ECG 
assessment under one footnote
1.3. Schedule of 
ActivitiesUpdated text specifying PK sample 
collection in participants randomized to 
LY3209590To better reflect that PK samples were only 
collected for participants randomized to the 
LY3209590 group
CONFIDENTIAL I8H-MC-BDCL (d)
LY3209590 100Section # and 
NameDescription of Change Brief Rationale
1.3. Schedule of 
ActivitiesDeleted ‘HDL, LDL’ from the ‘Lipid 
Panel’ procedureThe evaluated parameters within ‘Lipid Panel’ 
are already presented in Appendix 2, and 
therefore were deleted from the Schedule of 
Activities
1.3. Schedule of 
ActivitiesAdded ‘X’ at Visit 3 for the procedure 
‘Review SMBG, basal insulin dose, and 
hypo data to make dose
individualization assessment’Corrected an error -initial dose selection based 
on the diary entries between V2 and V3 is to be 
done at V3
1.3. Schedule of 
ActivitiesUpdated footnotes d and e to 
accommodate the language in the notes 
section for the 12-l ead ECG and to 
indicate that PK samples were not to be 
collected for participants in the insulin 
degludec treatment groupTo streamline presentation of all relevant 
information under the footnotes and to better 
reflect that PK samples were only collected f or 
participants randomized to the LY3209590 
group
4.3. Justification 
for DoseDeleted ‘after consultation with Lilly 
Medical’ in the statement regarding 
dose alterations recommended by dose 
adjustments algorithms, under the 
discretio n of investigators.  A dded text 
regarding documentation required in 
case of deviation from the algorithm -
recommended doseCorrected an error –prior consultation with Lilly 
Medical is not required for the investigator for 
dose alterations of LY3209590
5.2. Exclusion 
CriteriaUpdated the exclusion criteria to 
explicitly  exclude women of child 
bearing potential w ho are not using 
adequate contraception, pregnant 
women, women intending to become 
pregnant, o r lactating womenPer regulatory feedback
5.2. Exclusion 
CriteriaUpdated exclusion criteria numbering 
due to the addition of the exclusion 
criteria per regulatory feedbackUpdate in formatting
6.1.2.1. Standards 
of Medical CareAdded the statement ‘Standards of 
prevention of persistent hyperglycemia 
and ketone monitoring must be 
followed during the course of the study 
to prevent DKA’Per regulatory feedback, to further clarify the 
steps/mitigate the risk of hyperglycemia and 
DKA when starting LY3209590 or transitioning 
to other therapies (at the end of the trial)
6.1.2.2. 
Mana gement of 
Increased 
Hypoglycemia 
RiskDeleted ‘symptomatic’ from the 
definition of increased risk of 
hypoglycemia. Added the definition of 
documented hypoglycemia Per regulatory feedback
6.4. Study 
Intervention 
ComplianceUpdated text regarding IP 
accountabilityTo better reflect the process for IP accountability
CONFIDENTIAL I8H-MC-BDCL (d)
LY3209590 101Section # and 
NameDescription of Change Brief Rationale
7.1.1. Permanent 
Discontinuation 
from Study 
TreatmentAdded text for discontinuation from 
following occurrence of a systemic 
hypersensitivity reactionTo clarify better the circumstances u nder which 
participants will be discontinued from the IP
8.3.7.1. 
HypoglycemiaDeleted ‘ED2’ as one of the last visits ED2 is not necessarily the last study visit if 
patient continues the study without IP
8.3.7.1. 
HypoglycemiaAdded text regarding the re porting of 
hypoglycemiaTo clarify how information regarding 
hypoglycemia is to be collected
8.3.7.1. 
HypoglycemiaDeleted text describing the thresholds 
for analysisThese thresholds will be used for analyses, and 
do not need to be included in the protocol. The 
thresholds for algorithms are updated in Section 
10.8.1
8.3.7.3. Systemic 
Hypersensitivity 
ReactionsAdded a section on systemic 
hypersensitivity reactions as adverse 
events of special interestTo update the protocol with systemic 
hypersensitivity as an adverse event of special 
interest
8.4. Treatment of 
OverdoseUpdated the text to provide guidance 
regarding the management of overdose 
with LY3209590Per regul atory feedback
8.5. 
PharmacokineticsUpdated the text to clarify that PK 
samples were not to be collected for 
participants randomized to insulin 
degludecTo better reflect that PK samples were only 
collected for participants randomized to the 
LY3209590 gr oup
9.4.6.3. 
Hypoglycemia 
EpisodesAdded text to clarify that hypoglycemia 
will be analyzed according to the 
definitions in the ADA classification 
systemTo explain the analysis of hypoglycemia
10.1.6. Data 
Quality  AssuranceReplaced ‘captured’ with ‘entered by 
patient’ to clarify that hypoglycemic 
events will be entered by patients in the 
eCOATo clarify the text regarding data collection for 
hypoglycemic events
10.2.
Appendix 2Updated the text to clarify that the 
investiga tors must document their 
review of each laboratory safety report 
and updated the footnotesTo correct errors, add information, and improve 
readability
10.8.1. 
Appendix 8Updated the text regarding the 
LY3209590 algorithm 1 (paper 
algorithm)Per regulator y feedback
10.9.
Appendix 9Added an appendix to describe 
recommended laboratory testing for 
hypersensitivity eventsTo update the protocol with systemic 
hypersensitivity as an adverse event of special 
interest
Throughout the 
protocolMinor editorial and formatting changes Minor, therefore not described
Abbreviations:  ECG =electrocardiogram; eCOA =electronic Clinical Outcome Assessment ; ED2 (visit) =Early  
Discontinuation 2 (visit); IP =investigational product; PK =pharmacokinetic.
CONFIDENTIAL I8H-MC-BDCL (d)
LY3209590 10211. References
[ADA] American Diabetes Associat ion. Standards of medical care in diabetes—2016. Diabetes 
Care . 2016;39(suppl 1):S4
-S108.
[ADA] American Diabetes Associat ion. Standards of medical care in diabetes - 2019. Diabetes 
Care . 201 9;42(S uppl 1):S4 -S193.
Blonde L, Brunton SA, Chava P, Zhou R, Mey ers J, Davis K, Dalal M, Di genio A. Achievement 
of Goal  A1C (<7 %) by  U.S. Pati ents wi th T2DM on Basal Insulin in Both Rando mized, 
Controlled Trials (RCTs) and in Clinical Practice. Diabetes. 2014;63(Suppl 1):A235.
[FDA] Food and Drug Administration. Guidance for Industry . Diabetes Mellitus:  Developing 
Drugs and Therapeut ic Biologics for Treatment and Prevent ion. 2008.  Available at:  
https://www.fda.gov/media/71289/download. Accessed : December 3, 2019.
Heise T, No sek L, Bottcher SG, Hastrup H, Haahr H . Ultra-long-acting insulin degludec has a 
flat and stable glucose -lowering effect in ty pe 2 diabetes. Diabetes Obes Metab.
2012;14(10):944-950.
Inzucchi SE, Bergenstal RM, Buse JB, Diamant M, Ferrannini E, Nauck M, Pe ters AL, Tsapas 
A, Wender R, Matthews DR. Management of Hy perglycemia in Ty pe 2 Di abetes, 2015: A 
Patient-Centered Approach: Update to a Posit ion Statement of the American Diabetes 
Associ ation and the European Associat ion for the Study  of Diabetes. Diabetes Care . 2015, 
38(1):140 -149.
Riddle MC, Rosenstock J, Gerich J, Insulin Glargine 4002 Study  Investi gators. The Treat -to-
Target Trial: Rando mized addit ion of glargine or hum an NPH insulin to oral therapy  of type 2 
diabetic pat ients. Diabetes Care . 2003;26 (11):3080 –3086.
Strange P. Treat -to-target insulin titration algorithms when init iating long or intermediate acting 
insulin in t ype 2 diabetes. J Diabetes Sci Technol. 2007;1(4):540 -
548.
Tresiba® prescribing informat ion [USPI 2015]. Available at: 
https://www.accessdata.fda.gov/drugsatfda_docs/label/2015/203314lbl.pdf . Accessed January  
11, 2018.
L e o  D o c u m e n t  I D  =  1 b 0 0 a b e 7 - 3 7 0 0 - 4 c 8 b - 8 e a 2 - 6 b 4 3 7 9 e 0 c f 8 a 
A p p r o v e r : 
A p p r o v a l  D a t e  &  T i m e :  2 8 - O c t - 2 0 2 0  1 6 : 0 9 : 2 2  G M T 
S i g n a t u r e  m e a n i n g :  A p p r o v e d 
A p p r o v e r : 
A p p r o v a l  D a t e  &  T i m e :  2 8 - O c t - 2 0 2 0  1 6 : 2 1 : 5 5  G M T 
S i g n a t u r e  m e a n i n g :  A p p r o v e d P P D P P D 